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“Experiments on rats show that if the organism is severely damaged by acute non-
specific nocuous agents (…) a typical syndrome appears, the symptoms of which are 
independent of the nature of the damaging agent or the pharmacological type of 
the drug employed, and represent rather a response to damage as such.”
- Hans Selye (Nature, 1936)
The discovery of the general stress response and its effects in organisms is typical 
for many great findings in that serendipity was of the essence. Endocrinologist 
Hans Selye recurrently injected rats with a cow ovarian extract to find new female 
sex hormones. Upon pathological examination, he discovered that the animals 
had developed enlarged adrenal glands, and gastrointestinal ulcers whereas 
immunological tissues as the thymus, spleen, and lymph glands had become 
smaller (1). Subsequent experiments in which the rats were exposed to other (non-
hormonal) agents or conditions such as cold or excessive involuntary exercise 
yielded however similar findings. This led to the hypothesis that organisms exert 
a non-specific response to diverse stimuli which he labelled as the “general 
adaptation syndrome” (1). These “non-specific nocuous agents” would later be 
termed “stressors” whereas the typical syndrome is nowadays known as the stress 
response. This response is mediated by a hormonal symphony orchestrated by 
the hypothalamus-pituitary-adrenal (HPA) axis. Upon activation, it induces the 
secretion of glucocorticoids from the adrenal glands which in turn can directly or 
indirectly affect practically every element of an organism. 
1. Glucocorticoids
1.1 Endogenous glucocorticoids
The secretion of glucocorticoids is under neurohormonal control of the HPA axis 
(see Figure 1). This class of steroid hormones, with the stress hormone cortisol 
being the most important, are produced in the adrenal glands. The primary signal 
for its secretion is generated in specialized neuronal cells in the paraventricular 
nucleus of the hypothalamus. These cells secrete among others the corticotropin-
releasing hormone (CRH) which is transported down to the anterior pituitary 
gland to stimulate the secretion of adrenocorticotropic hormone (ACTH). From 
there, ACTH enters the circulation to start its journey with the adrenal glands as 
its main destination. As it hits the adrenal glands it finally results in the synthesis 
and secretion of glucocorticoids from cells in the zona fasciculata located in the 
adrenal cortex. Negative feedback of glucocorticoids on the hypothalamus and 
pituitary gland reduces the secretion of CRH and ACTH in order to facilitate 
termination of glucocorticoid secretion (2). Glucocorticoids are essential in mental 
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and physical health giving their involvement in reproduction, metabolism, 
inflammation, cognition, and many other processes. Its relevance also becomes 
evident giving the presence of the glucocorticoid receptor in many tissues (3). 
This widespread engagement makes glucocorticoids highly suitable effectors by 
default in regulating adaption to changing situations. 
Figure 1: The hypothalamus-pituitary-adrenal axis.
The secretion of glucocorticoids, cortisol as the most important hormone, is under the control of the 
hypothalamus-pituitary-adrenal (HPA) axis. The primary signal originates from the hypothalamus and is 
executed by secretion of the corticotrophin-releasing hormone which subsequently prompts secretion 
of adrenocorticotrophic hormone (ACTH) from the adenohypophysis (i.e. anterior pituitary of the 
pituitary gland).  ACTH subsequently stimulates the adrenal glands to secrete cortisol which in turn 





















1.2 Glucocorticoid receptor 
The glucocorticoid action does in essence dependent on the activation of the 
glucocorticoid receptor. This nuclear receptor is encoded by the NR3C1 gene 
located on chromosome 5 which consists of one noncoding and eight coding exons 
(see Figure 2). Inactive glucocorticoid receptors remain in the cytoplasm coupled 
in a complex of heat shock proteins and kinases. Activation of the receptor 
occurs with binding to glucocorticoids after which it translocates to the nucleus. 
There it can up- and downregulate the transcription of certain genes. These 
transactivational and transrepressional effects are carried out in various ways 
including binding to specific glucocorticoid response elements and interaction with 
other transcription factors (4). In addition to genomic actions, glucocorticoids can 
also induce rapid nongenomic effects through changes in intracellular signaling 
and other mechanisms (5). 
Figure 2: The glucocorticoid receptor and functional single nucleotide polymorphisms.
The BclI and N363S polymorphisms of the NR3C gene are associated with relatively increased 
glucocorticoid sensitivity, whereas the ER22/23EK and 9β variants are linked to relative glucocorticoid 
resistance. Missense mutations occur with the N363S and ER22/23EK polymorphisms where the 
amino acid asparagine (N) is changed to serine (S) in the former and arginine (R) to lysine (K) in the 
latter. Abbreviations: A, nucleotide adenine; C, nucleotide cytosine; G, nucleotide guanine; SNP, single 
nucleotide polymorphism; UTR, untranslated region. Adapted from Savas and van Rossum. Encyclopedia 
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SNP BclIER22/23EK N363S 9β
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Increased transactivational activity is generally held responsible for cardiometabolic 
adverse events (6) as is often observed in patients with autonomous overproduction 
of glucocorticoids (i.e. Cushing’s syndrome). The transrepressional activities of 
glucocorticoids are on the other hand accountable for immunosuppressive and 
anti-inflammatory effects of glucocorticoids (6). Many glucocorticoid receptor 
polymorphisms have been found in the past decades. A handful of functional 
variants has however been linked to altered glucocorticoid receptor sensitivity and 
eventually distinct glucocorticoid effects. 
Chapter 1
16
1.2.1 Glucocorticoid receptor hypersensitive variants
The most abundant polymorphism involves an intronic nucleotide change in intron 2 
and has been linked to an increased glucocorticoid sensitivity. Carriers of this 
BclI variant were more likely to have central adiposity (7,8), insulin resistance (9), 
and major depressive disorder (10) which is in common with higher glucocorticoid 
action. Another hypersensitive variant concerns the N363S polymorphism which 
results in a missense mutation due to a nucleotide change in exon 2. Earlier studies 
have shown an increased transactivational activity with isolated peripheral blood 
mononuclear cells (11) corresponding to clinical observations as enhanced cortisol 
suppression with low-dose 0.25 mg dexamethasone suppression test (12) and 
cardiometabolic features as increased body mass index (12,13) and dyslipidemia (14).
1.2.2 Glucocorticoid receptor resistant variants
Two functional polymorphisms have been associated with a relative glucocorticoid 
resistance. The ER22/22EK variant concerns two linked nucleotide changes in 
adjacent codons resulting in the change of the second amino acid from arginine 
to lysine. This yields glucocorticoid receptors with less transactivating activity (15) 
as observed with functional assays (11). Another nucleotide change in exon 9β 
increases the stability of the splice variant glucocorticoid receptor β (16), which acts 
as a dominant-negative inhibitor of the active receptor isoform, and decreases the 
transrepressional glucocorticoid activity. The ER22/23EK and 9β  polymorphisms 
have been linked to a smaller waist circumference (17,18) and beneficial metabolic 
profile (18,19). Moreover, individuals with the 9β polymorphisms were found to have 
elevated inflammatory markers as well as increased incidence of cardiovascular 
disease possibly due to a pro-inflammatory status (20). 
1.3 Glucocorticoid measurements
Glucocorticoids are secreted and can be quantified in different bodily fluids. 
Secretion of cortisol follows a circadian and pulsatile rhythm with the lowest 
levels at midnight and the highest concentrations in the early morning (21). Besides 
the natural fluctuations, physical and mental stressors (22) as well as conditions 
like poorly controlled diabetes mellitus, polycystic ovary syndrome, or excessive 
alcohol consumption can also alter cortisol levels (23). Blood, saliva, and urine have 
traditionally been used as matrices for cortisol assessment. The current guideline 
of the Endocrine Society for diagnosis of Cushing’s syndrome recommend 
screening with dexamethasone suppression test, late-night salivary cortisol, and 
24-hr urinary free cortisol measurements (24). These tests are convenient in the 
assessment of relatively short-term cortisol exposure with periods ranging from 
seconds to minutes (with serum and saliva) and hours to days (with urine) depending 




also requires repeated testing and can be compromised by several factors such as 
patient compliance (e.g. collection of urine output, intake of dexamethasone), and 
interference with other commonly used drugs (24). Moreover, physical or mental 
disabilities or living remote from the clinic site could also complicate the diagnostic 
process. 
An increasing amount of research is being conducted regarding scalp hair as a novel 
instrument for cortisol assessment. Scalp hair grows with approximately one cm 
per month which provides the opportunity to assess long-term cortisol exposure 
over months to years depending on hair sample length (25). It can easily be collected 
at every moment and stored at room temperature without the need to impose 
patients to certain instructions or limitations. Hair cortisol concentrations have 
been investigated in a wide range of clinical settings concerning not only patients 
with Cushing’s syndrome (26), but also obesity (27), mental health disorders (28), and 
many other stress-related diseases (29). Earlier studies performed immunoassays 
to assess hair cortisol concentrations (30), nowadays we can quantify cortisol as well 
as the inactive variant cortisone in scalp hair with high sensitivity and specificity 
by using state-of-the-art liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) (31). 
Exogenous glucocorticoids
Glucocorticoids induce potent anti-inflammatory and immunomodulatory effects 
as was also noticed in the experimental rats of Selye. The first reported application 
of exogenous glucocorticoid, isolated from bovine adrenal glands, was in a young 
female with rheumatoid arthritis at the Mayo Clinic in 1948 (32). Since then the 




Numerous synthetic corticosteroid compounds have been developed over time 
with different glucocorticoid and mineralocorticoid activity as well as duration of 
action. The availability of corticosteroids in different administration forms makes 
them a valuable addition in the treatment of a broad spectrum of inflammatory 
diseases. The systemic administration forms are applied by oral and parenteral 
route, whereas the local corticosteroids can be delivered by inhalation, nasal 
sprays, dermal applications, ocular and otological droplets, and various other ways. 
In the Netherlands, there were more than 13 million corticosteroid formulations 
prescribed last year according to data from the Dutch National Health Care 
Institute (33). Some longitudinal population-based studies and large cohort 
studies are showing an increasing number of corticosteroid users over time. The 
prevalence of long-term (at least three months) systemic corticosteroid use in the 
United Kingdom increased with one third from 0.6% to 0.8% over a time span of 
twenty years (34). Inhaled corticosteroids were for instance used by 1.1% and o.8% 
in respectively the United Kingdom and The Netherlands in the early 90s and this 
proportion of users rose to 1.7% and 1.4% in 1996 (35).
Figure 3: Impression of the variability and coverage of traditional matrices and scalp 
hair for assessment of cortisol concentrations.
The red dotted line represents the actual increase in cortisol concentrations over time in a fictional 
situation. Scalp hair cortisol analysis allows assessment of cortisol changes over a prolonged period of 
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1.5 Adverse effects of glucocorticoids
The immune-dampening effects of corticosteroids are much appreciated in many 
inflammatory diseases. Use of corticosteroids is unfortunately often accompanied 
by adverse effects which are often not limited to specific tissues. The downside of 
supraphysiological exposure to glucocorticoids becomes clear with endogenous 
Cushing’s syndrome. These patients are prone to develop cardiometabolic 
disturbances, cardiovascular events, neuropsychiatric pathologies, and a wide 
range of other comorbidities (36). Endogenous Cushing’s syndrome has however 
an extremely low incidence of less than five in million individuals annually. 
The main cause of Cushing’s syndrome is the administration of exogenous 
glucocorticoids. Serious adverse events of corticosteroids occur when the agents 
enter the circulation as it ensues with the use of systemic formulations. Systemic 
availability of exogenous glucocorticoids suppresses the HPA axis which could lead 
to decreased glucocorticoid secretion and eventually adrenal gland atrophy and 
adrenal insufficiency. The relatively high potency and long half-life of the synthetic 
variants make this sequela even more likely (37). A large meta-analysis demonstrated 
that users of oral or intra-articular corticosteroids had approximately 50% risk of 
developing adrenal insufficiency (38). Systemic corticosteroid users also are more 
likely to develop serious Cushingoid-like features such as abdominal adiposity, 
diabetes mellitus, hypertension, dyslipidemia, mood disorders, and osteoporosis (39). 
Interestingly, the most frequently observed adverse event was corticosteroid-
induced lipodystrophy (i.e. abnormal accumulation of fat mass such as moon face) (40) 
and weight gain (41). From patient’s perspective, these were also reported as the 
most distressing event (40) and were mainly experienced as very bothersome (41). 
Concerning serious corticosteroid-related adverse events, the focus has 
predominantly been put on the systemic forms although the majority of the 
prescriptions are for local corticosteroid types. One possible reason for this may be 
that health care providers assume that local corticosteroids can only induce ‘minor’ 
local adverse events as they do not enter the circulation. The previously mentioned 
meta-analysis showed however that users of locally applied corticosteroids, 
especially of the inhaled forms, also have a significantly increased risk of adrenal 
insufficiency hinting at systemic availability of these types (38). It would therefore 
be of great clinical importance to assess whether the use of local corticosteroids is 
indeed associated with major corticosteroid-related adverse events. 
2. Obesity
The World Health Organization has ranked overweight and obesity in the top 5 
leading risk factors for mortality worldwide and as the third most important 
health risk in high-income countries (42). The global prevalence of overweight and 
obesity has shown an impressive increase in the past decades (43) and is currently 
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responsible for more deaths than underweight (42). Unhealthy nutrition and physical 
inactivity are commonly referred to as the obvious causes of obesity. Reversing 
obesity would seem relatively simple based on this, however, in practice patients 
with obesity do not always lose (sufficient) weight and/or maintain weight loss 
with a healthy lifestyle. The etiology of obesity is complex and includes weight-
inducing as well as weight-maintaining factors covering a broad range of topics 
such as lifestyle, genetics, and hormonal composition. An attempt to categorize 
the main factors involved in obesity are listed in Figure 4.
Obesity is often associated with metabolic syndrome components such as 
hypertension, dyslipidemia, and impaired glucose tolerance or diabetes mellitus. It 
has been proposed that glucocorticoid excess may play a role in the development 
of obesity since these comorbidities are also often observed in patients with 
hypercortisolism (44). Previous studies investigating individuals with obesity have 
indeed found increased cortisol concentrations with traditional assessments of 
Figure 4: Overview of potential causes of obesity.
Adapted from van der Valk et al. Obes Rev. 2019;20(6):795-804.
clinical signs and symptoms
• Unhealthy food intake
• Lack of exercise




















• Lack of exercise
• Nocturnal eating
• Obstructive sleep apnea
• Repeated (very) low caloric diets with yoyo effect
examples






• Other specified feeding and eating disorders
• Weight increase related to initiation or dose increase














• History of radiotherapy
or severe head trauma
• Polycystic ovary syndrome
• Hypogonadism
• Post-pregnancy weight retention
• Menopause
• (Cyclic) Cushing’s syndrome
• Hypothyroidism
• Growth hormone deficiency









































short-term cortisol values (45,46). Moreover, we reported significantly higher long-
term cortisol concentrations, as measured in scalp hair, in individuals with obesity 
when compared to normal weight and overweight subjects (47) with a substantial 
part having levels even far above the applied cut-off for normal range values. The 
underlying etiology, direction, and magnitude of the association remain a topic 
of ongoing research, but it is a fact that individuals with obesity often encounter 
a multitude of physiological and psychological stressors that could induce and/
or maintain a hypercortisolistic state. A thorough evaluation of potential weight-
inducing and weight-maintaining factors should hence be a key principle in tackling 
obesity.
3. Stress-related diseases
Comorbidities of glucocorticoid excess are not limited to patients with Cushing’s 
syndrome or obesity. Since activation of the stress system depends on stressors 
rather than specific conditions, it is possible that other chronic diseases, life-events, 
or ongoing stressful circumstances (e.g. work- or school-related) also activate the 
HPA axis and lead to higher secretion of cortisol. It would therefore be plausible 
that these individuals could develop glucocorticoid-related symptoms depending 
on genetic factors as well as various stress-related aspects such as the duration, 
intensity, and personal coping abilities. Since many of the serious comorbidities 
manifest after prolonged exposure to elevated glucocorticoid levels, hair cortisol 
analysis could provide more understanding of whether there is such an association 
in specific diseases and conditions of interest.
Aims and outline of thesis
Glucocorticoids are essential for survival and adaptation to changing situations. Too 
much glucocorticoids can however yield a variety of symptoms and comorbidities. 
In this thesis, we aimed to investigate the role of endogenous and exogenous 
glucocorticoids in various stress-related diseases with a special focus on obesity. 
We additionally evaluated the diagnostic accuracy of scalp hair glucocorticoids in 
the screening of Cushing’s syndrome as well as the clinical application in obesity 
and stress-related conditions.  
In chapter 2 we assessed the prevalence of a comprehensive set of potential 
weight-inducing and weight-maintaining factors including the use of exogenous 
glucocorticoids in a cohort of adults with obesity. Chapter 3 describes our findings 
from a systematic evaluation for systemic and local corticosteroid use in subjects 
with obesity compared to non-obese controls from two independent cohorts. 
In chapter 4 we investigated the relationship between the use of different 
corticosteroid types with anthropometric features and metabolic syndrome in 
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the general population. We further zoomed into this association on the level of 
glucocorticoid receptor polymorphisms in chapter 5. In a population-based study, 
we also assessed the link between exogenous glucocorticoid use and the presence 
of mood and anxiety disorders as well as executive cognitive functioning as 
described in chapter 6. With respect to scalp hair glucocorticoids, we performed 
a multicenter, international, prospective, case-control study to investigate 
the diagnostic efficacy of scalp hair cortisol and cortisone in the screening of 
endogenous Cushing’s syndrome of which the results are presented in chapter 7. 
Giving the link between glucocorticoids and adiposity, we assessed the association 
between scalp hair cortisol and cortisone with anthropometrics and body 
composition parameters in chapter 8. Here we also present the results of our 
prospective longitudinal combined lifestyle intervention with cognitive behavioral 
therapy in individuals with obesity in which we among others investigated whether 
weight loss was associated with changes in scalp hair glucocorticoids and if use 
of systemic corticosteroids could impact the efficacy of the intervention. We 
further assessed the link between scalp hair cortisol with cardiometabolic and 
psychological outcomes in patients with Turner syndrome and erythropoietic 
protoporphyria in respectively chapter 9 and chapter 10. We also performed a 
prospective comparative cohort study to investigate school-related stress as 
induced by raising performance standards in first-year medical students. Chapter 11 
describes the difference in academic performance as well as psychological and 
biological stress levels in these students. In chapter 12 we have investigated 
potential school-related stress in children entering third grade. We measured long-
term cortisol exposure in scalp hair before and after school entry and assessed 
whether changes were mediated by individual characteristics as temperament, 
academic skills, and executive functioning. In the final chapter 13, we performed 
functional magnetic resonance imaging to assess the link between long-term 
cortisol exposure as quantified with scalp hair cortisol and neural correlates in 
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Extensive Phenotyping for 
Potential Weight-Inducing Factors 






Background: Obesity has been associated with miscellaneous weight-inducing 
determinants. A comprehensive assessment of known obesity-related factors other 
than diet and physical activity within one cohort is currently lacking. 
Objectives: To assess the prevalence of potential contributors to obesity and self-
reported triggers for marked weight gain in an adult population with obesity and 
between obesity classes. 
Methods: In this observational cohort study, we assessed 408 persons with obesity 
(aged 41.3 ± 14.2 years, BMI 40.5 ± 6.2 m2) visiting our obesity clinic. They were 
evaluated for use of weight-inducing drugs, hormonal abnormalities, menarcheal 
age, (high) birth weight, sleep deprivation, and obstructive sleep apnea syndrome 
(OSAS). We additionally assessed self-reported triggers for marked weight gain and 
performed genetic testing in patients suspected of genetic obesity. 
Results: Nearly half of the patients were using a potentially weight-inducing drug, 
which was also the most reported trigger for marked weight gain. For the assessed 
hormonal conditions, a relatively high prevalence was found for hypothyroidism 
(14.1%), polycystic ovary syndrome (12.0%), and male hypogonadism (41.7%). A 
relatively low average menarcheal age (12.6 ± 1.8 years) was reported, whereas there 
was a high prevalence of a high birth weight (19.5%). Sleep deprivation and OSAS 
were reported in, respectively, 14.5 and 13.7% of the examined patients. Obesity 
class appeared to have no influence on the majority of the assessed factors. Of the 
genetically analyzed patients, a definitive genetic diagnosis was made in 3 patients 
(1.9%). 
Conclusions: A thorough evaluation of patients with obesity yields a relatively high 
prevalence of various potentially weight-inducing factors. Diagnostic screening of 
patients with obesity could therefore benefit these patients by potentially reducing 
the social stigma and improving the outcomes of obesity treatment programs by 
tackling, where possible, the weight-inducing factors in advance.
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Introduction
In the last decades, there has been an evident increase worldwide in the prevalence 
of obesity [1]. This ominous trend brings along many health problems given the 
strong associations between adiposity and noncommunicable diseases. In addition 
to metabolic and cardiovascular diseases, obesity carries an increased risk of 
various cancer types, depression, and other illnesses compromising the quality of 
life.
The multifactorial etiology of obesity makes it difficult to find a long-lasting 
solution. Dietary composition and reduced physical activity, also acclaimed as the 
“big two” by Keith et al. [2], have always been of major concern regarding the epidemic 
and treatment of obesity. However, this approach tends to undervalue other 
factors also described to contribute to or at least maintain obesity. For instance, 
various genetic alterations have been found to induce obvious monogenic (e.g., 
melanocortin 4 receptor [MC4R] and pro-opiomelanocortin [POMC] mutations) 
or syndromic forms of obesity (e.g., Prader-Willi and Bardet-Biedl syndromes) or 
have been linked to non-syndromic obesity in which the onset and severity depend 
on interaction with the environment. Other relatively more prevalent factors that 
increase the risk of obesity are, for example, an early age at menarche, [3] a high 
birth weight, [4, 5] and various hormonal causes such as hypothyroidism, (endogenous 
or exogenous) Cushing’s syndrome, and hypothalamic abnormalities [6]. 
Additionally, there are also diverse potentially modifiable weight-inducing factors 
such as the use of obesogenic drugs [7], and diminished sleep duration [8, 9], or 
factors for which the direction of association has not yet been fully understood or 
is bidirectional (e.g., low testosterone levels [10], polycystic ovary syndrome [PCOS] 
[11], and obstructive sleep apnea syndrome [OSAS] [12]).
Most experimental and observational studies regarding obesity usually highlight 
one particular factor. One of the targets of our multidisciplinary referral center for 
obesity is to systematically evaluate and identify those factors that could induce 
and/or maintain excess body weight in adults. Hence, the main purpose of this 
study was to extensively phenotype and assess multiple potential weight-inducing 
factors, as mentioned above, within our total obese cohort and stratified by adult 
obesity classes. Our secondary objectives were to evaluate the relationship with 
self-reported triggers for marked weight gain and to assess the yield of targeted 





Patients with obesity were referred to our academic obesity center CGG for 
assessment of potential contributing factors to adiposity. After registration, a 
comprehensive standardized medical questionnaire was sent to the patients for a 
more thorough evaluation of, among other things, their medical history, drug use, 
family history, and other factors as assessed here. We assessed data of patients 
who were seen at the outpatient clinic between June 2011 and August 2016. After 
excluding individuals who had a BMI below 30.0 at the time of the clinic visit or 
insufficient data, a total of 408 patients with obesity were included in the current 
study.
Sociodemographic Factors
Weight, height, and blood pressure were measured during the site visit. BMI was 
computed by dividing weight (kg) by height (m2). Nationality was determined 
according to Statistics Netherlands [13]. The highest attendant education level was 
coded as follows: low (i.e., no education, primary education, or special education), 
middle (i.e., secondary education or vocational studies), or high (i.e., higher 
professional education or university education).
Assessment of Potential Weight-Inducing Factors
Medical history and drug use were assessed using the referral letter of the primary 
care provider and completed medical questionnaires and were subsequently 
confirmed and further detailed during the outpatient clinic visit.
Currently used drugs were assessed for potential weight-inducing adverse 
events. Accordingly, we compiled a list of drugs which were previously reported 
to be associated with weight gain (Table 1) [7, 14–21]. For exploratory purposes, 
we additionally included drugs which were less frequently been reported as 
weight-inducing (e.g., antihistamines and proton pump inhibitors) as compared 
to the well-established obesogenic drugs. Hormonal contraceptives, other than 
medroxyprogesterone, were not included due to the controversy about their 
weight-altering effects [22].
Thyroid function was categorized into the following 4 groups based on the 
availability of both medical history and current thyroid function measurements: 
(1) euthyroid (i.e., no history of a thyroid disorder and normal thyroid function 
tests), (2) hypothyroidism (including all patients who were previously or newly 
diagnosed with hypothyroidism and patients who underwent thyroidectomy; these 
patients were subdivided into groups of patients who were currently inadequately 
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Table 1: Overview of drugs described to be associated with weight gain.[7,14-21]











































































a Ziprasidone is reported to both induce weight gain [7] as weight loss [15]; current use of ziprasidone was not observed 
in our sample; bAlso known as “glyburide” in the United States.
treated [increased thyroid-stimulating hormone (TSH) levels], patients who were 
adequately treated or had a resolved hypothyroidism [normal TSH and free 
thyroxine (FT4) levels], patients who were overtreated [lowered TSH levels], and 
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patients with other thyroid function test results), (3) subclinical hypothyroidism, 
and (4) other thyroid states. For this, blood samples were drawn for determination 
of, among other things, TSH and FT4 as part of our routine lab measurements.
PCOS was classified as previously diagnosed if the patient indicated having been 
investigated earlier and the diagnosis was established. For screening purposes, 
patients suspected to have PCOS were referred to a specialized gynecological 
outpatient clinic. Clinically suspected patients who were not (yet) further 
investigated or for whom the results were still pending due to investigations 
elsewhere were classified as a separate category.
In male patients without testosterone replacement therapy, total testosterone 
and sex hormone-binding globulin (SHBG) were measured if necessary to 
determine male hypogonadism. Due to the association of SHBG with body weight, 
we calculated non-SHBG-bound testosterone according to de Ronde et al. [23]. Male 
hypogonadism was defined as non-SHBG testosterone levels lower than 2 SD from 
the mean according to the corresponding age category as noted by de Ronde et 
al. [23], with patients younger than 40 years belonging to the youngest category.
Subjects were also evaluated for age at menarche (years), self-reported birth 
weight (g), and average sleep duration (h/night). With respect to OSAS, we referred 
suspected cases to an otolaryngologist and classified the patients using the same 
format as for PCOS.
Assessment of Marked Weight Gain
In order to also evaluate subjective reasons for weight gain, we assessed self-
reported data about potential causes of any previous period of marked weight 
gain. For this purpose, we assessed reasons other than unhealthy eating behaviors 
and/or physical inactivity and categorized these as related to: health, psychosocial 
stress, work, pregnancy, drug use, substance cessation, and other causes.
Genetic Analysis
A genetic test was performed in a selection of 162 patients (39.7%). They fulfilled the 
criteria for requesting this analysis based on clinical suspicion of syndromic obesity 
(e.g., early-onset obesity with dysmorphic features/congenital malformations 
with or without an intellectual deficit, behavior problems, hyperphagia, and/or 
a striking family history), had intractable obesity despite a healthy lifestyle and 
repeated weight-loss attempts without other potential secondary causes, or had 
an insufficient response or a non-response to our intensive combined lifestyle 
treatment programs. Targeted diagnostic DNA sequencing of 52 obesity-related 
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genes, including 3 genes related to type 2 diabetes mellitus (Table 2), covering 
protein coding exons and flanking splice site consensus sequences, was performed 
at the ISO15189 accredited genome diagnostics department of UMC Utrecht. 
DNA was enriched using an Agilent SureSelectXT custom enrichment assay 
(ELID#0561501) followed by next-generation sequencing on an Applied Biosystems 
5500XL SOLiD sequencer at a minimum of 100× median coverage. Horizontal 
coverage of the targeted sequence at >15× was >95%. The poorly captured fourth 
exon of the POMC gene (transcript NM_001035256.1) was analyzed via the Sanger 
sequencing method to reach >99% coverage for this gene (primer sequences are 
available on request).
Statistical Analysis
IBM SPPS Statistics version 21 (IBM Corp., Armonk, NY, USA) was used for statistical 
analyses. Age at menarche was assessed continuously. For exploratory purposes, 
we also evaluated the prevalence of precocious menarche (i.e., younger than 9 
years). Sleep duration and birth weight were assessed both as continuous and as 
categorical variables (i.e., <6.0, 6.0–8.0, and ≥8.0 h/night for sleep duration; <4,000 
g and ≥4,000 g [i.e., high birth weight] for birth weight). In order to compare the 
differences in outcomes by severity of obesity, we analyzed our cohort using the 
following 3 BMI classes according to the WHO classification of adult obesity [24]: 
class I obesity for BMI between 30.00 and 34.99, class II for BMI between 35.00 and 
39.99, and class III for BMI ≥40.00. Crude between-group differences in categorical 
variables were tested using a χ2 test or Fisher’s exact test, and for continuous 
variables ANOVA or the Kruskal-Wallis test was used when appropriate. The Mantel-
Haenszel test for trend was performed to assess trends in prevalence numbers 
across the obesity classes. Logistic regression models and ANCOVA were used for 
between-group analyses with adjustments for sex and/or age as indicated. For all 
tests, p < 0.05 was considered statistically significant.



























































The general characteristics for the entire group and stratified by the 3 classes of 
adult obesity are provided in Table 3. About half of our cohort was classified as 
having class III obesity. No differences were found between classes with regard to 
sociodemographic factors.
Table 3: Descriptive characteristics of the study sample.
Subjects, 
n
Overall Adult obesity classesa
I (N=69) II (N=144) III (N=195)
Age, years 408 41.3 (±14.2) 39.8 (±14.5) 41.0 (±13.7) 42.1 (±14.5)
Sex, female 408 308 (76%) 48 (70%) 109 (76%) 151 (77%)


























































































Data are shown as numbers (frequency), mean (±SD), and median (10th-90th percentile). aObesity classes are classified 
as according to the WHO classification of adult obesity [24], i.e. class I for BMI between 30.00-34.99 kg/m2, class II for 
BMI between 35.00-39.99 kg/m2, and class III for adults with a BMI equal to or greater than 40.00 kg/m2. Abbreviation: 
BMI, body mass index.
Potentially Weight-Inducing Factors
Overall, 48.0% of the patients were using any potentially weight-inducing drug 
at the time of the clinic visit. Corticosteroids (local and systemic) were the most 
used weight-inducing drugs (23.8%), followed by proton pump inhibitors (11.3%), 
antihistamines (8.6%), antidepressants (8.3%), hypertension drugs (8.3%), diabetes 
drugs (5.9%), anticonvulsants (2.5%), antipsychotics (2.0%), and other drugs (0.7%) 
such as medroxyprogesterone (0.5%) and protease inhibitors (0.2%). Except for 
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proton pump inhibitors, the 3 obesity classes did not differ in use of any of the 
potentially weight-inducing drugs (Fig. 1).
The majority of the patients had no history of any thyroid disorder in combination 
with normal thyroid hormone test results (Table 4). Five hypothyroid patients 
(10.0% of the hypothyroid group) were undertreated with thyroxine analogs. A 
new diagnosis of hypothyroidism and subclinical hypothyroidism was made in, 
respectively, 2 (0.6%) and 9 (2.5%) of the screened cases. No significant differences 
were noted in prevalence rates of (subclinical) hypothyroidism between the 3 
obesity classes.
Figure 1: Current use of potentially weight-inducing drugs (Table 1) by subjects with 
obesity in the overall group and stratified by obesity class (i.e., class I, BMI = 30.00–
34.99; class II, BMI = 35.00–39.99; and class III, BMI ≥40.00).
Between-group analyses, with class I as the reference group, were performed with logistic regression 
analyses with adjustments for sex and age. * p < 0.05. HT, hypertension; PPI, proton pump inhibitor.
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Thirty female patients (9.7%) presented with PCOS at the first visit. After 
consultation, 17 (5.5%) women were additionally suspected of having PCOS. The 
diagnosis could be confirmed in 7 women, yielding a prevalence rate of PCOS in our 
female obese sample of at least 12.0% given the fact that some were evaluated 
elsewhere or decided not to undergo any further investigation at that moment 
(Fig. 2a). A higher obesity class was associated with a lower PCOS prevalence rate 
(20.8, 14.7, and 7.3% from the lowest to the highest class), but this did not reach 
statistical significance after adjustment for age.
Thirty-six male patients, aged 44.0 ± 14.7 years, had their total testosterone 
and SHBG levels measured. Non-SHBG-bound testosterone levels showed an 
incremental decrease across the obesity classes (p = 0.035, adjusted for age). 
Hypogonadism was present in 41.7% of the investigated men, with prevalences 
ranging from 20.0 (1/5) to 47.1 (8/17) and 42.9% (6/14) in the consecutive 
classes. No novel cases in endogenous Cushing’s syndrome or growth hormone 
deficiency were diagnosed. Obesity due to iatrogenic damage to the pituitary and/
or the hypothalamus was suspected in 2 patients; one of whom had developed 
hyperphagia after excision of suprasellar craniopharyngioma and the other 
of whom gained substantial weight after undergoing surgery with adjuvant 
radiotherapy for a nonfunctioning pituitary macroadenoma.




I (N=69) II (N=144) III (N=195)
Euthyroid 280 (79.1%) 43 (71.7%) 100 (82.0%) 137 (79.7%)
Hypothyroidism












































Othersc 9 (2.5%) 3 (5.0%) 3 (2.5%) 3 (1.7%)
Data are shown as number (frequency). 
a Obesity classes are classified as according to the WHO classification of adult obesity [24], i.e. class I for BMI between 
30.00-34.99 kg/m2, class II for BMI between 35.00-39.99 kg/m2, and class III for adults with a BMI equal to or greater 
than 40.00 kg/m2; 
b Includes one patient with hypothyroidism during block and replace therapy for Graves’s disease and one patient 
with untreated hypothyroidism in history with recent altered thyroid hormone tests suspected of amiodarone-
induced thyrotoxicosis; 
c Includes nine patients with no known thyroid disorder in the past, but laboratory testing showed a subclinical 
hyperthyroidism (n=2), normal TSH with lowered FT4 values (n=6), and normal TSH with increased FT4 levels (n=1).
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The age at menarche was on average 12.6 ± 1.8 years with a median (10th to 90th 
percentile) of 12.0 (11.0–15.0) years (Table 3). Precocious menarche was present 
in 2 women with class III adult obesity. No significant differences were found 
between the classes and there were no differences by nationality.
The mean birth weight was 3,402 ± 744 g in the overall group (Table 3). The 
prevalence of a high birth weight was 19.5%. No significant between-group 
difference or trend was found among the obesity classes.
The average amount of sleep in the total obese group was 7.1 ± 1.4 h/night, which 
was consistent across classes. Sleep deprivation, defined as a sleep duration of 
less than 6 h, was reported in 14.5% of the outpatients (Table 3). The diagnosis 
of OSAS was confirmed in 45 outpatients (11.0%) prior to the clinic visit. After 
examinations for suspected OSAS, there were in total 56 outpatients (13.7%) with 
confirmed OSAS, excluding those who declined further assessments or decided to 
be investigated elsewhere (Fig. 2b). With regard to the obesity classes, there was a 
significant positive trend between OSAS and obesity class (4.4, 15.3, and 15.9% in 
the consecutive classes, respectively; p = 0.027, adjusted for sex and age).
Figure 2: Prevalence rates of PCOS (a) and OSAS (b) in subjects with obesity.
The pulled slices represent the status of adult subjects with obesity suspected of having PCOS or OSAS 
after the clinic visit.
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Self-Reported Causes of Marked Weight Gain
A total of 224 (54.9%) outpatients reported having experienced at least one 
moment of marked weight gain. The most common reported trigger was the use of 
medical drugs, which occurred in 69 out of 408 (16.9%) subjects in the total study 
population. Among these patients, weight gain was most frequently preceded 
by use of corticosteroids (33.3%), followed by use of antidepressants and/or 
antipsychotics (24.6%), hormonal contraceptives (23.2%), and other drugs (18.8%). 
A health-related cause (e.g., thyroid disorder, menopause, and joint disorder) 
was the second most reported precipitating factor (52/408; 12.8%) for marked 
weight gain. Other reported main causes were psychosocial stress (30/408; 7.4%; 
e.g., relationship difficulties or divorce, death of a relative, and overall increased 
perceived stress), pregnancy-related causes (29/408; 7.1%), substance cessation 
(15/408; 3.7%; stopped smoking or taking illicit drugs), and work-related factors 
(14/408; 3.4%; e.g., change to a sedentary work style, shift work, retirement or 
cessation of work for other reasons). Sixteen patients (3.9%) reported other 
reasons such as sleep deprivation, moving out of the parental home, or in vitro 
fertilization treatment, while 34 outpatients (8.3%) were unaware of a potential 
cause. A moment of marked weight gain was most frequently reported in patients 
with class II obesity (63.9%), which was significantly higher than in those with class 
III obesity (48.2%; p = 0.003, adjusted for sex and age) but not compared to class I 
obesity (55.1%).
Genetic Analysis
A definitive genetic diagnosis could be made in 3 female patients (1.9%) with class 
III obesity and this was based on known pathogenic mutations in the MC4R (n = 2) 
and POMC (n = 1) genes (Table 5). Likely pathogenic contributing genetic variants 
were identified in 9 patients (5.6%), and another 15 patients (9.3%) were shown 
to be carriers of mutations associated with autosomal recessive diseases probably 
conferring no or only a low increased risk for obesity. Two patients were identified 
as having a mutation in one of the screened comorbidity genes (i.e., IRS1 [n = 1] 
and IRS2 [n = 1]). Mutations were found to be more present in the higher obesity 
classes; however, inferential analysis for differences between classes was not 
performed due to low numbers.
41
2





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Extensive Phenotyping for Potential Weight-Inducing Factors in an Outpatient Population With Obesity
Discussion
In the present study, we extensively phenotyped subjects with obesity for various 
factors potentially contributing to obesity, including genetic predispositions, and 
assessed self-reported causes of marked weight gain. Interestingly, we found 
that about half of the obese subjects were using one or more prescribed drugs 
associated with weight gain. The use of corticosteroids was particularly high in our 
sample, which was especially remarkable since drug use, in general, was reported 
as the most common triggering factor for marked weight increase. In this light, it 
is interesting to mention that we recently found strong associations between local 
corticosteroids (e.g., inhaled or nasal) and an increased BMI in a large population-
based study [25].
Obesity is frequently associated with the onset or exacerbation of different 
comorbidities which often require a pharmacological intervention, such as 
hypertension, type 2 diabetes mellitus, gastroesophageal reflux disease, asthma, 
and depression. Unfortunately, some of these drugs may induce weight gain 
or complicate the process of weight loss. Interestingly, drug use was the most 
self-reported triggering factor for marked weight gain in our study population. 
Highest user rates were mainly found for corticosteroids, and we previously 
reported evident differences in recent use of these between obese and nonobese 
subjects [26]. It was notable that, besides corticosteroids and psychotropic drugs, 
also hormonal contraceptives were frequently suggested as a trigger for marked 
weight gain in women. However, a Cochrane review by Gallo et al. [22] could not 
establish a causal relationship between the popular combination contraceptives 
and weight gain. Unfortunately, the type of hormonal contraceptive used during 
periods of marked weight gain in our female users was largely unknown.
First-line assessment of obesity generally includes investigation of the more 
generally known weight-inducing disorders which are mainly of hormonal origin. 
This could explain why we only found few new cases of hypothyroidism and PCOS 
and none for Cushing’s syndrome and growth hormone deficiency. With regard to 
the thyroid functioning, the prevalence rate of hypothyroidism was much higher 
compared to the rate in the general population [27, 28]. This may have attributed to 
weight gain over time and could perhaps still be a contributing factor in 10% of 
our hypothyroid patients who are (biochemically) undertreated [29]. Moreover, we 
found a high prevalence of PCOS as compared to previous findings in unselected 
populations [30, 31]. In men, we found a high percentage of new hypogonadism cases. 
The reverse causality between hypogonadism and obesity in men in combination 
with the lack of data on clinically related signs and symptoms complicates 
the contributing role of low testosterone with regard to obesity in our male 
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outpatients. Nevertheless, testosterone suppletion in obese hypogonadal men 
seems to be effective with regard to sustained weight loss in the long term [32] 
while, importantly, weight loss by itself can also increase testosterone levels [33].
With regard to menarche, we found a relatively younger median age of onset 
in comparison to the general Dutch female population (12.0 vs. 13.1 years) [34]; 
however, the reason for this difference is not necessarily clear. The direct link 
between age at menarche and adulthood obesity seems less evident and both 
are considered to be subsequent to a high childhood BMI and/or increased sexual 
maturation due to other factors [3], while a low socioeconomic status has also been 
suggested to give rise to both menarche at a young age and obesity in adult life [35].
A high weight at birth, which appears to have a differentiating capacity with regard 
to weight and BMI in adulthood, was 2-fold more common in our cohort when 
compared to the general population [36, 37]. Various studies have shown that adults 
but also children with a high birth weight have more adverse anthropometric 
and body compositional features in comparison to normal birth weight subjects, 
whereas no differences have been found for subjects with a low birth weight [5, 37]. 
Similar findings were also found in a comprehensive meta-analysis which showed a 
positive association between a high birth weight and adult obesity [4].
We found a relatively higher percentage of subjects with a self-reported sleep 
duration of less than 6 h/night when compared to numbers from the general 
population [8, 38]. In spite of differences in sleep requirement, such a short sleep 
duration is in general associated with a higher body weight and obesity [39]. In 
addition to the longer time awake increasing the opportunity for food consumption, 
it has been found that sleep deprivation can lead to derangement of appetite-
regulating hormones (e.g., leptin, ghrelin, and cortisol) which can result in a greater 
appetite and a more energy-dense food intake [9, 40]. The interplay between sleep 
deprivation, OSAS, and obesity [41] further supports the importance of sufficient 
sleep for a healthy body weight.
Genetic analysis is relatively new in the diagnostic workup of non-syndromic 
obesity. We here identified a definite genetic cause for the obesity phenotype in 3 
patients. The identified underlying molecular defects (MC4R and POMC mutations) 
could offer (future) personalized treatment programs for these patients [42, 43]. 
One could also hypothesize that certain mutations could possibly indicate a 
contraindication for certain obesity treatment options in cases with a negative 
response to treatment. For patients themselves, it is often a psychological burden 
to be blamed by society for not being able to lose weight. In our clinical experience, 
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a genetic diagnosis could perhaps aid in understanding and accepting why they 
show a different treatment response when compared to others and thereby 
increase the social support and decrease stigmatization. Our results, however, 
showed that the majority of the patients who received an abnormal result were 
carriers of a variant of unknown significance that could possibly contribute to the 
obesity phenotype. An individual combination of different variants of unknown 
significance (polygenic inheritance), each having a small effect on weight gain, 
might well add up to a larger obesity risk for such a person. Besides, most of 
these comprised the BBS gene mutations for which heterozygosity has been 
postulated as a risk factor in obesity [44]. Frequency analysis in an obesity cohort 
and segregation analysis in family members showed, however, that BBS carriage is 
probably not an important risk factor for obesity [45]. Future studies are needed to 
assess the clinical significance and confirm a possible association between obesity 
and the uncertain variants we identified here.
In the current study, we comprehensively and systematically evaluated various 
medical conditions as well as lifestyle, iatrogenic, and genetic factors related to 
weight gain in a single study population of subjects with obesity. Despite the 
distribution of the patients over all obesity classes, it is conceivable that our 
patients are more prone to underlying disorders in comparison to the general 
obese population given the setting of our clinic as an obesity expertise center. 
Unfortunately we did not have a control cohort and hence used literature based 
on general population data for comparison. Additionally, some of the data are 
self-reported and could hence be subject to recall bias. Furthermore, it should be 
emphasized that the number of genetic variations found may be underestimated 
since it does not include other genetic (syndromic) causes, chromosomal 
abnormalities (e.g., Turner syndrome), genomic microdeletions and duplications 
(e.g., 16p11.2 deletion syndrome), methylation abnormalities (e.g., Prader-Willi 
syndrome), uniparental disomy (e.g., UPD14), or triplet repeat expansions (e.g., 
fragile X syndrome) associated with obesity, as these are not detectable by the 
applied method. However, during our clinical assessment and physical examination 
we observed no signs or symptoms of these syndromes in this group of patients 
with obesity.
Conclusion
In conclusion, a thorough evaluation of potential weight-inducing factors in 
subjects with obesity showed especially a high prevalence of use of weight-
inducing drugs and hormonal abnormalities, with virtually no differences across 
the distinct degrees of obesity. Drug use was additionally reported to be the 
most frequent trigger for marked weight gain, with corticosteroids being the 
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most prevalent culprit. Although we could only confirm a definite genetic obesity 
diagnosis in 2% of the patients who were offered a genetic test, a personalized 
treatment option can (perhaps) be offered in a future clinical trial setting. This 
exemplifies the importance of genetic analysis in the diagnostic workup of obesity 
in specific patient groups (e.g., patients with symptoms suggesting monogenetic 
or syndromal obesity). Future large prospective cohort studies should focus on 
the factors as assessed here but also on others that could contribute to adiposity 
or impede weight loss (e.g., brown fat activity, endocrine disruptors, ambient 
temperature, and maternal age [2, 46]). This in order to better understand the 
bidirectional relationship between most of the obesogenic factors and adiposity 
and to eventually decrease the social stigma surrounding obesity and optimize and 
develop more efficient and tailored weight loss interventions.
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Background: Although the use of corticosteroids has been linked to high incidence 
of weight gain, no data are available concerning the differences in corticosteroid use 
between a diverse obese population and non-obese individuals. The main purpose of 
this study was to systematically explore the use of corticosteroids in obese subjects 
compared to non-obese controls. In addition, we also explored self-reported marked 
weight gain within obese subjects. 
Methods: Two hundred seventy-four obese outpatients (median [range] BMI: 
40.1 kg/m2 [30.5-67.0]), and 526 non-obese controls (BMI: 24.1 kg/m2 [18.6-29.9]) 
from two different Dutch cohort studies were included. Corticosteroid use at the 
time of clinic or research site visit for up to the preceding three months was recorded 
in detail. Medical records and clinical data were evaluated with regard to age and 
body mass index in relation to corticosteroid use, single or multiple type use, and 
administration forms. 
Results: Recent corticosteroid use was nearly twice as high for obese subjects 
than for non-obese controls (27.0% vs. 11.9% and 14.8%, both P<.001). Largest 
differences were found for use of local corticosteroids, in particular inhaled forms, 
and simultaneous use of multiple types. Marked weight gain was self-reported during 
corticosteroid use in 10.5% of the obese users. 
Conclusion: Corticosteroid use, especially the inhaled agents, is higher in obese than 
in non-obese individuals. Considering the potential systemic effects of also local 
corticosteroids, caution is warranted on the increasing use in the general population 
and on its associations with weight gain 
Conclusions: A thorough evaluation of patients with obesity yields a relatively high 
prevalence of various potentially weight-inducing factors. Diagnostic screening of 
patients with obesity could therefore benefit these patients by potentially reducing 
the social stigma and improving the outcomes of obesity treatment programs by 
tackling, where possible, the weight-inducing factors in advance.
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Introduction
Synthetic corticosteroids are invaluable in the treatment of a wide range of somatic 
disorders and have shown their value in many physically demanding conditions. 
Their different administration routes (e.g. topical, inhaled, nasal, ocular, intra-
articular, oral, intra-venous) encourage the use of these medications in both local 
and systemic disorders in which their mitigating effect on inflammation and the 
immune system is desired. The widespread use of corticosteroids becomes obvious 
in national surveys since it is prescribed at least 5.8 million times annually in the 
17 million-strong Dutch population [1], whereas in the United States prescription 
numbers reach over 40 million [2]. These numbers may even underestimate the 
total use when taking into account over the counter sale of corticosteroids and the 
use in alternative medicine, since some of the non-registered herbal creams have 
been found to contain potent corticosteroids [3, 4]. In regard to oral corticosteroids, 
its use substantially increased with thirty percent over the past two decades, 
with a prevalence of current use around 1% of the population [5-7]. For inhaled 
corticosteroids, the percentage of users even doubled between 1990 and 1997 in 
both the United Kingdom and the Netherlands [8].
In addition to their therapeutic effects, corticosteroids are well known to induce a 
variety of adverse effects affecting virtually all body systems [9, 10]. Corticosteroid 
users often experience endocrine and metabolic changes, in particular an increase 
in weight [11]. This is not surprising, since it is known that high cortisol levels can 
lead to increased appetite, (truncal) fat accumulation, and altered lipid and glucose 
metabolism [12-14]. Prolonged use, especially of oral corticosteroids, is notorious for 
inducing hypercortisolism related side effects and is archetypal for exogenous 
Cushing’s syndrome [15]. However, those systemic side effects are not confined to 
systemic use, but were also found in local use of corticosteroids. In a recent meta-
analysis Broersen et al. investigated different characteristics of corticosteroid use 
and their effects on adrenal suppression. They found that use of nearly all forms 
of corticosteroids resulted in an increased risk of adrenal insufficiency [16]. The 
highest numbers were found for intra-articular injections and oral use (absolute 
risk of 52.2% and 48.7%, respectively), while similar numbers were also found in 
patients using multiple administration forms, including combinations of only local 
corticosteroids. These results indirectly indicate that also local agents result in high 
systemic corticosteroid exposure and a subsequent suppression of the adrenal 
gland function due to negative feedback mechanisms, irrespective of the route of 




Although various studies have shown an increasing effect of corticosteroids on 
body mass index (BMI), it still remains unknown whether there is a difference in 
overall corticosteroid use or in use of particular administration forms between 
obese and non-obese in the general population. Based on the results of the above-
mentioned meta-analysis [16] and given the fact that weight gain is one of the most 
common undesirable effects of corticosteroid use, we hypothesized an overall 
higher user rate in obese subjects. Hence, in the present study we systematically 
investigated the use of corticosteroids in an obese outpatient population in 
comparison to two independent non-obese control cohorts. Moreover, in the same 
obese population, we also specifically examined if marked weight gain could be 
correlated to corticosteroid use.
Subjects and Methods
Obese subjects
Two hundred eighty-two obese patients visiting the Obesity Center CGG of the 
Erasmus Medical Center (Rotterdam, The Netherlands) between June 2011 and 
September 2015 were initially included. Before visiting the outpatient clinic, which 
is a multidisciplinary referral center for diagnostic testing and tailored treatment 
of obesity, all patients were requested to complete an extensive questionnaire 
regarding factors related to their overweight. With this questionnaire, we obtained 
data on self-reported marked weight gain, including questions about whether the 
patient recalled a time period where they experienced a marked increase in weight, 
and if so, if they suspected any triggering factor for that. The questionnaire also 
included questions concerning current and previous medication use, including 
specific questions about the use of corticosteroids. Recent corticosteroid use was 
defined as use at the time of  visit and/or in the preceding three months  and was 
categorized as local (topical, inhaled, nasal, ocular, intra-articular) or systemic (oral/
intra-venous) use and as single or multiple type (i.e., combinations of different 
administration routes) use. All completed questionnaires were scrutinized by 
experienced physicians and discussed with the patient at the clinic visit in order 
to avoid incomplete information or misinterpretation of the questions. These 
questionnaires and electronic medical records, including records of the visit, were 
also used to assess weight and height. BMI was computed by dividing weight 
(kg) by height squared (m2). Patients in whom the time of corticosteroid use was 
unknown (N=8) were excluded from the analyses. Ethical approval was obtained 
for the present study.
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Non-obese controls
In order to assess the use of corticosteroids in non-obese subjects, we included 
participants of two different Dutch cohort studies: the Lifelines and the 
Netherlands Study of Depression and Anxiety (NESDA) cohort.
The Lifelines cohort is a large population-based cohort study from the Northern 
Netherlands (www.lifelines.nl) [17]. Participants are observed over an extended 
period of time and are subjected to multiple moments of data and sample 
collection. One of the collection procedures requires the patients to complete a 
questionnaire about corticosteroid use in the past three months. For this study, we 
included a sample of 295 participants who had completed this self-report research 
questionnaire. In these persons, we assessed the same anthropometric features 
and corticosteroid-related characteristics  (yes/no  current corticosteroid use, 
types of administration forms, and single or multiple type use) as in the obese 
outpatients.
The other control cohort was recruited from NESDA, a large ongoing longitudinal 
cohort study among adult participants with a current or past psychopathological 
diagnosis together with healthy controls with no previous psychiatric diseases [18]. 
Here, we evaluated the clinical data and questionnaires of 355 psychiatrically 
healthy controls in whom the same research questionnaire as in the Lifelines cohort 
was collected [19]. In order to minimize recall bias with regard to corticosteroid use, 
we assessed both completed questionnaires and minutely detailed information 
about medication use that was checked during each visit at the research site. 
For comparative analyses, we excluded participants with underweight (BMI<18.50) 
or obesity (BMI ≥30.00) from both Lifelines (control group I) and NESDA (control 
group II) cohorts, which resulted in the exclusion of respectively 60 (20.3%) and 61 
(17.2%) subjects. From the latter group, also three healthy controls were excluded 
because of inconclusive data on corticosteroid use. Subsequently, a total number 
of 526 non-obese controls (control group I, N=235; control group II, N=291) were 
enrolled in this study. In order to investigate if there was a relationship between 
corticosteroid use and age and whether the numbers of recent users between 
obese and non-obese subjects differed with age, we analyzed the differences 
between both groups in weighted age-tertiles. This resulted in the classification 





Statistical analysis was performed with IBM SPPS Statistics version 21 (IBM 
Corp., Armonk, NY) and GraphPad Prism version 5.01 (GraphPad Software Inc., La 
Jolla, CA) for Windows. Differences in demographic and clinical characteristics 
were analyzed using Chi-square tests and ANOVA’s, when appropriate. Trend 
analysis for corticosteroid use in relation to age-tertiles was performed with the 
Cochran-Armitage test for trend. Logistic regression analyses were conducted 
for comparative analyses between the obese and the control groups and were 
adjusted for age and sex as indicated. P-values below 0.05 were considered to 
indicate statistical significance for all analyses.
Results
Baseline characteristics
The demographic and clinical characteristics of the three groups are summarized 
in Table 1. The average BMI in the obese group was 40.7±6.3 kg/m2 versus 24.7±2.6 
(control group I, P<.001) and 24.0±2.8 kg/m2 (control group II, P<.001) in the non-
obese cohorts. All groups consisted primarily of women, with percentages ranging 
from 64.9% (control group II) up to 75.2% (obese group). Obese participants were 
on average younger compared to control group II (41.5±14.3 vs. 46.7±14.9 years, 
P<.001) but were not different in age compared to control group I.
Corticosteroid use obese versus non-obese
In the obese group, 55.8% of all patients reported having used any form of 
corticosteroids at any time point. Among the obese subjects, 74/274 (27.0%) 
subjects were currently using or had used corticosteroids in the past three months. 
Among the recent users, the inhaled and nasal agents were most commonly used 
(Table 2). Asthma, hay fever/rhino(-sinusitis), and psoriasis were the main known 
indications for corticosteroid use (25.7%, 8.9%, and 7.9%; Table 3). Recent use of 
corticosteroids in the obese group was significantly higher compared to non-obese 
Table 1: Demographic and clinical characteristics of study participants.
Obese Non-obese
Control group I Pdiff Control group II Pdiff












Age, years 41.5 (14.3) 42.0 (11.7) .662 46.7 (14.9) <.001
BMI, kg/m2 40.7 (6.3) 24.7 (2.6) <.001 24.0 (2.8) <.001
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from both control cohorts (11.9%, P<.001 [control group I] and 14.8%, P<.001 
[control group II]; Figure 1).














































Systemic (oral/i.v.) 7 (2.6%) 2 (0.9%) .180 8 (2.7%) .631
Multiple types 17 (6.2%) 4 (1.7%) .015 7 (2.4%) .038
Values are presented as number (percentage). Differences in use of each corticosteroid administration form between 
obese patients and the control groups were analyzed separately using logistic regression analyses adjusted for sex 
and age. Abbreviation: i.v., intra-venous.
Table 3: Indications for recent corticosteroid use in the obese group.
Corticosteroid prescriptions  (N=101)
Asthma, n (%) 26 (25.7)
Hay fever/rhino(-sinusitis), n (%) 9 (8.9)
Psoriasis, n (%) 8 (7.9)
Eczema, n (%) 7 (6.9)
COPD, n (%) 6 (5.9)
Nasal congestion, n (%) 3 (3.0)
Ocular diseases*, n (%) 3 (3.0)
Auto-immune diseases†, n (%) 2 (2.0)
Others‡, n (%) 12 (11.9)
Unknown, n (%) 25 (24.8)
Values are presented as number (percentage). *Includes iridocyclitis, scleritis, and uveitis; †Includes cerebral 
vasculitis and Crohn’s disease; ‡Includes among others alopecia areata, nasal polyps, panhypopituitarism, and renal 
transplantation.
Dividing the control groups into two weight classes, i.e. “normal weight” (BMI 
18.50–24.99) and “overweight” (BMI 25.00-29.99), and comparing these to the 
obese subjects still resulted in significant differences regarding the recent use 
of corticosteroids. Largest differences were observed between normal weight 
controls from both cohorts and the obese subjects (P<.001 [control group I] and 
P=.001 [control group II]; Figure 1).
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Figure 1: Recent corticosteroid use in obese and non-obese subjects.
Analyses between the obese group and the non-obese control groups as a whole (black bars), or 
stratified for two weight classes (light gray = normal weight, dark gray = overweight) are controlled for 
sex and age. All asterisks depict P-values for the comparisons with the obese group. **P<.01, ***P<.001.
Figure 2: Relation between different age groups and use of corticosteroids.
The three age groups represent weighted age-tertiles of obese and the combined non-obese 
participants from both control groups. Logistic regression analyses between obese and non-obese age 
groups are adjusted for sex. *P<.05, **P<.01. Abbreviations: OB, obese; NO, non-obese.
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With regard to age-tertiles, we found significantly higher corticosteroid use in 
obese subjects for each age group with the smallest difference in the oldest tertile 
(mean difference per tertile: 14.3%, P=.005 [first tertile], 15.5%, P=.001 [second 
tertile], and 11.4%, P=.039 [third tertile];  Figure 2). Separate trend analyses showed 
a significant trend in the non-obese group (χ2=4.520, P=.034) and no significance in 
the obese (χ2=0.679, P=.410).
Administration routes of corticosteroids
In the obese group, the use of local corticosteroids was significantly higher 
compared to both non-obese controls (25.5% vs. 11.5% [control group I] and 
13.1% [control group II], both P<.001; Table 2). In addition, stratification for the 
different administration routes revealed significantly higher rates for inhaled 
corticosteroids in the obese subjects. There were, however, no differences in use 
of the other local corticosteroids or the systemic administration forms.
Use of multiple types of corticosteroids was present in 17 obese patients (6.2%). 
This was significantly higher than in the control groups I (1.7%, P=.015) and II 
(2.4%, P=.038). The majority of the multiple type users of both the obese and the 
non-obese groups were using at least one inhaled corticosteroid (88% and 73%, 
respectively). The combination of inhaled corticosteroids with at least one topical 
corticosteroid was most common in the obese group (47%), whereas in the non-
obese controls inhaled forms were frequently combined with nasal corticosteroids 
(55%; Table 4). 
Table 4: Combination of corticosteroids in users of multiple types of corticosteroids.
Obese (N=17) Non-obese (N=11)
Inhaled with topical, n (%) 5 (29) 1 (9)
Inhaled with nasal, n (%) 5 (29) 4 (36)
Inhaled with topical and nasal, n (%) 2 (12) 0 (0)
Inhaled with nasal and oral, n (%) 1 (6) 2 (18)
Topical with nasal, n (%) 0 (0) 2 (18)
Others, n (%) 4 (24) 2 (18)
Values are presented as number (percentage) within the group of multiple types users for the obese group and 




Of the obese subjects who reported recent or ever use of corticosteroids, 10.5% 
considered the use of corticosteroids as the underlying cause of a period of marked 
weight gain. The oral administration form was reported most frequently (12/16 
subjects) as the triggering factor, followed by two patients who had previously 
received corticosteroid injections. Majority of the patients from the former 
administration form (67%) had used or were currently using prednisone for over 
3 months continuously, two subjects had been prescribed prednisone for a short-
term period (<3 months) and two patients had used it for an unknown duration.
Discussion
To the best of our knowledge, this is the first study to systematically examine 
corticosteroid use in a diverse sample of obese and non-obese individuals. 
Here, we have shown that the use of corticosteroids was significantly higher in 
obese outpatients when compared to non-obese subjects from two separate 
control groups. This finding was consistent across all age groups but became less 
evident in the oldest group. Higher rates of use were primarily found for the local 
corticosteroids, in particular for the inhaled administration forms. In addition, 
we also found that a significantly higher percentage of the obese individuals 
were simultaneously using multiple corticosteroid types in comparison to non-
obese subjects. However, no differences were observed with respect to oral 
corticosteroid use.
Cushing’s syndrome is most commonly induced by exogenous corticosteroid 
administration, typically attributed to (long-term) systemic corticosteroid use, 
and is frequently accompanied by weight gain [20, 21]. However, the increased risk of 
occurrence of adrenal insufficiency even with local administration forms [16] shows 
the importance of surveillance for systemic effects of all administration types. We 
found that more than half of our obese sample have used corticosteroids at any 
point in time and that their recent use more often involves multiple administration 
routes, with the latter been strongly linked to supraphysiological systemic levels 
of glucocorticoids (based on high absolute risk of adrenal insufficiency) [16]. These 
findings tend to support our hypothesis that local corticosteroid forms, as being the 
most common prescribed agents in our obese group, could eventually contribute 
to amongst others a higher weight and/or a more laborious weight loss. But given 
the nature of this study, it is not possible to demonstrate temporality and to infer 
a causal relationship between corticosteroid use and obesity.
Regardless of the fact that in this study we did not assess the effect of 
corticosteroids on weight gain, physicians should be vigilant for corticosteroid-
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induced side effects in all patients gaining weight in a short period of time since 
approximately 10% of the marked weight gain in the ever corticosteroid users 
seemed to be preceded by corticosteroid use. In concordance with previous 
reports by Berthon et al, who showed that weight gain as a result of oral 
corticosteroids is unlikely in short-term users (<3 months) in contrast to long term 
users (≥3 months) [22, 23], majority of our corticosteroid induced marked weight 
gainers reported to have used corticosteroids for at least couple of months to 
several years. The cumulative exposure to corticosteroids seems therefore to be 
an essential factor in inducing weight changes. Since inhaled corticosteroids are 
generally prescribed for chronic conditions, and multiple type use most often 
includes inhaled agents, it is reasonable to hypothesize that these forms more 
gradually contribute to weight gain. The increasing prevalence of obesity [24] as 
well as increased corticosteroid use in the past decades [5, 8] additionally nourish 
the idea that corticosteroid use could be a substantial contributing factor for 
overall weight gain in the Western world. This is especially important given the 
fact that corticosteroids not only promote the accumulation of abdominal fat but 
also stimulate the appetite for high calorie “comfort” foods [12].
However, the cause-and-effect relationship between corticosteroid use and obesity 
seems to be bidirectional. Besides the well-known cardiometabolic diseases such 
as diabetes mellitus, dyslipidemia, and atherosclerosis, obesity has been linked 
to low-grade inflammation and various immune-mediated conditions [25, 26]. In the 
present study, we found that obese patients are using inhaled corticosteroids 
more frequently, which are mainly prescribed for asthma and chronic obstructive 
pulmonary disease (COPD). This is in line with literature where both conditions 
have been linked to higher BMI [27-29]. Interestingly, in a study with asthmatic obese 
patients, Van Huisstede et al. showed that weight loss after bariatric surgery 
was associated with improved asthma control and lower systemic inflammation 
markers [30]. Similar results were found in other studies in which weight loss 
was associated with less asthmatic symptoms and increased lung function [31, 32]. 
In addition, weight loss and lower BMI have also been associated with reduced 
disease severity or better therapeutic response in other immune-related disorders 
including psoriasis [33, 34], rheumatoid
arthritis [35, 36], and ankylosing spondylitis [37, 38]. This emphasizes the mentioned 
relationship between obesity and inflammation and could be an alternative reason 
for high corticosteroid use in our obese sample. Another plausible explanation 
would be that there is not a causal link between these parameters but that other 
factors, such as a low social-economic status and a pro-inflammatory genetic 
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profile, lead to both obesity and more inflammation subsequently requiring the 
use of corticosteroids.
Nevertheless, it still remains disputable which of the two directions, i.e. 
corticosteroid use preceding obesity or vice versa, prevails in clinical practice. 
Patients with COPD, for instance, commonly present with overweight or obesity [39]. 
Since corticosteroids are an important part of the medical treatment of COPD, it 
could be proposed that the overall high BMI in these patients is partly the result of 
corticosteroid use. Aside from the reverse causality between these characteristics, 
it would be advisable to screen all obese patients for corticosteroid use. In the case 
of corticosteroid use, one should reconsider if the use is still necessary and if so, 
whether an alternative treatment is available. The importance of this can be derived 
from a previous study in asthmatic obese patients for whom the diagnosis could 
not be confirmed in 41% of the cases after extensive pulmonary testing, although 
23% of these patients were still currently using inhaled corticosteroids [40]. In these 
cases, ceasing of corticosteroids under medical supervision could potentially help 
in losing weight more easily. Otherwise, patients may succumb to a vicious cycle of 
weight gain, obesity-related comorbidities, and further corticosteroid need.
One of the strengths of the present study is the use of two different non-obese 
control groups and the fact that both the study group and the control groups 
are from the same country. Moreover, the same detailed questionnaire on 
corticosteroid use was administered in both non-obese cohorts.
An important study limitation worth noting is that information about the dose 
and duration of corticosteroid use was incomplete and hence not used in this 
study. Both components are known to play an important role in the accumulative 
exposure and induction of side effects in corticosteroid users [41]. Nevertheless, 
medical conditions requiring corticosteroids are most often of a chronic nature 
and demand corticosteroid use for a longer period of time or at least with frequent 
intervals. Moreover, various studies have shown that weight gain can also occur in 
response to relatively low doses of corticosteroids. In a study of more than two 
thousand long-term corticosteroid users, Curtis et al. have found that weight 
gain manifested in 70% of the low-dose systemic users and was indeed the most 
prevalent self-reported adverse event [11].
In conclusion, corticosteroid use is high in obese individuals who have been 
referred due to their obesity and common across all ages. High user rates were 
especially prevalent for inhaled corticosteroids and the simultaneous use of 
different administration forms. This warrants stricter monitoring of corticosteroid 
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use in obese as these medications can potentially induce weight gain and maintain 
excess weight. However, large longitudinal prospective cohort studies are needed 
to specifically determine the individual effect of the different corticosteroid 
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Context: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic 
alterations, potentially leading to obesity and metabolic syndrome (MetS). Although 
evidence is accumulating that local CSs have considerable systemic effects, their 
effects on cardiometabolic factors in the general population remain unclear. 
Objective: To investigate the association between overall CS use and specific CS 
types with MetS, body mass index (BMI), and other cardiometabolic traits. 
Design: Cross-sectional cohort study. 
Setting: General population from the northern Netherlands. 
Participants: A total of 140,879 adult participants in the population-based Lifelines 
Cohort Study. 
Main Outcome Measures: BMI, waist circumference, systolic and diastolic blood 
pressure, fasting metabolic serum parameters, and a comprehensive set of potential 
confounding factors. 
Results: In women, overall, systemic, and local CS use was associated with higher 
odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% 
confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 
1.49)] users were more likely to have MetS. In men, no association was found between 
overall and specific CS use and presence of MetS. Use of local-only CSs in women, 
specifically inhaled CSs in both sexes, was associated with higher BMI.
Conclusions: Use of local CSs, particularly inhaled types, as well as systemic CSs, 
was associated with higher likelihood of having MetS, higher BMI, and other adverse 
cardiometabolic traits, especially among women. Because the inhaled agents are the 
main group of prescribed CSs, this might be a substantial risk to public health in case 
of a yet-to-be-proven causal relationship.
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Introduction
Synthetic glucocorticoids, also known as corticosteroids (CSs), are widely used 
potent anti-inflammatory drugs with multiple indications and many administration 
forms used for both systemic and local disorders (1). Due to the increased 
prevalence of diseases frequently requiring CS therapy, prescriptions of CSs have 
increased markedly in the last decades (2, 3). There are increasing concerns that use 
of systemic administration forms can lead to supraphysiological glucocorticoid 
exposure and induce adverse cardiometabolic changes such as obesity, diabetes, 
dyslipidemia, and hypertension, all of which are components of the metabolic 
syndrome (MetS) (4, 5). The relationship between high glucocorticoid exposure and 
induction of various cardiometabolic alterations has been consistently reported in 
patients with Cushing syndrome who frequently develop these adverse metabolic 
changes during the course of the disease (6). Because of these known adverse 
events, systemic CS users are generally well-monitored after starting treatment (5), 
in contrast to users of the various local administration forms in whom systemic 
absorption is usually less expected. However, a recent meta-analysis suggests 
that local CSs may also be associated with an increased systemic glucocorticoid 
exposure exemplified by the increased risk of adrenal insufficiency in users of local 
types (7). Because many of the CS users are often prescribed a local administration 
form, it could be hypothesized that use of local CSs is a contributing factor to MetS 
and obesity in the general population. Nevertheless, most studies on this topic 
have been focused on systemic CS therapies (4), and evidence regarding the effect 
of local CS use on MetS and its components in the general population is scarce. 
Hence, we assessed the associations between overall CS use and specific CS types 
with MetS, body mass index (BMI), and other cardiometabolic risk factors in a large 
population-based cohort study.
Methods
Study design and population
Lifelines is a multidisciplinary, prospective, population-based cohort study 
examining, in a unique three-generation design, the health and health-related 
behaviors of 167,729 persons living in the northern Netherlands (8). It employs 
a broad range of investigative procedures in assessing the biomedical, socio-
demographic, behavioral, physical, and psychological factors that contribute 
to the health and disease of the general population, with a special focus on 
multimorbidity and complex genetics. For this study, we included baseline 
information on 152,180 adult participants. Subjects with incomplete report on 
drug use, nonfasting laboratory blood values, or missing information on any of 
the MetS components or BMI were excluded from the analyses, which resulted 
in a total study sample size of 140,879 participants. Informed consent and ethical 
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approval of the study protocol were obtained according to the principles of the 
Declaration of Helsinki and in accordance with the research code of the University 
Medical Center Groningen.
Assessment of drug use
Drug use was evaluated with a self-reported questionnaire and a visual drug 
container inspection. All prescribed drugs were coded according to the World 
Health Organization Anatomical Therapeutic Chemical (ATC) classification system. 
Concurring with the ATC methodology, we classified CSs into the following 
categories of administration forms: systemic (i.e., oral and parenteral, including 
intra-articular injections), topical (i.e., dermatological), nasal, inhaled, otological, 
ocular, intestinal, local oral, hemorrhoidal, and gynecological forms. The last three 
forms were combined as “other CSs” due to their low prescription numbers. For 
assessment of the presence of MetS and its components, we assessed the use of 
antihypertensives, blood glucose–lowering drugs, and lipid-modifying drugs. We 
also determined the use of hormonal replacement therapy in women and the use of 
other exogenous sex hormones and potentially weight-inducing psychotropics (9, 10) 
in all subjects to adjust for their potential metabolic alterations (see Supplemental 
Table 1 for further details).
Measures of MetS risk factors
All measurements were done consistently following standardized operating 
protocols by trained technicians. Body weight (in kg) and height (in cm) were 
measured without shoes and accurately to the nearest half unit. BMI was calculated 
by dividing body weight by height in meters squared. Waist circumference (WC) 
was measured in an upright position and in the middle between the front edge 
of the lower ribs and the iliac crest. Blood pressure was measured 10 times with 
a 1-minute interval with an automatic blood pressure monitor (DinaMap Monitor; 
GE Health Care, Freiburg, Germany) and proper-sized cuff. The last two successive 
measurements most representative of resting blood pressure were used to 
calculate mean systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
Blood samples were taken in the morning after an overnight fast and were processed 
for measurements on the same day. Measurements for triglycerides, high-density 
lipoprotein (HDL)-cholesterol, and glucose were performed on a Roche Modular 
P chemistry analyzer (Roche, Basel, Switzerland) by using enzymatic colorimetric 
and hexokinase methods. Data on BMI, WC, SBP, DBP, and fasting serum levels of 
triglycerides, HDL-cholesterol, and glucose were complete  for all subjects.
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Assessment of MetS
MetS was defined according to the joint interim statement criteria (11). The diagnosis 
could be established if at least three of the following components were present: 
(1) WC ≥88 cm in women and ≥102 cm in men; (2) SBP ≥130 mm Hg, DBP ≥85 mm 
Hg, and/or use of antihypertensives in patients with known hypertension; (3) 
triglycerides ≥1.7 mmol/L and/or use of lipid-modifying drugs; (4) HDL-cholesterol 
<1.3 mmol/L in women and <1.0 mmol/L in men and/or use of lipid-modifying 
drugs; and (5) fasting serum glucose ≥5.6 mmol/L and/or use of blood glucose–
lowering drugs.
Assessment of covariates
To adjust for factors that might influence the outcome of the analyses, we 
assessed data for various potential covariates. Ethnicity was grouped into two 
categories (i.e., Dutch natives and others) and was based on the reported country 
of birth of both parents. Education was based on the highest completed level and 
was classified as no education, primary education, lower or preparatory vocational 
education, lower general secondary education, intermediate vocational education 
or apprenticeship, higher general secondary education or preuniversity secondary 
education, higher vocational education, university, and others. Smoking was 
categorized under the following three statuses: nonsmokers (i.e., not smoked in 
the past month and never smoked for a full year), former smokers (i.e., stopped 
smoking, had not smoked in the past month but had smoked for a full year or more 
in the past), and current smokers (i.e., currently smoking or smoked in the past 
month). Alcohol use was based on self-reported drinking frequency of alcoholic 
beverages in the past month and the average amount per drinking day and was 
computed into categories of nonusers and users of up to one drink per day, one to 
two drinks per day, or more than two drinks per day. Physical activity was assessed 
by the reported average days per week of at least half an hour of doing odd jobs, 
gardening, bicycling, or exercises combined and classified into three categories: 
inactives (0 days per week), semiactives (1 to 4 days per week), and norm-actives 
(≥5 days per week). In women, we additionally assessed their menstrual status 
(yes/no currently menstruating) at the moment of inclusion.
Diabetes mellitus was defined according the definition of World Health 
Organization/International Diabetes Federation (12) and was deemed present in 
case of fasting serum glucose level ≥7.0 mmol/L and/or use of blood glucose–
lowering drugs. Corresponding to the report of the Seventh Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (13), hypertension was defined as SBP ≥140 mm Hg, DBP ≥90 mm Hg, 
and/or use of antihypertensives. Cardiovascular diseases were assessed by self-
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reported health questionnaire items and were defined as a history of stroke and/
or coronary heart disease(s) (i.e., myocardial infarction, balloon angioplasty, and/
or bypass surgery in the past). The other weight-related comorbidities [i.e., cancer, 
osteoarthritis, chronic obstructive pulmonary disease (COPD), and asthma] were 
all deemed present if the subject had indicated to be known with the diagnosis 
and, in the case of asthma, the diagnosis was confirmed by a doctor.
Statistical analysis
Crude differences in continuous variables were assessed with analysis of variance 
and in categorical variables with χ2 tests. Triglyceride levels were positively skewed 
and were therefore log10-transformed to achieve normal distribution. Initial 
inferential analyses showed strong interaction effect (Pint <0.001) for sex; hence 
we decided to stratify all analyses for women and men. We used multivariable 
logistic regression models to assess the relation of overall and specific CS use 
with the presence of MetS. Considering the multiple potential combinations of 
the five components required for the diagnosis, we also analyzed the association 
of CS use with each component separately and with all possible combinations. CS 
users were analyzed (1) by combining all types of CSs and (2) by differentiating 
between systemic users (i.e., systemic only or combined with local forms) and 
local-only users (i.e., any of the forms except the systemic). Further, we additionally 
performed analyses for single-type users and multiple administration forms, 
because the last has been previously shown to be associated with substantial risk 
of adrenal insufficiency (7). In the first model, the association between CS use 
(total and specified groups) and MetS was adjusted for age. In the second model, 
we concurrently adjusted for all covariates. We used analysis of covariances to 
assess the association of CS use with BMI and other cardiometabolic traits. 
Adjustments were done similarly as in the second logistic regression model, with 
additional corrections for diabetes mellitus, use of lipid-modifying drugs, and 
antihypertensive use. Data on the covariates were missing in <4% of the subjects, 
except for physical activity (5.9%), alcohol use (7.1%), and menstrual status (8.2%). 
Missing data were iteratively imputed in five imputation data sets by using the 
Markov Chain Monte Carlo method. All analyses were conducted two sided, with 
0.05 as level of significance, and performed with IBM SPSS Statistics version 
21.0.01 (IBM Corp., Armonk, NY).
Sensitivity analyses
Adjustment of the main analysis for menstrual status did likely not fully 
differentiate the effect of menopause on MetS diagnosis. Due to the expected 
higher prevalence of MetS in postmenopausal women and with increasing age, we 
repeated these analyses stratified for age below, and equal to, or above 50 years. 
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To explore the presence of confounding by indication, we additionally repeated 
the analysis in both sexes in subjects with and without osteoarthritis, asthma, and/
or COPD. Moreover, because adiposity is evidently related to MetS and adverse 
cardiometabolic traits, we also stratified our main analysis by obesity levels (BMI 
<30.0 and ≥30.0 kg/m2).
Results
Overall, 58.5% of the subjects were women and a total of 10.9% was currently 
using any form of CSs. All descriptive characteristics for both sexes and stratified 
for CS use are shown in Table 1. CS use was present in 11.7% and 9.8% of female 
and male subjects, respectively, and comprised predominantly the use of local-
only administration forms (95.4% and 95.3%) and single-type users (81.9% and 
84.8%). The most prescribed CSs in both single- and multiple-type users were 
inhaled, nasal, and topical agents, consecutively (Table 2). MetS was more common 
in men when compared with women. Both male and female CS users were more 
likely to have MetS when compared with nonusers, but the relative difference in 
women was much higher than in men (+5.3% vs +2.7%, P<0.001).
CS use and MetS diagnosis
Female CS users had higher likelihood of having MetS in comparison with nonusers, 
which remained statistically significant after full adjustments for covariates (odds 
ratio [OR], 1.24 [95% confidence interval (CI), 1.17 to 1.32], P<0.001; Table 3). 
Stratified analyses for systemic and local-only female CS users revealed increased 
odds for both group of users, with the strongest association in users of systemic 
agents [ORs, 1.68 (95% CI, 1.34 to 2.10) and 1.22 (95% CI, 1.14 to 1.30), both 
P<0.001, respectively]. The associations in female users of local-only CSs were 
mainly driven by subjects using nasal [OR, 1.20 (95% CI, 1.06 to 1.36), P=0.005] and 
inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49), P<0.001]. In contrast, for men, there 
was no association between CS use, neither for systemic nor local-only use, and 
MetS.
CS use and MetS components
CS use in women was associated with significantly higher odds for each of the five 
MetS components and all of the possible combinations required for MetS diagnosis 
(Fig. 1). These findings were consistent for both users of systemic and local-only 
CSs, except for the reduced HDL-cholesterol component in the former group [OR, 
1.20 (95% CI, 0.96 to 1.49), P=0.102]. In men, CS use was only associated with the 
elevated WC component  [OR,  1.14  (95%  CI,  1.06  to  1.21),  P<0.001].  Considering 
administration route, the relation with WC component in men remained in local-
only users [OR, 1.15 (95% CI, 1.07 to 1.23), P<0.001], whereas systemic CS use was 
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associated with decreased odds of having the elevated fasting glucose component 
[OR,  0.57  (95%  CI,  0.41  to  0.80),  P=0.001].  Moreover, in men, an inverse relation 
was found between systemic CS use and nearly all MetS combinations consisting 
of at least the HDL-cholesterol and fasting glucose components.
 
CS use and cardiometabolic traits
The associations between overall CS use and specific CS administration forms and 
types with cardiometabolic traits are presented in Fig. 2 (see also Supplemental 
Table 2 for adjusted mean differences). 
Female CS users had higher BMI [+0.47 kg/m2 (95% CI, 0.38  to 0.57)], WC [+1.38  cm 
(95% CI, 1.13 to 1.63)], SBP [+0.37 mm Hg (95% CI, 0.06 to 0.68)], and triglycerides 
[+0.007 log mmol/L (95% CI, 0.003 to 0.011)] when compared with nonusers. Similar 
findings together with nominally significant higher fasting serum glucose levels 
[+0.01 mmol/L (95% CI, 0.001 to 0.03)] were also present in users of local-only CSs. 
Systemic CS users, by contrast, had increased HDL-cholesterol [+0.09 mmol/L (95% 
CI, 0.06 to 0.13)] and decreased fasting serum glucose levels [–0.26 mmol/L (95% 
CI, –0.32 to –0.21)] in addition to an increased WC [+1.72 cm (95% CI, 0.66 to 2.79)] 
and triglycerides [+0.050 log mmol/L (95% CI, 0.033 to 0.068)]. Inhaled CS users 
also had higher BMI [+0.86 kg/m2 (95% CI, 0.70 to 1.02)], WC [+2.43 cm (95% CI, 
2.02 to 2.83)], SBP [+0.69 mm Hg (95% CI, 0.20 to 1.19)], and fasting serum glucose 
levels [+0.03 mmol/L (95% CI, 0.01 to 0.05)]. 
In men, local-only CS use was associated with a higher WC [+0.79 cm (95% CI, 
0.51 to 1.08)] and DBP [+0.52 mm Hg (95% CI, 0.26 to 0.78)]. Systemic CS use was 
associated with higher HDL-cholesterol [+0.18 mmol/L (95% CI, 0.14 to 0.21)] 
and lower fasting serum glucose [–0.34 mmol/L (95% CI, –0.42 to –0.26)]. Of the 
different administration types, use of inhaled CSs in men was also associated with 
higher  BMI [+0.25  kg/m2  (95%  CI, 0.09 to 0.41)],  WC [+1.44 cm (95% CI, 0.97 to 
1.90)], and SBP [+0.74 mm Hg (95% CI, 0.11 to 1.37)], in addition to higher DBP 
[+0.60   mm  Hg   (95%   CI,   0.18   to   1.01)] and HDL-cholesterol [+0.02 mmol/L 
(95% CI, 0.01 to 0.04)].
Sensitivity analyses
Analyses stratified by menopause status in women, age, and presence of 
inflammatory diseases yielded nearly similar results with the main analyses 
(Supplemental Tables 3 and 4). Stratification by BMI did not change the results 
in men but revealed higher likelihood of having MetS in local-only users only 
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Discussion
Overall, we found that use of local CSs is associated with MetS, especially in women 
in the general population. Moreover, users of local CSs in both men and women 
had more adverse cardiometabolic traits when compared with nonusers. Among 
the various local CSs, the strongest associations were found in users of inhaled 
administration forms.
It is unclear why CS use is associated with the presence of MetS in women but not 
in men. Sex-differences in side effects of CS use have been reported previously, 
with women being more susceptible (14–16). Emerging evidence shows that CSs are 
associated with a decrease in bone mineral density (14, 15) and increased rate of 
skin bruising in women but not in men (16). CS-induced lipodystrophy is also more 
common in women than in men and is associated with hypercholesterolemia, 
hypertriglyceridemia, and insulin resistance (17–19). Sex differences exist in drug 
absorption, distribution, metabolism, and elimination, and therefore men and 
women might differ in their response to drug treatment (20). Furthermore, women 
use inhaled CSs more often than men and have a higher reported adherence and 
positive attitude in regard to their medication (21). Moreover, administration of CSs 
reduces the levels of sex hormones, including estrogen and testosterone, which 
have sex-specific cardiometabolic effects (22–25). Also, high glucocorticoid exposure 
is well known to induce visceral fat accumulation (6, 26), which is recognized as a key 
driver of metabolic alterations (26). Given the sexual dimorphism in fat distribution, 
with women having a more gynoid fat deposition, changes in fat differences due 
to exogenously administered CSs may be more obvious in women.
The strongest relation between local CS use and both increased presence of MetS 
and adverse cardiometabolic traits was found in inhaled CS users. Previous studies 
have assessed the safety of inhaled CSs by investigating the risk on various systemic 
adverse events other than MetS and found, for example, a higher risk for cataract 
formation (27), loss of bone mineral density (14, 15, 28), and cutaneous atrophy (29). These 
and our findings correspond to the general hypothesis that inhaled CSs can induce 
serious systemic effects. Despite several small, prospective trials demonstrating 
systemic absorption of inhaled CSs (30–32), large and long-term randomized, placebo-
controlled trials in CS-naive subjects focusing on cortisol-related metabolic effects 
are currently lacking. Nevertheless, the pharmacological characteristics of in- 
haled CSs have been extensively studied and support the hypothesis that these 
agents possess a high potential to induce systemic alterations (33–35). It is known, for 
example, that the largest proportion of the inhaled dose (i.e., around 50% to 90%) 
is deposited in the oropharyngeal area, swallowed, and eventually absorbed in the 
gut as it is for the systemic variants. Besides, a fraction of the inhaled CSs will be 
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deposited in the lungs and directly absorbed into the circulation without being 
subjected to the presystemic metabolism of the liver (33, 34).
The distribution of the different types of inhaled CSs in this study were similar 
in both sexes and consisted predominantly of agents containing budesonide or 
fluticasone (Supplemental Fig. 1), which bind to the glucocorticoid receptor with 
an affinity of 9.4 and 18.0 times greater, respectively, than dexamethasone (33, 35). 
Moreover, a relatively high fraction of these two agents is unbound when present 
in the circulation, in contrast to the more recently developed CSs (e.g., ciclesonide 
and mometasone furoate) (33, 35). These and other factors such as particle size, 
lipophilicity, and clearance rate, as well as the type of inhaler device, determine 
the net amount of systemic availability and the potential for systemic adverse 
events in inhaled CS users (33–35). Additionally, most of the inhaled users were using 
combination agents of CSs with beta-agonists, with the latter also being related 
to metabolic alterations (36). It would therefore be conceivable that part of the 
increased MetS difference is due to the systemic availability of these agents. 
However, after full adjustment for covariates relevant to MetS as an outcome, 
we found rather similar likelihoods for users of only inhaled CSs with and without 
beta-agonists in both sexes (Supplemental Table 6).
In the current study, we additionally demonstrated an increased likelihood for MetS 
in women using only nasal CSs. The prescription pattern of the nasal CSs differed 
slightly from the inhaled forms in our sample, with fluticasone and mometasone 
furoate comprising the majority of the agents being used (Supplemental Fig. 2). 
These agents can, just as the inhaled forms, be absorbed directly into the 
circulation by local uptake in the nasopharynx or via the gastrointestinal tract after 
transportation by the nasociliary mucosa and hence theoretically exert systemic 
effects (34, 37). However, both agents are considered to have very low systemic 
bioavailability  of  <1%  with nasal administration (37) and have previously been 
shown not to evidently alter the hypothalamic-pituitary-adrenal axis function even 
when regularly administered or in high doses (38–40). Because the main indications 
for nasal and inhaled forms (i.e., allergic rhinitis and asthma) are often present 
alongside (41), the effects of nasal CSs could perhaps be overestimated by prior use 
of inhaled CSs.
The relevance of this work could be put in context with the results of a previous 
large observational study by Souverein et al. (42) showing that users of systemic 
CSs, including also systemic with inhaled CS users, have increased risk for ischemic 
heart disease and heart failure events. Similar results were also shown in other 
large studies in which use of CSs was found to be associated with higher risk of 
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cardiovascular events (43, 44). This was especially evident in the proportion of the CS 
users who eventually developed an iatrogenic Cushing syndrome, who were found 
to have higher risk in comparison with both nonusers and CS users not developing 
a Cushing-like phenotype (45). Given the fact that from the different administration 
forms our findings were especially evident in users of systemic and inhaled CSs 
(both agents with high potential to enter the bloodstream) and because patients 
with Cushing syndrome are known to have increased cardiovascular disease risk (6), 
our results strengthen the hypothesis that these users could also be at risk for 
MetS complications.
There are several strengths of our present study. This is, to our knowledge, the 
first population-based study to examine the association between overall and 
specific use of CSs and the presence of MetS and its components. High-quality 
information about exposure and well-characterized participants are other 
strengths of the current investigation. Furthermore, the large sample size allowed 
us to perform several subgroup analyses. However, there are several limitations 
that need to be taken into account. First, the cross-sectional design does not allow 
us to address the temporality of the observed associations. Therefore, we cannot 
draw any conclusions with regard to the causality of the observations. Second, we 
cannot rule out that confounding by indication may be present. However, analysis 
restricted to nonobese participants and inflammatory diseases confirmed the 
findings in the general population. Although we corrected for a broad range of 
confounding factors in our analysis, we cannot exclude the possibility of residual 
confounding because of the observational study design.
Conclusions
Use of local CSs, particularly inhaled types, as well as systemic CSs was 
associated with higher likelihood of having MetS, higher BMI, and other adverse 
cardiometabolic traits, especially among women. Because the inhaled CSs are the 
main group of prescribed CSs, this might be a substantial risk to public health. 
Further studies are needed to confirm these findings and evaluate the direction of 
causality and mechanisms behind these associations.
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Figure 1: Associations between CS use and MetS components. The associations (OR 
with 95% CI) between CS use and the five MetS components separately and combined 
in (A) all CS users and stratified for (B) local-only CS users and (C) systemic CS users.
All analyses are adjusted for age, ethnicity, smoking, education level, alcohol use, physical activity, 
cardiovascular diseases (i.e., stroke and/or coronary heart disease), other comorbidities (i.e., cancer, 
osteoarthritis, COPD, and/or asthma), use of potentially weight-inducing psychotropics, HRT [only 
female sex hormones (in women) and other sex hormones (in both sexes)], and menstrual status (in 







Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index
Figure 2: CS use and differences in cardiometabolic traits. Red tints indicate 
unfavorable differences, whereas the blue tints signify favorable differences in 
cardiometabolic traits between users and nonusers of CSs (see Supplemental Table 2 
for adjusted mean differences).
The associations are shown for (A) the main CS users groups and specified for (B) the multiple-type 
and the various single-type users in both sexes. All analyses are adjusted for age, ethnicity, smoking, 
education level, alcohol use, physical activity, cardiovascular diseases (i.e., stroke and/or coronary heart 
disease), other comorbidities (i.e., cancer, osteoarthritis, COPD, and/or asthma), diabetes mellitus, use 
of potentially weight- inducing psychotropics, use of lipid-modifying drugs, use of antihypertensives, 
HRT [only female sex hormones (in women) and other sex hormones (in both sexes)], and menstrual 
status (in women). Non-CS users were taken as reference group for all analyses. GLU, fasting plasma 
glucose; HRT, hormonal replacement therapy; TG, triglycerides.
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*For each drug group of the psychotropics, we only assessed the substances which were likely to induce weight gain 
as an adverse event (1,2).
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Supplemental Figure 1: Distribution of use of inhaled corticosteroid agents in single 
type corticosteroid users.
Abbreviation: CS, corticosteroids.
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Introduction: Corticosteroids are widely prescribed and their use has been linked 
to adverse cardiometabolic outcomes. A pivotal role in the action of corticosteroids 
is reserved for the glucocorticoid receptor (GR). Here, we assessed the relationship 
of glucocorticoid sensitivity altering GR polymorphisms with anthropometrics and 
metabolic syndrome (MetS) in corticosteroid users.
Methods: In this population-based cohort study (Lifelines), we genotyped 10,621 adult 
participants for GR hypersensitive (1/2 copies BclI and/or N363S) and GR resistant 
(1/2 copies ER22/23EK and/or 9β) variants. We assessed the relationship between 
functional GR polymorphisms with body mass index (BMI), waist circumference (WC), 
and MetS in users of corticosteroids.
Results: Overall corticosteroid use was associated with a significantly higher BMI 
and WC in GR wild-type users (BMI: +0.63 kg/m2 [0.09-1.16], P=.022; WC: +2.03 cm 
[0.61-3.44], P=.005) and GR hypersensitive (BMI: +0.66 kg/m2 [95% CI, 0.31-1.01); 
WC: +2.06 cm (1.13-2.98), both P<.001), but not in GR resistant users. Significantly 
higher WC in GR resistant carriers was observed only for inhaled corticosteroid users. 
With respect to MetS, again only GR wild-type users (odds ratio [OR] 1.44 [1.07-1.94], 
P=.017) and GR hypersensitives (OR 1.23 [95% CI, 1.00-1.50], P=.046) were more 
likely to have MetS; even more pronounced in only inhaled corticosteroid users (GR 
wild-type users, OR 1.64 [1.06-2.55], P=.027; GR hypersensitive users, OR 1.43 [1.08-
1.91], P=.013).
Conclusions: Polymorphisms associated with increased GR sensitivity and wild-type 
GR are related to increased BMI, WC, and an increased MetS presence in corticosteroid 
users, especially of the inhaled types, when compared to nonusers. The adverse 
effects of corticosteroid use are less pronounced in users harboring GR resistant 
polymorphisms.   
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Introduction
Corticosteroids are among the most commonly used drugs. We previously 
reported that more than 10% of the Dutch general population was using any 
type of corticosteroids [1], which could be explained by the high effectiveness and 
applicability of corticosteroids in extensive number of illnesses. Unfortunately, 
use of corticosteroids is also accompanied with widespread adverse effects. 
These adverse effects are especially observed with use of systemic corticosteroids 
due to their high systemic availability. Corticosteroid users have reported to 
suffer mainly from weight gain and neuropsychiatric changes [2], which are also 
frequently observed in patients with Cushing’s syndrome. There is however 
increasing evidence that local corticosteroids can also induce systemic adverse 
effects. A large meta-analysis including users of corticosteroids showed that use 
of local forms, particularly of the inhaled formulations, also have increased risk of 
developing adrenal insufficiency [3]. 
The mode of action of corticosteroids does, however, not only depends on the 
amount of exposure but also on conditions at cellular level. An essential role in the 
pathway of glucocorticoid (GC) action is reserved for the glucocorticoid receptor 
(GR). Various GR polymorphisms have been reported of which some functional 
variants have extensively been investigated and shown to be associated with 
altered GC sensitivity [4]. In vivo as well as clinical studies assessing these have 
suggested that the intronic BclI variant and the N363S variant, the latter leading 
to a missense mutation in exon 2, are associated with increased GC sensitivity [5, 6]. 
On the other hand, the ER22/23EK and the 9β polymorphisms have been linked 
to GC resistance with carriers having for instance less cortisol suppression after 
dexamethasone administration [7] and smaller waist circumference (WC) in 
comparison to noncarriers [8]. 
These GR polymorphisms have been shown to be associated with alterations in 
body composition and several cardiometabolic parameters [9]. It remains unclear 
whether the GC sensitivity-altering polymorphisms could affect the vulnerability 
for developing adverse effects in corticosteroid users. This would especially be 
interesting for local types since the vast majority of the corticosteroid users 
are prescribed one of these forms, and therefore has a higher prevalence of 
users [1]. Moreover, our previous findings hint at systemic availability of the 
local corticosteroids, particularly of the inhaled forms, giving the association 
between these types with unfavorable cardiometabolic profile and metabolic 
syndrome (MetS) [1] as well as neuropsychiatric conditions and reduced executive 
functioning [10]. Hence, we investigated the relationship between four functional 
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GR polymorphisms with anthropometric measurements and MetS in corticosteroid 
users in the general population.
Subjects and Methods
Study Population
Data of adult individuals participating in the Lifelines cohort study were evaluated 
for the current study. Lifelines is a multi-disciplinary prospective population-based 
cohort study examining in a unique three-generation design the health and health-
related behaviours of 167,729 persons living in the North of The Netherlands. It 
employs a broad range of investigative procedures in assessing the biomedical, 
socio-demographic, behavioural, physical and psychological factors which 
contribute to the health and disease of the general population, with a special 
focus on multi-morbidity and complex genetics [11]. GWAS data were available 
for 13,378 participants of whom we included 10,621 after exclusion for subjects 
harboring both hypersensitive and resistant variants, non-reliable drug use data, 
non-fasting lab, and missing data on anthropometrics and/or MetS components. 
Written informed consent was provided by participants and study approval was 
obtained from the medical ethical committee of the University Medical Center 
Groningen, Groningen, The Netherlands. 
Genetic Analysis
Participants were genotyped using the Illumina HumanCytoSNP GWAS platform. 
GWAS data was enriched using imputation with 1,000 genomes as a reference. 
Using PLINK verion 1.08p (Shaun Purcell, Harvard University), we extracted 
genotypes of functional GR SNPs: BclI, rs41423247; N363S, rs56149945; 
ER22/23EK, rs 6189 and 6190; and GR9β, rs6198. Users of corticosteroids were 
based on their genotype classified as either GR resistants (1/2 copies of ER22/23EK 
and/or 9β polymorphisms), GR wild types (WT; in case of two wild-type alleles), or 
GR hypersensitives (1/2 copies of BclI and/or N363S polymorphisms).
Use of Corticosteroids
The currently used drugs were after on-site container inspection classified conform 
the WHO Anatomical Therapeutical Chemical (ATC) code. We listed the ATC codes 
belonging to the various systemic corticosteroids (i.e. oral and parenteral) and 
local corticosteroids (i.e. dermal, nasal, inhaled, otological, ocular, intestinal, local 
oral, hemorrhoidal, gynecological). Participants using any type of corticosteroids 
were classified as “corticosteroid users” and further specified as “systemic users” 
(i.e. systemic with or without local types) or “local users” (i.e. users of only local 
type[s]). To assess the specific associations with the different local administration 
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forms, we additionally subclassified local users according to single-type use of 
three most prevalent forms: “inhaled types”, “nasal types”, and “dermal types”. 
Anthropometrics and Metabolic Syndrome
Trained technicians performed all measurements according to standardized 
operating protocols as described previously [1]. Weight (kg) and height (m) were used 
to compute body mass index (kg/m2). WC was measured at halfway the distance 
between front edge of lower ribs and the iliac crest. MetS was deemed present in 
case of at least three of the following five criteria as defined by the Joint Interim 
Statement [12]: [1] WC ≥88 cm (women) or ≥102 cm (men); [2] systolic blood pressure 
≥130 mmHg, diastolic blood pressure ≥85 mmHg, and/or use of antihypertensive 
agents given a previous diagnosis of hypertension; [3] triglycerides ≥1.7 mmol/L 
and/or use of lipid-modifying drugs; [4] HDL-cholesterol <1.3 mmol/L (women) or 
<1.0 mmol/L (men) and/or use of lipid-modifying drugs; [5] fasting serum glucose 
≥5.6 mmol/L and/or use of blood-glucose lowering drugs.  
Covariates
We considered data on age, sex, educational attainment, smoking and physical 
activity in order to control for confounding in the analyses. All covariates were 
self-reported and explained in detail elsewhere [1]. Educational attainment is 
related to the highest completed educational level and was categorized as: low 
(i.e. no education, primary, lower or preparatory vocational education, and lower 
general secondary education), middle (i.e. intermediate vocational education 
or apprenticeship, and higher general secondary education or pre-university 
secondary education), high (i.e. higher vocational education, and university) and 
other. With regard to smoking, participants were classified as nonsmoker, former 
smoker, or current smoker. Physical activity was based on the average number 
of days per week in which participants did at least half an hour of odd jobs, 
gardening, bicycling, or exercises combined. The percentage of missing data was 
0.7% (educational attainment), 15.6% (smoking), and 9.0% (physical activity).  
Statistical Analysis
Analyses were carried out with IBM SPSS Statistics version 22.0.0.2 (IBM Corp., 
Armonk, NY, USA). Student t test, Mann-Whitney U test or Chi Square test was 
performed to assess the crude differences in descriptive characteristics between 
nonusers and users of corticosteroids. Categorical variables were computed 
for separate analyses regarding specific corticosteroid user groups. For this, 
all nonusers were taken as reference group with each of the following user 
groups labelled separately based on GR genotypes (i.e. GR resistant, WT, or GR 
hypersensitive): “overall users”, “systemic (with or without local) type users”, 
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“local-types-only users”, “inhaled-types-only users”, “nasal-types-only users”, and 
“dermal-types-only users”. With respect to BMI and WC, we performed analyses of 
covariance to analyze the differences between nonusers and corticosteroid user 
groups. Logistic regression analyses were carried out for the association between 
MetS and corticosteroid use. For both type of analyses, we report the main models 
in which adjustments were made for age, sex, educational attainment, smoking, 
and physical activity. Interaction with sex was additionally assessed in all main 
models. Multiple imputation was carried out to handle missing data on covariates. 
P-values <.050 were considered statistically significant.
Results
Baseline Characteristics
Descriptive characteristics are shown in Table 1. Corticosteroids were used by 9.8% 
of the study population. A large proportion of the study population was harboring 
at least one GR hypersensitive variant (58.1%) with no significant differences in 
the distribution of the different genotypes between corticosteroid users and 
nonusers (P=.185). Distribution of the GR variants in nonusers and user groups are 
depicted in Table 2. The group of users consisted of more women (61.1% vs 57.9%, 
P=.049) and was on average older (50.2 [±11.7] vs 48.3 [±11.4] years, P<.001) in 
comparison to nonusers. Majority was using only local corticosteroids (94.7%) 
with highest number of users for inhaled (n=575), nasal (n=312) and dermal 
(n=226) types whereas 55 subjects were using systemic corticosteroids. After 
excluding 155 multiple type users, the number and percentage of single-type local 
corticosteroid use was as follows: 444 (77%) inhaled corticosteroids, 201 (64%) 
nasal corticosteroids, and 178 (79%) dermal corticosteroids. 
Body Mass Index and Waist Circumference by GR Genotypes in Corticosteroid 
Users
Differences in BMI and WC between nonusers and users are shown in Figure 1. 
In the complete  group  of  users, overall corticosteroid use was associated with 
increased BMI (+0.69 kg/m2 [95% CI, 0.41 to 0.96]) and WC (+2.11 cm [95% CI, 1.34 
to 2.88], both P<.001). All three genotypes had on average higher BMI and WC when 
compared to nonusers, however differences reached only statistical significance in 
GR WT users (BMI, +0.63 kg/m2 [95% CI, 0.09 to 1.16], P=.022; WC, +2.03 cm [95% 
CI, 0.61 to 3.44], P=.005) and GR hypersensitive users (BMI, +0.66 kg/m2 [95% CI, 
0.31 to 1.01], P<.001; WC, +2.06 cm [95% CI, 1.13 to 2.98], P<.001). 
No significant differences were found in systemic type users regarding BMI, 
however GR WT users had an increased WC (+6.55 cm [95% CI, 1.16 to 11.94], 
P=.017) in comparison to nonusers. In the combined group of users of locally 
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applied corticosteroids, only participants with GC hypersensitive variants had 
higher BMI (+0.72 kg/m2 [95% CI, 0.36 to 1.08], P<.001), whereas all three genotypes 
had increased WC as compared to nonusers (GR resistant, +1.67 cm [95% CI, 0.16 to 
3.17], P=.030; WT, +1.71 cm [95% CI, 0.24 to 3.17], P=.022; GR hypersensitive, +2.18 
cm [95% CI, 1.24 to 3.13], P<.001). 
Stratification for single-type users showed that differences were mainly due to 
inhaled corticosteroid use. BMI was only significantly increased in inhaled type 
users with GR WT (+1.17 kg/m2 [95% CI, 0.34 to 1.99], P=.005) and GR hypersensitive 
genotypes (+1.69 kg/m2 [95% CI, 1.16 to 1.21], P<.001) and not in GR resistant 
users (+0.60 kg/m2 [95% CI, -0.24 to 1.45], P=.163). WC was however higher in 
users of each GR genotype group when compared to nonusers (GR resistant, +2.34 
cm [95% CI, 0.10 to 4.59], P=.040; WT, +3.80 cm [95% CI, 1.62 to 5.97], P<.001; GR 
hypersensitive genotype, +4.72 cm [95% CI, 3.34 to 6.11], P<.001). No interaction 
with sex was observed in any of the analyses. 








Age (years) 48.5 (±11.5) 48.3 (±11.4) 50.2 (±11.7) <.001















































BMI (kg/m2) 26.4 (±4.3) 26.3 (±4.2) 27.0 (±4.8) <.001
Waist circumference (cm) 92.1 (±12.1) 91.8 (±12.1) 94.0 (±12.7) <.001
Metabolic syndrome 2,446 (23.0) 2,153 (22.5) 293 (28.1) <.001
Genotype*
• GR resistant












Data are shown as numbers (percentage) and mean (±standard deviation). Abbreviation: GR, glucocorticoid receptor.
* GR resistant group includes participants with 1/2 copies of the ER22/23EK and/or 9β polymorphisms.  
GR hypersensitive group includes participants with 1/2 copies of the BclI and/or N363S polymorphisms.
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Metabolic Syndrome and Corticosteroid Use by GR Genotype  in 
Corticosteroid Users
Table 3 depicts the findings regarding differences in MetS presence between 
nonusers and users. MetS was in general more prevalent in corticosteroid users 
when compared to nonusers (28.1% vs 22.5%, P<.001). Within complete group of 
users, only those with a GR WT genotype (OR 1.44 [95% CI, 1.07 to 1.94], P=.017) 
or GR hypersensitive genotype (OR 1.23 [95% CI, 1.00 to 1.95], P=.046) were more 
likely to have MetS. Similar outcome was also observed in the combined local 
corticosteroid group, whereas no significant association was found in systemic 
type users. With respect to the former group, only inhaled corticosteroid use 
was linked to higher prevalence of MetS with GR WT and GR hypersensitive users 
being, respectively, 1.64 (95% CI, 1.06 to 2.55, P=.027) and 1.43 (95% CI, 1.08 to 
1.91; P=.013) times more likely to have MetS in comparison to nonusers. There was 
no significant interaction with sex.
Figure 1: Differences in body mass index and waist circumference between nonusers 
and corticosteroid users by glucocorticoid receptor genotype.
Mean differences with the reference group of nonusers of corticosteroids (N=9,577) are shown in kg/
m2 (95% CI) for body mass index and cm (95%  CI) for waist circumference. Analyses are adjusted for 
age, sex, educational attainment, smoking, and physical activity. Individuals with multiple type use are 
excluded for the analyses regarding inhaled, nasal, and dermal corticosteroid use.
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In this study, we investigated the relevance of functional polymorphisms of 
the GR in the association between systemic and local corticosteroid use with 
cardiometabolic outcomes in the general population. Corticosteroid users, in 
particular of the inhaled forms, have an increased BMI, WC and are more often 
burdened with MetS in comparison to nonusers. These differences are significantly 
evident in users harboring GR polymorphisms associated with GR hypersensitivity 
(BclI and/or N363S) and WT users, but less in users with GR resistant polymorphisms 
(i.e. ER22/23EK and/or 9β).
Genomic actions of activated GR are traditionally classified as transactivating or 
transrepressing. Adverse effects of supraphysiological GC exposure are considered 
to be mainly due to transactivation whereas the preferred anti-inflammatory 
response is induced by transrepression [13]. Earlier studies have performed 
functional assays to assess these GR-dependent effects in leukocytes of individuals 
with functional GR variants. Transactivational activity was increased with the 
N363S variant and decreased in case of ER22/23EK polymorphism [14], while the 
in vitro transrepressional effects were decreased in 9β carriers [15]. These in vitro 
observations are in line with the differences as observed in the current study with 
more adverse cardiometabolic effects in GR hypersensitive users of corticosteroids 
and vice versa in GR resistant users. Interestingly, Eipel and colleagues previously 
observed that pediatric patients harboring the N363S polymorphism more often 
developed GC-related hepatotoxicity and glucose abnormalities in the course of 
acute lymphoblastic leukemia (ALL) treatment [16]. Moreover, previous studies 
also with pediatric ALL patients showed that BclI carriers were also more likely 
to develop Cushingoid-like symptoms (e.g. adiposity, hypertension, diabetes) 
and depression during treatment with systemic corticosteroids [17], as well as a 
longer period of adrenal insufficiency after high-dose corticosteroid therapy in 
homozygous BclI carriers [18].
Supraphysiological exposure to GCs is known to induce lipogenesis and 
accumulation of central adipocytes conceivably due to the higher presence of GR 
in visceral area [19]. GCs can additionally increase (high-caloric) food intake [20, 21] 
and promote redistribution of fat tissue to central regions [22] which could further 
fuel these changes on adipocyte level. In the current study we found that overall 
use of corticosteroids was indeed associated with higher WC but mainly in users 
with GR WT and GR hypersensitive genotype. This could hint on protective effects 
of the GR resistant variants on changes in abdominal obesity with corticosteroid 
use, especially given the previous findings of (tendency to) lower WC in unselected 
carriers [8, 23]. Our findings in the current study were mainly evident for inhaled 
111
5
Anthropometric Measurements and Metabolic Syndrome in Relation to 
Glucocorticoid Receptor Polymorphisms in Corticosteroid Users
corticosteroids and showed nevertheless that also users with GR resistant 
genotype had significantly higher WC albeit the difference was less pronounced 
in comparison to other users. It is conceivable that frequent and chronic use of 
these powerful agents, as would be anticipated in many inhaled type users, and 
often in combination with systemic corticosteroids would somehow outweigh the 
potential beneficial effects of GR resistant variants. 
Similar differences were also evident with regard to BMI with greatest contrast 
between nonusers and inhaled corticosteroid users harboring GR hypersensitive 
variants. In contrast to WC, no significant differences were found for individuals 
with GR resistant variants. Despite the fact that both anthropometric measures 
are strongly linked to cardiovascular events [24], WC is, as an estimate for abdominal 
fat mass, the most important predictor and is in particular of interest in the 
context of GC effects. Excess of GCs stimulate redistribution of peripheral fat 
and accumulation of visceral fat by increasing synthesis and storage of lipids 
and adipose tissue hyperplasia by increasing differentiation of preadipocytes to 
mature adipocytes [25]. GCs also promote proteolysis in skeletal muscles while 
inhibiting protein synthesis which together could eventually lead to muscle atrophy 
[26]. Moreover, GCs also affect bone mineral density through various pathways 
leading to increased osteoclast activity and diminished osteoblast function which 
ultimately lead to bone loss [27]. This highlights the differential effects of GCs on 
body composition which can ultimately lead to varying effects regarding BMI. 
Furthermore, we previously showed that male carriers of the ER22/23EK variant 
had on average more lean mass and muscle strength [23] which could also contribute 
to the current observation. 
The increased prevalence of MetS in corticosteroid users is in line with our 
previous observations in the complete cohort population [1]. As shown here, it 
seems however that this association is only significantly present in users carrying 
variants linked to GR hypersensitivity or those with a GR WT genotype. We have 
previously conducted the only study, as far as we know, on the link between GR 
polymorphisms and MetS in the general population and found increased risk in 
specific subgroups with the N363S (GR hypersensitive) variant [28]. Other smaller 
studies have investigated the association between GR variants and cardiometabolic 
features and demonstrated differences corresponding to altered GR sensitivity [29-
31], however findings have not been consistent [5, 32, 33]. Since these studies did not 
take corticosteroid use into account, and given the relatively high percentage of 




Contrary to our expectations, the differences in all outcomes between nonusers 
and users of systemic corticosteroids were highly variable and less consistent. 
This could largely be due to the small number of systemic corticosteroid users in 
the current study population (0.5%) and within the total group of users (5.3% vs 
94.7% users of local types). In the group of locally applied corticosteroids, adverse 
outcomes were only consistently present in users of inhaled types. The majority of 
the inhaled type only group was using inhalers containing fluticasone (propionate) 
or budesonide, which are pharmacologically active upon use and are known to 
have relatively high GR binding affinity and lower protein-binding capacity [34] 
and thus to be more likely to induce systemic GC-related adverse events when 
entering circulation. Unfortunately, we have no data regarding the therapeutic 
effect of corticosteroids in user groups according to GR variants. In studies with 
selected study populations, however, it was shown that having two BclI variants is 
associated with a better treatment response to inhaled corticosteroids in asthmatic 
children [35]. Carriers of GR hypersensitive variants were also found to have a better 
therapeutic response to systemic corticosteroids in ALL [16, 36], inflammatory bowel 
disease [37], and nephrotic syndrome [38]. The opposite was observed in patients 
harboring GR resistant ER22/23EK or 9β variants and being treated with systemic 
corticosteroids [38, 39]. 
This is the first population-based study to assess cardiometabolic profile in users 
of systemic as well as local corticosteroid types in relation to GR variations. Among 
the strengths are the reliable and large-scale data collection on drug use and 
integrity of data regarding genotyping, BMI, and the MetS components. Since it 
concerns an observational study design, we cannot exclude residual confounding, 
despite adjustments for relevant confounders, and are not able to prove causality. 
Moreover, it remains unknown whether the findings can be extrapolated to other 
ethnicities given the fact that the study population involves mainly individuals from 
Caucasian race. Finally, larger longitudinal studies are needed to perform analyses 
for the separate polymorphisms and to confirm whether in systemic and local 
corticosteroid use the development of cardiometabolic features but also other 
clinically relevant GC-related adverse events (e.g., neuropsychiatric conditions) 
depend on GR variations and/or other factors in the GC pathway.
Conclusion
Corticosteroid users, in particular of inhaled corticosteroids, have an increased 
BMI, WC, and more often MetS in comparison to nonusers. These relationships 
are significantly evident in carriers of common GR genotypes associated with GR 
hypersensitivity or the WT genotype, but little to none present in users harboring 
GR resistant polymorphisms. 
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Systemic and Local Corticosteroid 
Use is Associated With Reduced 






Background: Use of local corticosteroids, especially the inhaled types, has increasingly 
been associated with systemic uptake and consequent adverse effects. In this study, 
we assessed the associations between the use of different corticosteroid types 
with cognitive and neuropsychiatric adverse effects related to high glucocorticoid 
exposure. 
Methods: In 83,592 adults (mean age 44 years, 59% women) of the general population 
(Lifelines Cohort Study), we analyzed the relationship between corticosteroid use 
with executive cognitive functioning (Ruff Figural Fluency Test), and presence of 
mood and anxiety disorders (Mini-International Neuropsychiatric Interview survey). 
We performed additional exploration for effects of physical quality of life (QoL; 
RAND-36), and inflammation (high-sensitive C-reactive protein [CRP]). 
Results: Cognitive scores were lower among corticosteroid users, in particular of 
systemic and inhaled types, when compared to nonusers. Users of inhaled types 
showed lower cognitive scores irrespective of physical QoL, psychiatric disorders, 
and high-sensitive CRP. Overall corticosteroid use was also associated with higher 
likelihood for mood and anxiety disorders. Users of inhaled corticosteroids were more 
likely to have mood disorders (OR 1.40 [95% CI 1.19–1.65], p < 0.001) and anxiety 
disorders (OR 1.19 [95% CI 1.06–1.33], p = 0.002). These findings were independent 
of physical QoL. A higher likelihood for mood disorders was also found for systemic 
users whereas nasal and dermal corticosteroid users were more likely to have anxiety 
disorders. 
Conclusions: Commonly used local corticosteroids, in particular inhaled types, and 
systemic corticosteroids are associated with reduced executive cognitive functioning 
and a higher likelihood of mood and anxiety disorders in the general adult population.
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Introduction
Adverse effects of the glucocorticoid cortisol are usually observed in case of 
supraphysiological exposure as seen in patients with endogenous or exogenous 
Cushing’s syndrome. Given the extent of cortisol action, high levels can lead to 
various physical as well as mental alterations. Cushing’s syndrome patients, 
for example, develop obesity, hypertension, menstrual irregularities, and 
neuropsychiatric pathologies [1]. The incidence of endogenous Cushing’s syndrome 
is extremely low with approximately 1–2 new cases per million persons annually [2]. 
However, the main cause of excessive glucocorticoid exposure is due to 
exogenous administration of drugs containing synthetic glucocorticoids [3]. 
These corticosteroids are one of the most prescribed drugs given their high anti-
inflammatory and immunomodulatory potential, and many indications. Besides, 
the availability of corticosteroids in many systemic and local administration 
formulations makes them readily feasible and convenient for clinical use. We 
previously showed that nearly 11% of the adults of the general population of 
the Netherlands was using any type of corticosteroid, which is comparable with 
prescription numbers in ambulatory care in the United States [4].
The common assumption is that only systemic corticosteroid variants can induce 
systemic adverse events, and that the effects of the local forms are generally 
limited to the application site. However, mounting evidence is questioning this 
notion. A large meta-analysis, for example, demonstrated an increased risk 
of adrenal insufficiency also with local corticosteroid forms [5]. Moreover, we 
previously demonstrated that users of systemic corticosteroids as well as the 
local forms, in particular of the inhaled types, were more likely to have metabolic 
syndrome, increased waist circumference, higher body mass index (BMI), and 
other adverse cardiometabolic derangements in comparison to nonusers [6]. 
Both increased adrenal insufficiency risk and higher likelihood of frequent 
corticosteroid-related metabolic effects in local corticosteroid users support the 
idea of systemic absorption and subsequent systemic adverse effects of local 
corticosteroids. In this regard, it would be reasonable to also expect effects on the 
brain in the case of systemic availability of these types. Despite previous studies 
observing cognitive impairments [7, 8] and psychiatric disorders [9] in endogenous 
Cushing’s syndrome patients and systemic corticosteroid users [10], there are, to 
our knowledge, no large population-based studies that have investigated the 
associations between cognitive and psychiatric indices and use of the various 
local corticosteroid types. In this study, we therefore assessed the relationship of 
systemic and local corticosteroid use with cognition and neuropsychiatric health in 





We included data of adult participants of the Lifelines research program, which is a 
multi-disciplinary prospective population-based cohort study examining in a unique 
3-generation design the health and health-related behaviors of 167,729 persons 
living in the north of The Netherlands. It employs a broad range of investigative 
procedures in assessing the biomedical, socio-demographic, behavioral, physical 
and psychological factors that contribute to the health and disease of the general 
population, with a special focus on multi-morbidity and complex genetics [11]. 
Participants were included in case of complete data regarding outcomes of the 
assessment for cognitive functioning, neuropsychiatric health, and physical quality 
of life (QoL). After exclusion of participants with inconclusive information on drug 
use, there were in total 83,592 subjects eligible for the current study.
Corticosteroid Use
Current drug use was assessed by questionnaire and on-site inspection of drug 
containers. Drugs were subsequently coded ac- cording to their corresponding 
WHO Anatomical Therapeutic Chemical code. We filtered users of any type of 
corticosteroid and grouped them as being “corticosteroid users.” Drugs with 
only mineralocorticoid action were not included. Subclassification was made for 
users of only local administration forms or users of systemic corticosteroids (i.e., 
oral and/or parenteral) with or without any of the other types. To elaborate the 
associations with specific administration forms, we further classified single-type 
users ac- cording to their use of only systemic, inhaled, nasal, dermal or other (i.e., 
otological, ocular, intestinal, local-oral, hemorrhoidal, or gynaecological) types.
Cognitive Functioning
The Ruff Figural Fluency Test (RFFT) is a measure of nonverbal fluency as part 
of executive cognitive functioning. The test contains 5 sheets each consisting of 
35 identical frames of 5-dot patterns with or without distracting elements. For 
each part, participants are instructed to connect 2 or more dots per frame with 
straight lines and to make as many as possible unique designs without falling 
into repetition in 1 min [12]. The primary outcome is the total number of unique 
designs (i.e., unique design score), which can range from 0 to 175. The test was not 
performed in subjects who were consistently unable to properly hold a pen, had 
impaired vision, a score below 26 on the Mini-Mental State Examination, or had 
performed the test previously in another cohort study.
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Neuropsychiatric Assessment
The Mini-International Neuropsychiatric Interview is a structured interview 
intended for diagnosing psychiatric disorders ac- cording to DSM-IV and ICD-10 
diagnostic criteria [13]. Trained professionals administered the modules regarding 
the current diagnosis of major depressive episode, dysthymia, social phobia 
generalized anxiety disorder, agoraphobia without a history of panic disorder, and 
lifetime presence of panic disorder with or without agoraphobia. Patients were 
categorized as having a mood disorder if they met the diagnostic criteria for major 
depressive episode or dysthymia. Anxiety disorder was deemed present in case of 
any of the other assessed diagnoses.
Physical QoL
Due to potential confounding by disease burden, we planned to perform subgroup 
analyses with stratification for health-related QoL. For this purpose, we used 
the outcomes of the RAND-36 questionnaire, which is a commonly used survey 
consisting of 36 questions related to own health status. A weighted scoring and 
summation of selected items results in a score between 0 and 100 for 8 different 
domains [14]. By calculating the Z-score for each domain using Dutch reference 
population [15], we computed the aggregated physical component summary score 
[16] as a proxy for physical QoL. A higher score corresponds to a better QoL.
Covariates
To minimize confounding, we included potential covariates based on literature, 
biological plausibility, and statistical significance. Besides age and sex, we 
assessed self-reported educational attainment classified as low (i.e., no education, 
primary, lower or preparatory vocational education, and lower general secondary 
education), middle (i.e., intermediate vocational education or apprenticeship, 
and higher general secondary education or pre-university secondary education), 
high (i.e., higher vocational education, and university), and other. The use of 
psychotropic drugs was evaluated by screening current drug use for antiepileptics 
(ATC group N03), psycholeptics (N05; e.g., antipsychotics, anxiolytics), and/or 
psychoanaleptics (N06; e.g., antidepressants, psychostimulants). Lifestyle factors 
including physical activity, smoking, and alcohol use were assessed as previously 
described [6]. With regard to cardiometabolic factors, we included data on BMI, and 
presence of cardiovascular diseases. Trained technicians measured body weight 
(kg), and height (cm). Weight and height were used to compute BMI (kg/m2). For 
cardiovascular diseases, subjects were asked to report if they had a past event 
of stroke, myocardial infarction, balloon angioplasty, and/or coronary artery 
bypass grafting. Any of the latter 3 conditions are also presented as coronary 
heart diseases in the results. Data of some covariates were missing for <5% of the 
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subjects, however, this was higher for physical activity (6.8%), smoking (7.0%), and 
alcohol use (9.1%).
Statistical Analysis
Differences in descriptive characteristics between users and nonusers were analyzed 
with Student t test or Mann-Whitney U test for continuous variables, and chi-
square test for categorical data. Concerning the cognitive outcome, we performed 
analyses of covariance to assess differences in unique design score (RFFT analysis) 
between different routes of administration and for single-type users versus 
nonusers. We first analyzed crude differences, followed by adjustments for age, 
and sex. In the main model, we additionally adjusted for educational attainment, 
BMI, smoking, alcohol use, physical activity, cardiovascular diseases, and use of 
psychotropic drugs. The differences between users and nonusers in the binary 
outcomes for presence or absence of psychiatric disorders were assessed with 
logistic regression analyses. We performed similar adjustments for these analyses, 
and reported the crude and fully adjusted results. Interaction effects with sex and 
age were assessed in main analyses with complete group. With respect to disease 
burden, we additionally performed stratified analysis by either low (≤ median) or 
high (> median) physical component summary score. Moreover, given the recent 
finding that the unique design score is associated with anxiety and depression [17] 
we additionally repeated the analyses for cognitive functioning separately in 
participants with and without any of the assessed psychiatric disorders. IBM SPSS 
Statistics version 22.0.0.2 (IBM Corp., Armonk, NY, USA) was used to carry out 
multiple imputations for covariates with missing data, and to perform all analyses 
(2-sided). p values below 0.050 were considered statistically significant.
Sensitivity Analyses
Since corticosteroids are generally used in the presence of inflammatory processes 
and given the potential effect of inflammation on mental health and functioning, 
we performed sensitivity analyses to evaluate the relationship between the 
inflammatory marker C-reactive protein (CRP) with our outcomes and whether 
this contributed to the differences between users and nonusers. High-sensitive 
CRP (hsCRP) was measured with an immuno-nephelometric assay (CardioPhase 
hsCRP, Siemens Healthcare Diagnostics, Marburg, Germany). Data were available 
of 45,395 subjects of whom 89.6% were nonusers and 10.4% users. Coefficients 
were assessed in the main models for both cognition and psychiatric disorders.
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Results
Subject Characteristics
Characteristics of the study population as a whole and stratified for corticosteroid 
use are shown in Table 1. Subjects were on average 44.2 years old and 58.8% were 
women. Corticosteroids were being used by 10.8% of the study population, which 
largely consisted of users of inhaled corticosteroids. The majority of users of the 
different administration forms were single-type users (Fig. 1). Physical QoL was 
higher in nonusers in comparison to users (53.3 [±7.2] vs. 50.3 [±9.0], p < 0.001).
Corticosteroid Use and Executive Cognitive Functioning
The total unique design score was 81.3 (±23.3) in the total study population. Overall 
corticosteroid use was associated with a 1.6 (95% CI 1.1–2.1, p < 0.001) lower 
cognitive score, which remained statistically significant after full adjustments of 
all specified covariates. Users of only local types and users of systemic (with or 
without local corticosteroids) had a lower score in comparison to nonusers (–0.9 
[–1.4 to –0.4], p < 0.001; –3.0 [–5.1 to –1.0], p = 0.004 respectively). Within single-type 
users, only systemic corticosteroid users (–2.9 [–5.3 to –0.4], p = 0.024) and in- haled 
corticosteroid users (–2.1 [–2.9 to –1.4], p < 0.001) scored lower in unique design 
score when compared to non-corticosteroid users. Subgroup analyses stratified 
for either low or high physical QoL and for presence or absence of mood and/
or anxiety disorders revealed consistently lower scores in inhaled corticosteroid 
users compared to nonusers (Fig. 2). With respect to other forms, only the use of 
systemic corticosteroids was associated with a significant lower score in subjects 
without mood and anxiety disorders (–3.1 [–5.8 to –0.5], p = 0.021), whereas no 
significant differences were found for the remaining types. No interaction with sex 
or age was observed. Corticosteroid Use and Mood and Anxiety Disorders Current 
mood and/or anxiety disorders were present in 11.1% of the total population, and 
were both more prevalent in corticosteroid users in comparison to nonusers (both 
p < 0.001; Table 1). Stratification for the main route of corticosteroid administration 
revealed associations for local types with both mood disorders (OR 1.24 [1.11–
1.40]) and anxiety disorders (OR 1.18 [1.10–1.27], both p < 0.001; Table 2). 
Systemic corticosteroid use was only associated with mood disorders, which 
was especially evident in the single-type users (OR 1.75 [1.05–2.91], p = 0.031). 
Among users of local corticosteroids, users of only inhaled corticosteroids were 
more likely to have mood disorders (OR 1.40 [1.19–1.65], p < 0.001) and anxiety 
disorders (OR 1.19 [1.06–1.33], p = 0.002) in comparison to nonusers. For anxiety 
disorders, similar associations were present in nasal corticosteroid users (OR 1.21 
[1.05–1.39], p = 0.007) and dermal corticosteroid users (OR 1.18 [1.01–1.40], p = 
0.043). Interaction analyses for sex and age showed no significant differences. 
With subgroup analyses, inhaled corticosteroid use was found to be associated 
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Table 1: Characteristics of study sample.
Corticosteroid use
All (N=83,592) Nonusers (N=74,591) Users (N=9,001)
Demographics
Age (years)a 44.2 (±12.3) 44.1 (±12.3) 45.2 (±12.6)





















Use of psychotropic drugsa 7,441 (8.9) 6,331 (8.5) 1,110 (12.3)
High-sensitive CRP (mg/L)a,b 1.20 (2.20) 1.20 (2.10) 1.50 (2.90)
Lifestyle
Physical activity
• 0 days per week
• 1-4 days per week


















































BMI (kg/m2)a 26.1 (±4.3) 26.0 (±4.3) 26.7 (±4.8)
Cardiovascular diseasesa
• Strokea










Ruff Figural Fluency Test (executive cognitive functioning)
Unique designsa 81.3 (±23.3) 81.5 (±23.3) 79.9 (±23.4)
MINI (psychiatric disorders)












RAND36 (health-related quality of life)
Physical component summary scorea 52.9 (±7.5) 53.3 (±7.2) 50.3 (±9.0)
All values are depicted as median (interquartile range), mean (±SD), or numbers (percentage). 
Abbreviations: BMI, body mass index; CRP, C-reactive protein.
a Significant crude differences between nonusers and users;
b Data on high-sensitive CRP were available in 45,395 participants including 40,695 nonusers and 4,700 users.
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Table 2: Association between corticosteroid use and psychiatric disorders.
Mood Disorders
Crude model Adjusted modela































































Crude model Adjusted modela






























































The group of non-corticosteroid users is taken as reference. aThe analyses are adjusted for age, sex, educational 
attainment, body mass index, smoking, alcohol use, physical activity, cardiovascular diseases, and use of psychotropic 
drugs. *P<.050, **P<.010, ***P<.001.
with increased likelihood for mood and/ or anxiety disorders in both subjects with 
low physical QoL (OR 1.15 [1.01–1.29], p = 0.030) as well as high physical QoL (OR 
1.32 [1.08–1.62], p = 0.008; Table 3). Among users with low physical QoL, relatively 
high effect sizes were found for users of nasal corticosteroids and users of the 




Table 3: Corticosteroid use and presence of mood and/or anxiety disorders by physical 
quality of life.
Low Physical Quality of Life (N=41,796)
Crude model Adjusted modela






























































High Physical Quality of Life (N=41,796)
Crude model Adjusted modela






























































The group of non-corticosteroid users is taken as reference. Mood and anxiety disorders are combined together due 
to otherwise small number of cases in users. aThe analyses are adjusted for age, sex, educational attainment, body 
mass index, smoking, alcohol use, physical activity, cardiovascular diseases, and use of psychotropic drugs. *P<.050, 
**P<.010, ***P<.001.
Sensitivity Analyses
Corticosteroid users had in general a higher hsCRP than nonusers (median [IQR] 
1.50 [2.90] vs. 1.20 [2.10] mg/L, p < 0.001; Table 1). With regard to cognition, 
there was a negative association between hsCRP and unique design score (B = 
–0.087, SE = 0.022, p < 0.001). Nevertheless, the use of systemic as well as inhaled 
corticosteroids was persistently associated with significantly lower cognitive 
scores when adjusted for hsCRP (Table 4). Additional adjustment for mood and 
anxiety disorders did not affect these results (data not shown). There was no 
association between hsCRP and the presence of mood and anxiety disorders.
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Discussion
In the current study, we show that use of both systemic and local corticosteroids, 
particularly the inhaled types, is associated with a reduced executive cognitive 
functioning and a higher likelihood of mood and anxiety disorders. With regard 
to the inhaled forms, these findings were persistent in both individuals with low 
and high physical QoL suggesting potential drug effects regardless of physical 
condition. Despite an inverse association between hsCRP levels and cognition, 
the use of systemic and inhaled types was independently associated with lower 
cognitive performance.
A reduction in executive cognitive functioning in local and systemic corticosteroid 
users, as found in this study, could hint on corticosteroid effects on the brain. 
Although multiple studies have shown an association between corticosteroid 
use and central nervous system disorders, the pathophysiology of exogenous 
corticosteroid action on the brain is still not well understood [18]. Corticosteroids 
have been described to affect various aspects of brain physiology, including 
selective hippocampal atrophy [19], neuronal plasticity [20, 21], neurotoxicity [22], 
and neurogenesis [23]. The hippocampus in particular is an important target 
of corticosteroids and strongly expresses both mineralocorticoid as well as 
glucocorticoid receptors [24–26]. Excess corticosteroids could lead to reversible and 
irreversible damage to hippocampal structure and thus contribute to cognitive 
Table 4: Differences in cognition between users and nonusers with available hsCRP 
data (N=45,395).
Unique Design Score
N Model 1 Model 2
Nonusers 40,695 Ref. Ref.
Overall users 4,700 -1.12 [-1.76, -0.48]*** -1.07 [-1.71, -0.43]**
Route
Local 4,497 -0.94 [-1.59, -0.28]** -0.89 [-1.55, -0.24]**
Systemic 203 -5.18 [-8.10, -2.25]*** -5.04 [-7.97, -2.12]***
Single type
Systemic 153 -5.27 [-8.64, -1.90]** -5.13 [-8.50, -1.76]**
Inhaled 1,783 -2.33 [-3.34, -1.32]*** -2.28 [-3.29, -1.27]***
Nasal 1,078 -0.37 [-1.65, 0.92] -0.33 [-1.61, 0.96]
Dermal 856 0.99 [-0.45, 2.42] 1.00 [-0.44, 2.44]
Others 120 2.37 [-1.43, 6.17] 2.39 [-1.41, 6.19]
Adjusted mean differences (95% C.I.) in total unique design score between corticosteroids users and nonusers 
(reference). Model 1 is adjusted for age, sex, educational attainment, body mass index, smoking, alcohol use, physical 




impairment [26]. Another brain region that seems susceptible to corticosteroid 
effects is the medial prefrontal cortex. Chronic corticosterone administration [27] 
and behavioral stress [28] have been demonstrated to result in a reorganization of 
apical dendrites in pyramidal neurons of the medial prefrontal cortex in rodent 
models. This reorganization may have functional consequences as reflected in 
glucocorticoid-induced changes in cognition, working memory and stress-related 
behavioral disorders [27–29]. Interestingly, the RFFT used as a measure of non-verbal 
fluency in the present study is especially sensitive to function [30] and dysfunction 
[31] of the right frontal lobe. In line with this, a previous placebo-controlled, 
crossover, randomized trial with healthy subjects receiving supraphysiological oral 
hydrocortisone found that corticosteroids indeed induced cognitive impairments 
which were especially related to frontal lobe dysfunction [32]. It is therefore 
conceivable that in case of systemic availability of local corticosteroids, in particular 
of the inhaled forms, these regions would also be exposed to supraphysiological 
glucocorticoid levels and subsequently impaired in their functioning.
We found that users of systemic and inhaled corticosteroids scored nearly 2–3 points 
lower on the RFFT when compared to nonusers. It is noteworthy to mention that 
these differences are relatively modest. Nevertheless, it is especially interesting 
that the outcomes point repeatedly in the same direction in all analyses for the 
systemic and the inhaled types. Among important contributors to RFFT score, age 
has consistently found to be negatively associated [12, 33] as was also observed in our 
cohort. In terms of clinical relevancy, the worse scores with inhaled and systemic 
corticosteroid use would on average correspond to lower scores as found with 
an age increase of 4.3 and 5.8 years, respectively, in our group of nonusers while 
controlling for other covariates.
Neuropsychiatric disorders are known to be one of the most prevalent and 
distressing adverse effects in users of systemic corticosteroids. Fardet and 
colleagues observed that approximately half of these users reported to suffer 
from neuropsychiatric complaints, including anxiety and depression, after they 
had started with corticosteroid treatment [34]. In addition, a small study with 
physically and mentally healthy subjects also showed behavioral changes in 75% 
of the participants after high-dose oral prednisone administration for 5 days 
[35]. Moreover, endogenous Cushing’s syndrome has also frequently been linked 
with various psychopathologies [9, 36] among which mood and anxiety disorders 
as observed in the current study. In that sense, it would be conceivable that the 
inhaled types could also lead to these disorders in case of systemic absorption. 
This would even be more expected, given the high glucocorticoid receptor binding 
affinity of the frequently administered inhaled forms which is comparable to 
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nearly 10–20 times that of dexamethasone [37]. Interestingly, the unfavorable 
findings regarding cognition, mood and anxiety were especially evident in users 
of these types. However, it should be noted that the effect sizes are relatively 
small. Nevertheless, these and our previous findings of higher likelihood for 
metabolic syndrome, a higher BMI, and other cardiometabolic alterations in 
users of inhaled corticosteroids [6] are in line with frequently observed features in 
systemic corticosteroids users and Cushing’s syndrome patients. These findings 
are consistent with our hypothesis of systemic availability and effects of inhaled 
corticosteroids in which case both somatic and brain effects would be observed 
when exposed to supraphysiological dosages.
An important consideration in understanding the effect of corticosteroids on 
the brain is their penetration of the blood-brain barrier. While corticosteroids, 
in general, pass through cell membranes to enter the brain on account of their 
lipophilicity, cells comprising the blood-brain barrier express proteins of the 
multidrug transporter system, which limit the access of exogenous molecules 
to the brain [24, 38]. Further functional studies are essential to demonstrate the 
access of the various exogenous corticosteroids to different brain areas and the 
implications for cognitive and psychiatric functioning.
The strength of this work lies in the in-depth phenotyping, extensive assessment, 
and completeness for the outcome observations in large number of subjects 
from the general adult population. An important limitation to mention is the 
observational nature which hinders drawing conclusions on causality and is 
prone to residual confounding. Moreover, we assessed only one aspect of the 
various cognitive functioning domains and merely in persons with no significant 
impairments with the Mini- Mental State Examination. Finally, there were no 
data available on the cumulative dose exposure. However, our main findings are 
particularly driven by the inhaled forms that are conceivably used in a chronic 
fashion giving the underlying often chronic indications such as asthma.
Conclusions
Commonly used local corticosteroids, in particular the inhaled types, and systemic 
corticosteroids are associated with reduced executive cognitive functioning and a 
higher likelihood of mood and anxiety disorders in the general adult population. 
Future confirmatory studies are needed to ratify our findings and to prove 
temporality, while further research should also assess the associations with other 
cognitive processes and psychiatric disorders.
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Figure 1: Distribution of corticosteroid use in the study sample.
Superimposed pie chart illustrating for each corticosteroid type the total number of users and the 
proportion of single-type use. The former is presented as the size of each slice and is also written in 
text beside. The radial length marks the percentage of users within each type who were not using 
any other corticosteroid types. These groups of single-type users were used to assess the associations 
for the specific administration forms. Single-type use was most prevalent in dermal corticosteroid 
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Figure 2: Executive cognitive functioning in corticosteroid users in comparison to 
nonusers.
Adjusted mean differences (95% CI) in unique design score between the single-type corticosteroid 
users, and nonusers as reference (a). The same analyses stratified for subjects with either low or high 
physical component summary score as proxy for physical QoL (b), and for presence or absence of mood 
and/or anxiety disorders (c). Analyses are adjusted for age, sex, educational attainment, BMI, smoking, 
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Hair Glucocorticoids as Biomarker 
for Endogenous Cushing's 






Background/Aims: The current diagnostic workup of Cushing’s syndrome (CS) 
requires various tests which only capture short-term cortisol exposure, whereas 
patients with endogenous CS generally have elevated cortisol levels over longer 
periods of time. Scalp hair assessment has emerged as a convenient test in capturing 
glucocorticoid concentrations over long periods of time. The aim of this multicenter, 
multinational, prospective, case-control study was to evaluate the diagnostic efficacy 
of scalp hair glucocorticoids in screening of endogenous CS. 
Methods: We assessed the diagnostic performances of hair cortisol (HairF), hair 
cortisone (HairE), and the sum of both (sumHairF+E), as measured by a state-of-
the-art LC-MS/MS technique, in untreated patients with confirmed endogenous CS 
(n = 89) as well as in community controls (n = 295) from the population-based Lifelines 
cohort study. 
Results: Both glucocorticoids were significantly elevated in CS patients when 
compared to controls. A high diagnostic efficacy was found for HairF (area un- der 
the curve 0.87 [95% CI: 0.83–0.92]), HairE (0.93 [0.89–0.96]), and sumHairF+E 
(0.92 [0.88–0.96]) (all p < 0.001). The participants were accurately classified at the 
optimal cutoff threshold in 86% of the cases (81% sensitivity, 88% specificity, and 
94% negative predictive value [NPV]) by HairF, in 90% of the cases (87% sensitivity, 
90% specificity, and 96% NPV) by HairE, and in 87% of the cases (86% sensitivity, 
88% specificity, and 95% NPV) by the sumHairF+E. HairE was shown to be the most 
accurate in differentiating CS patients from controls. 
Conclusion: Scalp hair glucocorticoids, especially hair cortisone, can be seen as a 
promising biomarker in screening for CS. Its convenience in collection and workup 
additionally makes it feasible for first-line screening.
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Introduction
Cushing’s syndrome (CS) results from excessive exposure to glucocorticoid 
hormones and is associated with significant morbidity and mortality [1]. After 
exclusion of exogenous CS caused by glucocorticoid-containing drugs, a variety of 
endogenous diseases can give rise to increased secretion of cortisol. Approximately 
70% of the cases of endogenous CS are caused by a pituitary adenoma producing 
excessive ACTH, stimulating the adrenal to produce cortisol (i.e., Cushing’s 
disease). The remainder of endogenous CS cases mostly consist of adrenal causes 
and ectopic ACTH production [1].
Endogenous CS is rare but often presents with common and therefore nonspecific 
signs and symptoms such as weight gain, fatigue, metabolic syndrome features, 
and depression [2]. Features more specific for CS include easy bruising, facial 
plethora, and proximal myopathy, but these do not occur in all patients [3]. This 
clinical dilemma can cause a significant delay in diagnosis, which is often made 
when the condition has been existing for an extended period of time and patients 
display multiple signs and symptoms of CS. Current guidelines recommend 
three different first-line screening tests: 24-h urinary free cortisol (UFC), late-
night salivary cortisol (LNSC), and the 1-mg dexamethasone suppression test [4]. 
All three tests rely on patient compliance for the collection of samples or drug 
intake, and their limitations often necessitate repeated testing. Furthermore, they 
may be influenced by several factors such as kidney function (for UFC), gingival 
microtrauma (for LNSC), and drug use (for the dexamethasone suppression test).
Recently, we reported on the largest study thus far using measurements of scalp 
hair cortisol in patients with CS [5]. Scalp hair offers information about integrated 
cortisol exposure over months of time [6]. This may be particularly valuable in CS, 
where cortisol production may often vary across days. In our study, hair cortisol 
provided a 93% sensitivity and 91% specificity for CS, comparing well to first-line 
tests [5]. Furthermore, hair analysis can be used to create retrospective timelines of 
cortisol exposure, which can be helpful in cases of cyclic CS [7, 8]. 
All studies measuring hair cortisol in CS thus far relied on immunoassays to 
quantify cortisol. A recent advance in the development of hair steroid analysis 
is hair steroid profiling using liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). Recently, we have validated a method which measures hair values 
of cortisol, cortisone, testosterone, androstenedione, dehydroepiandrosterone 
sulfate, and 17α-hydroxyprogesterone [9]. In contrast to immunoassays, LC-MS/MS 
is less prone to interference, offers higher sensitivity, and can be used to measure 
multiple steroids simultaneously. The aim of this study was to assess the diagnostic 
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efficacy of hair cortisol (HairF) and cortisone (HairE) measured by LC-MS/ MS in two 
independently collected cohorts of patients with endogenous CS. 
Subjects and Methods
Study Participants
Our study population consisted of 295 controls from the general Dutch 
population, which had also been included in our previous study [10], and 89 patients 
with proven endogenous CS. All controls were recruited from Lifelines, which 
is a multidisciplinary, prospective, population-based cohort study examining 
in a unique three-generation design the health and health-related behaviors of 
167,729 persons living in the north of the Netherlands. It employs a broad range 
of investigative procedures in assessing the biomedical, sociodemographic, 
behavioral, physical, and psychological factors which contribute to the health 
and disease of the general population, with a special focus on multimorbidity 
and complex genetics [11]. Patients were recruited from two clinic sites, one in the 
Netherlands (Erasmus MC, Rotterdam; n = 19) and one in Germany (Klinikum der 
Ludwig-Maximilians-Universität München, Munich; n = 70). Diagnostic workup 
was performed ac- cording to the guideline [4] and the diagnosis of CS, de novo 
or recurrent, was biochemically established by experienced endocrinologists and 
proven by surgery and/or additional investigations (e.g., bilateral inferior petrosal 
sinus sampling).
Scalp Hair Measurements
In all participants, a scalp hair sample of approximately 100– 150 hairs was collected 
from the posterior vertex. The hair was cut as close to the scalp as possible and 
after sample collection stored in an envelope in the dark at room temperature. The 
protocol for hair processing and analysis was adapted from the previous method 
described in detail elsewhere [9]. In short, approximately 20 mg of the proximal 3 
cm (or the entire length of the hair sample, if the hair was shorter than 3 cm) was 
weighed and cut into 1-cm-long pieces. The hair was washed in 2 mL of LCMS-grade 
isopropanol for 2 min and allowed to fully dry. Steroids were extracted overnight 
in 1.4 mL of LCMS-grade methanol, and 100 μL of cortisol-d3 and cortisone-d8 as 
internal standards for 18 h at 25 °C while the samples were being gently shaken. 
After extraction, hair samples were centrifuged at 4,369 g (4,500 rpm) for 5 min, 
and 900 μL of the extract was transferred to a clean tube. We then added 750 μL 
of methanol to the hair samples, which were spun down again, after which another 
900 μL of extract was transferred to the tubes with the extract. The extracts were 
evaporated under a continuous nitrogen stream at 37 °C, reconstituted in 1 mL of 
purified water and 20 μL of methanol, and purified using solid-phase extraction. 
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Cortisol and cortisone concentrations were subsequently quantified by LC-MS/
MS using a Xevo TQ-S system (Waters, Milford, MA, USA). HairF and HairE were 
successfully determined in 91 and 97% of the study participants. Data on both 
hair glucocorticoids were available for 89% of the study population. The interassay 
coefficient of variation for cortisol and cortisone was 14.8 and 15.3%, respectively. 
The intra-assay coefficient of variation for cortisol and cortisone was <11 and <8%, 
respectively. The lower limit of quantification of cortisol and cortisone was <1.3 and 
<9.3 pg/ mg, respectively. For research purposes, HairF and HairE measurements 
below the lower limit of quantification were included in the analyses as quantitative 
measures, since no recognized substitution method exists.
Statistical Analysis
We used SPSS version 24 (IBM Corp., Armonk, NY, USA) and RStudio version 1.0.136 
(RStudio, Inc., Boston, MA, USA) with the pROC package [12] for the statistical 
analyses. The hair glucocorticoid values were logarithmically transformed to 
achieve a normal distribution and are reported as geometric means and 95% CI. 
The baseline characteristics were analyzed using ANCOVA if continuous, and using 
χ2 tests if categorical. Associations between HairF and HairE were assessed by 
Pearson’s correlation. The diagnostic efficacy of HairF, HairE, and the sum of HairF 
and HairE (sumHairF+E) for CS screening was assessed using receiver operating 
characteristic (ROC) curves.
Optimal cutoffs, defined as the curve points closest to the top-left corner, were 
initially determined for cohorts 1 and 2 separately. For the main analyses, both 
cohorts were combined and optimal cutoff values were determined for the complete 
population. De- Long’s test was used to compare ROC curves between the two 
cohorts. Paired analyses were additionally performed to assess the discriminating 
ability of the different outcomes relative to each other. Moreover, we computed 
the diagnostic accuracy (i.e., the percentage of correctly classified subjects) and 
other diagnostic performance parameters (i.e., sensitivity, specificity, positive 
predictive value [PPV], negative predictive value [NPV], positive likelihood ratio 
[LR+], and negative likelihood ratio [LR–]). Given the intraindividual and interassay 
coefficients of variation, we additionally calculated diagnostic performance 
parameters at 15 and 30% higher and lower levels than the optimal cutoffs. 
Furthermore, we performed sensitivity analyses in order to account for potential 
effects of exogenous glucocorticoids on hair glucocorticoid concentrations [10]. We 
repeated the main ROC analyses with only nonusers in the control cohort. This 
resulted in exclusion of a total of 38 controls who had used any type of exogenous 
glucocorticoids in the previous 3 months. Among these participants, hair analyses 
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were successful in 36/38 for HairF and sumHairF+E, and in 37/38 for HairE. All 
outcomes were considered statistically significant in case of a p value <0.05.
Results
Descriptive Characteristics and Hair Glucocorticoid Concentrations
The subjects’ characteristics and concentrations of hair glucocorticoids are shown 
in Table 1 and Figure 1. On average, the controls were younger (42.3 years) than 
the patients (50.2 years). The majority of the participants were women in both the 
control group (74.6%) and the CS group (74.2%). Hair glucocorticoids stratified by 
sex are shown in online supplementary Table S1. In general, men had higher levels 
on all measures; however, significant sex differences in the three in- dices were 
only present in the controls. Both male and female CS patients had higher values 
than the controls of same sex (all p < 0.001). Overall, there was a strong linear 
association between HairF and HairE (r = 0.821, p < 0.001). The geometric mean 
HairF was higher in the CS patients of cohort 1 (17.3 pg/mg [95% CI: 9.5–31.3]) and 
cohort 2 (11.7 pg/mg [95% CI: 8.5–16.2]) than in the controls (2.7 pg/mg [95% CI: 
2.5–2.9]) (both p < 0.001). HairE was also significantly higher in the patients (cohort 
1: 37.9 pg/mg [95% CI: 21.7–66.3]; cohort 2: 40.9 pg/mg [95% CI: 30.8–54.4]) than in 
the controls (8.2 pg/mg [95% CI: 7.8–8.7]) (both p < 0.001). The geometric mean of 
the sum of both hair glucocorticoids was also higher in the CS patients than in the 
controls. There were no statistically significant differences in hair glucocorticoids 
between the two patient cohorts. 
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Data are shown as numbers (percentage), median (±SD), and geometric mean (95% CI).
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Diagnostic Efficacy of Hair Glucocorticoids for Screening of CS
ROC curves with corresponding diagnostic performance parameters for HairF, 
HairE, and sumHairF+E are depicted in Figure 2. Analyses stratified by sex are shown 
in online supplementary Figure S1. All three indices showed a strongly significant 
differentiating efficacy among CS patients from both cohorts separately and 
combined (p < 0.001 for all areas under the curve [AUCs]). 
For HairF, an optimal cutoff of 4.7 pg/mg (AUC 0.87 [95% CI: 0.83–0.92]) was 
observed, with an accuracy of 86%, a sensitivity of 81%, and a specificity of 88%. 
A positive test result confirmed CS with 68% probability, whereas the NPV was 
94%. In regard to HairE, the ROC analysis yielded an optimal cutoff of 13.8 pg/mg 
(AUC 0.93 [0.89–0.96]). This allowed the correct identification of 74/85 CS patients 
and 261/289 controls, corresponding to 90% accuracy, 87% sensitivity, and 90% 
specificity. The PPV and NPV with HairE was 73 and 96%, respectively. The sum 
of both hair glucocorticoids also showed a high diagnostic efficacy with an AUC of 
0.92 (95% CI: 0.88– 0.96). The optimal sumHairF+E cutoff was 18.9 pg/mg, with a 
corresponding sensitivity of 86% and a specificity of 88%. At this cutoff, 69/80 CS 
patients and 230/262 controls were identified correctly, yielding an accuracy of 
87% with a PPV of 68% and an NPV of 95%.
In the context of sensitivity analyses to take potential influencing effects of 
glucocorticoid-containing drugs into account, we found nearly identical AUCs when 
only nonusers were considered as controls (p < 0.001 for all three indices; data not 
Figure 1: Distribution of hair glucocorticoid concentrations in controls and Cushing’s 
syndrome patients.
Hair cortisol (HairF), hair cortisone (HairE), and the sum of both (sumHairF+E) are shown for community 
controls, as well as for Cushing’s syndrome patients from two independent cohorts. The data for 
each group are summarized as the geometric mean with corresponding 95% CI. The solid black 
lines correspond to the optimal cutoff values, and the dashed lines above and below indicate levels 




shown). Moreover, the optimal cutoff levels with corresponding sensitivity and 
specificity were also roughly the same for HairF (4.7 pg/mg; 81% sensitivity, 87% 
specificity), HairE (13.8 pg/mg; 87% sensitivity, 89% specificity), and sumHairF+E 
(16.2 pg/mg; 89% sensitivity, 85% specificity). Diagnostic accuracy at these levels 
was 86% for HairF, 89% for HairE, and 86% for sumHairF+E.
The optimal cutoff for all outcomes was lower in cohort 2 than in cohort 1; however, 
only the sum of hair glucocorticoids was statistically significantly different in 
diagnostic efficacy between the two cohorts (Fig. 3). Paired ROC analysis of the 
hair glucocorticoids showed that HairE and sumHairF+E were more accurate than 
HairF in the screening of CS in the complete study population (both p < 0.010; Fig. 
4), whereas HairE was marginally more accurate than the sum value (p = 0.041). 
Figure 2: Receiver operating characteristic curve analyses of the diagnostic 
performance of hair glucocorticoids for Cushing’s syndrome.
The red dots refer to the OC value for screening of Cushing’s syndrome. The table summarizes the 
different diagnostic performance parameters at the OC level and other specified levels. AUC, area 
under the curve; HairE, hair cortisone concentrations; HairF, hair cortisol concentrations; sumHairF+E, 
sum of HairF and HairE; OC, optimal cutoff threshold; LR, likelihood ratio; NPV, negative predictive 
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Discussion
In this multicenter study, we evaluated, for the first time, the diagnostic efficacy 
of scalp hair cortisol and cortisone concentrations as measured by LC-MS/MS 
for the screening of CS in two independent patient cohorts. We showed that 
both glucocorticoids were significantly elevated in patients when compared to 
community controls, while there were no differences between the patient cohorts. 
With respect to diagnostic performance, we found a high differentiating capacity 
of HairF (accuracy 86%, sensitivity 81%, and specificity 88%), HairE (accuracy 
90%, sensitivity 87%, and specificity 90%), and the sum of both (accuracy 87%, 
sensitivity 86%, and specificity 88%). Excluding users of exogenous glucocorticoids 
in the control cohort revealed no significant effects on these findings. Paired 
Figure 3: Comparison of receiver operating characteristic curves for screening of 
Cushing’s syndrome by hair glucocorticoids between two independent patient cohorts.
HairE, hair cortisone concentrations; HairF, hair cortisol concentrations; sumHairF+E, sum of HairF and 
HairE.
Figure 4: Paired analyses for differences in diagnostic efficacy between hair 
glucocorticoids for screening of Cushing’s syndrome.
Hair cortisone (HairE) was more accurate than hair cortisol (HairF) and the sum of both glucocorticoids 
(sumHairF+E) in differentiating patients with Cushing’s syndrome from controls. sumHairF+E was also 
























































































































analyses showed that HairE was more accurate than HairF or the sum of both in 
distinguishing patients from controls. 
Assessment of cortisol concentrations in scalp hair has previously been performed 
by us and others to compare levels between CS patients and controls [5, 7, 8, 13, 14]. 
Published studies consistently showed clearly elevated levels in patients in the 
proximal 1- and 3-cm hair segments. Recently, we have also investigated the 
diagnostic efficacy of HairF in distinguishing CS patients from healthy controls, as 
well as patients suspected of CS but in whom the diagnosis was eventually excluded. 
High sensitivity and specificity were observed with similar optimal cutoffs for 
both analyses [5]. However, this and previous studies have only analyzed HairF and 
have performed analyses by immunoassay, which is, among others, prone to 
cross-reactivity and is inferior to LC-MS/MS with respect to selectivity and 
detection. Findings of local production of 11β-hydroxysteroid dehydrogenase 
(11β-HSD) types 1 and 2 – which are, respectively, responsible for the conversion 
of cortisone into cortisol and vice versa – in skin, hair follicles, and other cutaneous 
appendages [15-17] also complicate the interpretation of prior findings in CS 
patients. It therefore remains questionable whether the measured hair cortisol 
concentrations only reflect the actual past exposure to cortisol or whether these 
are altered due to local conversion by 11β-HSDs.
Here, we showed for the first time that HairF as well as HairE is elevated in 
CS patients and that both glucocorticoids possess a high diagnostic efficacy. 
Moreover, we showed a relatively better diagnostic performance of HairE in 
distinguishing patients from controls when compared to HairF. Another test that 
might also be prone to local conversion effects is the first-line screening test with 
salivary cortisol – this because of the 11β-HSD2 activity in parotid tissue [17]. A 
previous study by Perogamvros et al. [18] focused on both salivary glucocorticoids 
in non-cushingoid patients and found, similarly to the current work, higher 
concentrations of cortisone than of cortisol, whereas the opposite was true for 
the free fractions in serum. Interestingly, sampling after adrenal stimulation with 
ACTH injection showed salivary cortisone to reflect free serum cortisol more 
accurately than salivary cortisol. An evaluation of salivary cortisol and cortisone in 
another study with CS patients indeed revealed a high diagnostic accuracy of both 
measures [19]. Additionally, a recent study by Kapoor et al. [20] with radiolabeled 
cortisol experiments on primates confirmed that circulating cortisol is taken up in 
hair and can be measured. Importantly, the authors also showed that a substantial 
proportion of the administered cortisol was incorporated as cortisone. More 
research, however, is needed to understand the dynamics between cortisol and 
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cortisone at the local level and to investigate the additional value of cortisone 
measurements. 
The diagnostic efficacy of screening tests depends on the chosen cutoff value for 
differentiating patients from subjects without the disease. This makes it challenging 
to place our results in the context of the recommended tests. Nevertheless, 
Elamin et al. [21] have systematically summarized and pooled the results of the 
traditional tests in the diagnostic workup of CS. Based on this, the diagnostic 
efficacy of hair glucocorticoids, especially of HairE, seems to be quite similar to 
that of midnight salivary cortisol (pooled LR+ 8.8 and LR– 0.1) and UFC (pooled LR+ 
10.6 and LR– 0.2), even though most of the included studies had a small population 
with a fairly high prevalence of CS [21]. Since the diagnosis of CS could not rely on 
a single screening test, further research should especially address the diagnostic 
effectiveness of hair glucocorticoids in combination with other recommended 
tests. Besides, as mentioned in the guideline and also observed here, there is 
a substantial proportion of false positives with the screening tests, due among 
other things to the high prevalence of (mild) hypercortisolistic cushingoid-like 
conditions (e.g., psychiatric disorders, diabetes mellitus, and obesity) and the rare 
occurrence of CS [4]. Therefore, the recommendation to restrict testing to subjects 
with a high a priori probability of having CS could reasonably be ex- tended to hair 
glucocorticoid assessment.
The current screening tests are subject to several difficulties and limitations which 
are less severe or completely absent with scalp hair measurements. From the 
patient’s perspective, hair sampling is noninvasive and does not require following 
specific instructions (e.g., collection of urine output for at least 24 consecutive 
hours for UFC) or impose restrictions (e.g., fasting or no teeth brushing before 
saliva collection for LNSC) as with the recommended tests; also, hair samples can 
be collected, stored, and posted by mail with ease, which is especially useful for 
patients who have to cover long distances to a clinic site. For care professionals, 
it is convenient that hair measurements are not dependent on the time of day or 
patient compliance and are not influenced by acute stressors. The unique feature 
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of these measurements of covering long-term glucocorticoid exposure makes 
them additionally useful in the screening for cyclical CS. The current guideline 
recommends UFC or salivary cortisol measurements in case of suspicion of cyclical 
CS [4]; however, these tests can yield normal results when patients are screened 
after the periodical increase in cortisol levels. We previously demonstrated the 
usefulness of hair measurements in such situations in multiple patients who had 
normal screening test results at the time of evaluation but had retrospectively 
elevated cortisol concentrations in hair segments corresponding to the period of 
cushingoid signs and symptoms [7].
The large number of patients and controls and the multicenter evaluation are 
among the major strengths of the current work. Moreover, all hair glucocorticoid 
concentrations were determined with high sensitivity and specificity using a state-
of-the-art LC-MS/MS technique. This study is, however, limited in the way that 
controls from the community were not screened for CS. Nevertheless, given the 
rarity of this disorder, with less than 5 cases per million individuals [22], it is very 
unlikely that controls were misclassified. Moreover, the results were not adjusted 
for potential confounders such as UV exposure [23], hair washing, or diabetes 
mellitus [24]. It is, however, questionable whether these factors would have 
substantially influenced the outcomes, because of the large (5–6 fold) differences 
between controls and CS patients in hair glucocorticoid levels. 
In conclusion, scalp hair assessment for hair glucocorticoids, in particular for 
cortisone concentrations, shows a high diagnostic efficacy in differentiating CS 
patients from controls. Because of its simplicity and noninvasive sampling, as 
well as its diagnostic performance, it may be seen as a promising biomarker and 
a potential addition to the armamentarium of CS screening tests. To allow the 
uniform use of fixed cutoff values, we recommend further efforts to standardize 
or harmonize results between international centers. 
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Supplementary Data
Supplementary Table S1: Hair glucocorticoids in controls and Cushing’s syndrome 
patients by sex.
Cushing’s syndrome patients




Female 194 2.5 
(2.3 to 2.8)
15 14.9 


















































Data are shown as geometric mean (95% CI). 
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Supplementary Figure S1: ROC analyses for diagnostic performance of hair 
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Long-Term Cortisol Exposure and 
Associations With Height and 





Context: Turner syndrome (TS) usually manifests in traits as short stature and 
premature ovarian failure. Many patients also have an increased risk of cardiometabolic 
disorders and psychological distress, which are features that overlap with those of a 
prolonged state of hypercortisolism.
Objective: To investigate whether TS is associated with increased long-term 
cortisol concentrations as measured in scalp hair and whether these are linked to 
cardiometabolic and psychological parameters.
Design: Prospective observational case-control study.
Setting: Academic outpatient TS expertise center.
Participants: Fifty-five patients with TS (53% 45,X karyotype), and 110 age-matched 
female community control subjects from the general population-based Lifelines 
cohort study.
Main Outcome Measures: Hair cortisol concentrations (HCC), anthropometrics, 
biochemical parameters, and psychological questionnaires for perceived stress 
(Perceived Stress Scale–14), fatigue (Checklist Individual Strength–20), and health-
related quality of life (RAND-36).
Results: Compared with control subjects, patients with TS had higher HCC [geometric 
mean, 3.51 pg/mg (95% CI, 2.64 to 4.65) vs 2.39 pg/mg (2.13 to 2.68); P=0.003] and 
a worse cardiometabolic profile in terms of fasting glucose, and triglycerides. HCC 
was only associated with total cholesterol levels (standardized β=0.294; P=0.047) 
and was not associated with the psychological outcomes. A higher HCC was inversely 
associated with height only in patients with TS (standardized β=-0.307; P=0.023).
Conclusion: Patients with TS are chronically exposed to higher cortisol levels, which 
is associated with short stature and increased total cholesterol levels, and potentially 
contributes to the known elevated cardiovascular disease risk.
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Introduction
Turner syndrome (TS), one of the most prevalent genetic syndromes in women 
(1:2500 live-born females), derives from a (partial) loss or abnormality of one of the 
X chromosomes. Patients with TS are predisposed to a wide range of comorbidities, 
which require multidisciplinary care and thorough medical examination (1). Besides 
characteristic abnormalities such as short stature, webbed neck, and premature 
ovarian failure, patients are particularly prone to osteoporotic fractures, congenital 
cardiac defects, ischemic heart disease, and metabolic syndrome traits (2). 
With regard to the latter, patients with TS tend to be overweight or obese (3), and 
have hypertension (4), dyslipidemia (5), and glucose intolerance or diabetes mellitus 
type 2 (6). Despite the genetic alterations, it remains largely unknown whether 
these commonly encountered derangements are mainly a direct consequence of 
the genetic anomaly [e.g., SHOX gene (7)] or are secondary to physiological and 
endocrine changes, as frequently observed in patients with TS.
Interestingly, increased exposure to the stress hormone cortisol is known to 
induce cardiometabolic abnormalities, prompt psychological distress and fatigue, 
hamper growth, and decrease bone mineral density (8), which all are frequently 
observed in women with TS (2, 9). How- ever, relatively little attention has been paid 
to cortisol secretion in patients with TS. Only one study, to our knowledge, has 
investigated cortisol levels in TS in the past decade (10). Onder et al. (10) assessed 
cortisol levels before and after ACTH injection in a small group of patients with TS 
and observed high baseline and peak levels. Nonetheless, this concerned a time-
point measurement and the investigators did not assess the relationship between 
cortisol and metabolic outcomes or other cortisol-related comorbidities. To our 
knowledge, no information is available yet regarding long-term cortisol levels 
in patients with TS. This is especially of interest because previously mentioned 
comorbidities usually manifest after prolonged exposure to elevated cortisol 
levels.
The conventional methods for cortisol assessment in serum, saliva, and urine can 
only provide estimates of cortisol levels within a small time window and are highly 
variable due to the diurnal and pulsatile variability in cortisol secretion. Another 
method measures cortisol levels in scalp hair, which circumvents many limitations of 
the previous methods and enables retrospective assessment of cortisol secretion 
in the previous weeks to months, depending on the length of the collected 
sample (11). Earlier studies demonstrated relatively high intraindividual stability in 
cortisol levels in hair taken from the posterior vertex, with simultaneous as well 
as repeated sampling over time (12, 13). Moreover, the reliability of hair cortisol as a 
matrix for assessment of long-term cortisol exposure has been demonstrated by 
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Short et al. (14). Since hair is assumed to grow with approximately 1 cm/mo; Short 
et al. (14) investigated the relationship between cortisol levels measured in a single 
1-cm hair sample, with the average of salivary cortisol levels assessed with three 
daily measurements for 30 days. They found a strong association between both 
out- comes. We and others have shown that hair cortisol concentrations (HCCs) are 
associated with various outcomes related to chronic exposure to elevated cortisol 
levels, such as greater waist circumference (15), psychopathology (16), and Cushing 
syndrome (17, 18). Timelines of HCC also were demonstrated to be highly valuable 
in screening of patients suspected of cyclic Cushing syndrome, given the normal 
cortisol levels with traditional (i.e., short-term) assessments but increased HCC in 
segments matching with the course of Cushingoid features (19). Now, we are able to 
measure HCC with an advanced liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) method (20) that enables more sensitive and specific measurements in 
comparison with the traditional immunoassays.
Because many patients with TS experience a multitude of comorbidities that 
also occur in a state of hypercortisolism, we hypothesized that TS is associated 
with increased cortisol exposure and this would be associated with known stress-
related consequences commonly reported in TS. Hence, we assessed long-term 
cortisol levels in scalp hair of patients with TS and matched community control 
subjects. Among patients with TS, we also investigated HCC in relationship to 




Consecutive patients visiting our academic outpatient TS expertise center between 
August 2014 and May 2015 were asked to participate in this study. Sixty-seven 
patients with confirmed TS, stated in a genetic test report and/or documented 
by a treating physician in an electronic health record, and having scalp hair at the 
posterior vertex were initially included. As a control group, we included female 
participants in the Lifelines cohort study, from whom we previously had determined 
cortisol levels in scalp hair (21). Lifelines is a multidisciplinary, prospective, 
population-based cohort study examining, in a unique three-generation design, 
the health and health-related behaviors of 167,729 persons living in the north of 
the Netherlands. It uses a broad range of investigative procedures in assessing 
the biomedical, sociodemographic, behavioral, physical, and psychological factors 
that contribute to the health and disease of the general population, with a special 
focus on multimorbidity and complex genetics (22). Patients with TS and female 
control subjects were excluded in case of oral, intra-articular, or topical-on-scalp 
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corticosteroid use, which resulted in the exclusion of three patients and five 
control subjects. HCC were successfully determined in 55 patients, who were 
finally included in this study. All participants provided informed consent. The study 
protocol was approved by the local medical ethical committee and was conducted 
in accordance with the Declaration of Helsinki.
Anthropometrics and biochemical assessments
At site visits, weight and height were measured and used for computing body mass 
index (BMI; calculated as kg/m2). GH therapy was previously received by 37 of 50 
patients (74%) with available information regarding treatment. Blood samples 
were collected to determine values of the following cardiometabolic parameters: 
fasting glucose (mmol/L), total cholesterol (mmol/L), high-density lipoprotein and 
low-density lipoprotein cholesterol (mmol/L), and triglycerides (mmol/L). Analyses 
were separately performed for patients and control subjects on Roche Cobas c501 
and Roche Modular P chemistry analyzers, respectively (Basel, Switzerland).
Psychological parameters
Among patients with TS, self-reported data by questionnaires in Dutch were 
collected for subjective measures of perceived stress, fatigue, and health-related 
QoL. Perceived stress was assessed by using the Perceived Stress Scale–14, which 
consists of 14 items related to nonspecific stress appraisal in the past month (23). All 
answers are noted on a 5-point Likert scale (score range, 0 to 4) and are summed 
to a total score, which ranges between 0 and 56. A higher score represents a 
higher level of perceived stress. The Checklist Individual Strength–20 (CIS-20) was 
applied to assess perceived fatigue. This questionnaire consists of 20 statements 
assessing different aspects of fatigue in the past 2 weeks (e.g., “I feel tired”) on a 
7-point Likert scale with preset answer categories ranging from “yes, that is true,” 
to “no, that is not true” (24, 25). Scores are summed to a total fatigue score, with 
higher scores indicating higher levels of perceived fatigue. To measure health-
related QoL, the RAND-36 was applied. The answers on this 36-item survey were 
used to calculate scores for eight different health-related domains (26, 27). From 
these domains, the aggregated physical component summary (PCS) score and 
mental component summary (MCS) score can be obtained, which are, respectively, 
indicative of physical and mental QoL (28). We initially calculated sex-specific Z-scores 
for all domains, using previously collected reference data from a population study 
among Dutch individuals (29). Higher scores on PCS and MCS reflect more beneficial 
outcomes. The median time difference between collection of hair samples and 




Long-term cortisol exposure was assessed in scalp hair collected from the posterior 
vertex. We analyzed HCC in the proximal 3 cm, or complete length if the sample was 
shorter, which approximately corresponds to cortisol exposure in the preceding 
3 months. At time of sample collection, participants were asked to complete a 
questionnaire about hair-related factors, such as hair washing frequency, which 
could potentially affect cortisol concentrations. From the collected sample, 
about 20 mg of hair was cut and subsequently processed as described elsewhere 
(18). Cortisol concentrations were eventually quantified by LC-MS/MS (Xevo TQ-S 
System; Waters, Milford, MA).
Statistical analysis
All analyses were performed with SPSS Statistics, version 24 (IBM, Armonk, NY) 
and RStudio, version 1.0.136 (Boston, MA). To reduce residual confounding, 
we performed age-based optimal matching of patients with female control 
subjects from our historical cohort at 1:2 ratio by using the MatchIt package (30). 
Differences in baseline characteristics, anthropometrics, and cardiometabolic 
parameters between groups in continuous outcomes were analyzed with ANOVA 
or Mann-Whitney U test, and with x2 test or Fisher exact test in case of categorical 
parameters. HCCs were base 10–log transformed to achieve a normal distribution 
and are reported as geometric mean with corresponding 95% CIs. We used analysis 
of covariance to assess the crude difference in long-term cortisol exposure 
between patients with TS and matched control subjects. In a stepwise manner, 
we corrected for significant differences between the groups in hair characteristics 
and baseline variables. Within patients with TS, associations between transformed 
HCC and other measures were assessed with linear regression analyses (crude and 
adjusted for age) and noted as standardized coefficients (b) with corresponding 
P values. A two-tailed test with significance level of 0.05 was considered for all 
analyses.
Results
Baseline characteristics of patients and matched control subjects are shown in 
Table 1. Patients with TS were slightly younger than control subjects [median age, 
31.0 years (interquartile range, 18.0) vs 35.0 years (10.3); P=0.016]. There was a 
significant difference in body weight and height between groups, with patients 
being especially shorter [mean (6SD), 1.56 m (60.07) vs 1.71 m (60.06); P<0.001]. 
Within the patient group, 52.7% had the classical monosomy karyotype (45,X), 
whereas the  remaining  had  X-mosaicism  (45,X/46,XX  or  45,X/ 47,XXX; 18.2%), 
isochromosome Xq (18.2%), or other variants (10.9%). There were no significant 
differences between patients with classical monosomy and non-monosomy 
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karyotypes in any of the outcomes except for triglycerides (Table 2). With respect 
to GH treatment, patients who were previously treated were younger [median 
age, 26.0 years (interquartile range, 12.0) vs 44.0 years (26.0); P<0.001] and taller 
[1.59 m (0.09) vs 1.52 m (0.09); P=0.006] compared with untreated patients. There 
were no other significant differences in outcomes (data not shown).






Sex, female 55 (100%) 110 (100%) -
Age, years 31.0 (18.0) 35.0 (10.3) .016
Weight, kg 65.0 (18.2) 72.3 (17.5) <.001
Height, m 1.56 (±0.07) 1.71 (±0.06) <.001
Karyotype

























Hair washing frequency, p/weeka
• 0-2 times 
• 3-4 times 








Hair treatment, yesa,b 15 (27.3%) 53 (48.2%) .010
Values are shown as number (%), median (interquartile range), and median (±SD). 
a Hair washing frequency and hair treatment concern the three month period prior to sampling;  
b Hair treatment includes dyeing, bleaching, and perming.
Long-term cortisol exposure
Patients with TS had higher HCC compared with matched control subjects 
[geometric mean, 3.51 pg/mg (95% CI, 2.64 to 4.65) vs 2.39 pg/mg (2.13 to 2.68), 
P=0.003; Fig. 1]. Two overweight patients (with non- monosomy) with the shortest 
stature had particularly high HCC. With respect to hair characteristics, control 
subjects washed their hair more often and a greater proportion had undergone 
a hair treatment. Stepwise adjustments for these hair features, age, and weight 
did not change the results. However, the difference between the groups in HCC 
was no longer significant after additional adjustment for height. Simple linear 
regression analyses showed a strong inverse relationship between HCC and height 
for the complete study population; however, stratified analysis revealed only 
significant associations in TS (unadjusted, β=-0.307, P=0.023; adjusted for age, 
β=-0.353, P=0.014; Fig. 2A).
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• Physical QoL (PCS)





















Data are shown as median (interquartile range) and geometric mean (95% CI). 
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCS, Mental 
Component Summary score; PCS, Physical Component Summary score; QoL, quality of life.
Figure 1: Long-term cortisol concentrations as measured in scalp hair of patients with 
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HCC and cardiometabolic traits
The cardiometabolic parameters for the patient and control groups are listed in 
Table 3. Patients with TS had a worse cardiometabolic profile in terms of higher 
fasting glucose (P=0.011) and triglyceride (P<0.001) levels, with also a near-
significant higher BMI. Among patients with TS, HCC had a significant positive 
association with total cholesterol levels  (unadjusted,  β=0.294, P=0.047; adjusted 
for age, β=0.312, P=0.040; Fig. 2B). No associations were found with other 
cardiometabolic measures. There was a near-significant association with low-
density lipoprotein–cholesterol level (unadjusted, β=0.273; P=0.066). Adjustment 
for age did not affect these results.
HCC and psychological parameters
The scores on the questionnaires are shown in Table 3. The Perceived Stress 
Scale–14 score was positively, although not significantly, associated with HCC 
(β=0.257; P=0.178) in patients. There was neither a significant association between 
HCC and indices of fatigue (Checklist Individual Strength–20 β=-0.190; P=0.275), 
physical QoL (RAND-36 PCS β=-0.124; P=0.539), or mental QoL (RAND-36 MCS 
β=-0.249; P=0.210). Results were not affected by age. In exploratory analyses, we 
assessed the association between height and the psycho- metrics and did not find 
any significant relationships.
Figure 2: Associations between HCCs with height and total cholesterol levels in 
patients with TS.


































































g)Standardized β = -.307
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In this study, we found that long-term cortisol concentrations in scalp hair were 
elevated in patients with TS when compared with matched control subjects and 
that hair cortisol was positively associated with short stature and total cholesterol 
levels in patients with TS. Patients also had a worse cardiometabolic profile in 
terms of fasting glucose and triglyceride levels. No associations were found 
between HCC and perceived stress, fatigue, or health-related QoL.
The long-term consequences of elevated chronic cortisol exposure in patients with 
TS remain unknown. Our finding of ~50% higher cortisol levels, however, could 
be relevant because subtle hypercortisolism was previously found to be related 
to a higher risk of cardiovascular events and mortality (31). This is particularly 
important because cardiovascular diseases are among the primary causes of 
premature mortality in patients with TS (2). Previous research with scalp-hair 
assessments also hinted at a relation between long-term cortisol exposure and 
cardiac events. Retrospective assessment of cortisol exposure with scalp hair, for 
instance, revealed increasing levels in the months before an acute cardiac event 
and was found to be a primary predictor for such cases (32). We also showed that 
high HCC was independently associated with an increased cardiovascular disease 
presence after adjusting for various potential other risk factors (33). The worse 
cardiometabolic profile in combination with higher cortisol levels, which were 
associated with higher cholesterol levels, therefore may be detrimental in regard 
to cardiac outcomes. Because our patients were relatively young and cardiovascular 
events usually take a long time to develop, follow-up studies perhaps could reveal 















































• Physical QoL (PCS)












Values are shown as median (interquartile range) and median (±SD). 
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCS, Mental 
Component Summary score; PCS, Physical Component Summary score; QoL, quality of life.
187
9
Long-Term Cortisol Exposure and Associations With Height and Comorbidities in Turner Syndrome
if high HCCs contribute to elevated cardiovascular risk and reveal its potency to 
predict individual cardiometabolic diseases and eventually cardiac events among 
patients with TS.
Height was significantly negatively associated with HCC in patients, whereas no 
significant relation was found in control subjects (β=-0.122; P=0.205). The causal 
direction of this relationship remains uncertain; however, increased exposure to 
cortisol impairs growth rate, as observed in pediatric patients with endogenous and 
exogenous Cushing syndrome (34). Accordingly, patients should have been exposed 
to higher cortisol levels much earlier (i.e., during the growth phase), because our 
population was, on average, older than 30 years. On the other hand, short stature 
is associated with less social competence (35) and is perceived as problematic by 
a large proportion of patients (36), which could conceivably induce psychological 
and biological stress. Concordantly, an earlier randomized controlled trial with 
GH therapy in TS showed that a higher growth rate, indeed, was associated with 
better psychological state, including greater self-perception and less teasing (37).
On the basis of the various mechanisms controlling cortisol exposure, several 
hypotheses can be proposed for the relatively higher cortisol levels in TS. High 
levels of psychological distress are related to elevated HCCs, as seen in different 
patient populations (16). Many patients with TS eventually manage to become 
well integrated in society, but there are several issues that may affect the 
psychological burden over time. Regarding their motor, cognitive, and emotional 
development, young girls with TS tend to develop slightly slower than most of 
their age mates (35, 36, 38–40). Combined with their slow development, their atypical 
appearance may make these girls vulnerable for exclusion or teasing (41). With 
increasing age, more attention and consciousness might also be raised toward 
health and infertility, which, in turn, may contribute to the development of low 
self-concept, low self-esteem, social anxiety, or depression (42, 43). This could 
subsequently further increase psychological stress and eventually lead to increased 
levels of cortisol secretion. With respect to the assessed psychological parameters 
here, we did not find significant relationships between any of the assessments 
and HCC. This perhaps could be explained by differences in dynamics between 
psychological and biological stress, and differences in time coverage between the 
scalp-hair analysis and the included questionnaires.
Another underlying cause for the increased exposure could be related to the body 
composition. Various studies assessing HCCs found a positive relationship with 
visceral fat mass and waist circumference in children (44) and adults (15). Gravholt 
et al. (45) showed that patients with TS, with an average BMI comparable to that 
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of our patients, have relatively greater total fat mass and visceral fat mass in 
comparison with matched control subjects. Unfortunately, we have no data on 
body composition; however, based on the high rates of overweight and obesity 
in our patient population (i.e., 62%), a relatively high visceral fat mass would 
be expected. Furthermore, the liver is frequently involved in the spectrum of 
comorbidities associated with TS, and abnormalities range from elevated liver 
enzymes to nonalcoholic fatty liver disease and even fulminant liver cirrhosis (46). 
With regard to the latter, patients with TS have a nearly sixfold greater risk of liver 
cirrhosis developing (2). These changes are believed to be related to overweight 
and architectural hepatic changes with or due to changes in the vasculature (46). 
The relationship between cortisol levels and liver disease has been described and 
linked to various mechanisms that might lead to subclinical hypercortisolism (47). 
Targher et al. (48) showed, for example, that overweight patients with a biopsy-
based diagnosis of nonalcoholic fatty liver disease had higher levels of urinary free 
cortisol and postdexamethasone suppression–test cortisol compared with control 
subjects matched for age, sex, and BMI. Interestingly, they also found a strong 
positive relation between the severity of liver damage and cortisol concentrations 
(48). Hence, it could be proposed that potential liver abnormalities in patients with 
TS are associated with either overactivation of the hypothalamus-pituitary-adrenal 
axis and/or alterations in related hepatic processes (e.g., decreased breakdown by 
hepatic cortisol-metabolizing enzymes), which eventually lead to higher cortisol 
levels and vice versa.
In this study, we investigated long-term cortisol exposure in patients with TS. With 
the state-of-the-art LC-MS/MS technique, we measured cortisol levels with greater 
sensitivity and specificity than in previous assessments with immunoassays. Other 
strengths of this study include phenotyping for cardiometabolic and psychological 
parameters, and matching with a relatively large group of female control subjects 
from the general population. Our study, however, is limited by the retrospective 
assessment of hair characteristics, the absence of similar psychological assessments 
in control women, lack of data on other potential confounders (e.g., lifestyle, 
dietary intake), the different methods used to measure biochemical parameters, 
and because the observational study design does not omit residual confounding.
In conclusion, patients with TS had increased chronic exposure to cortisol, 
as measured in scalp hair, compared with matched control subjects. This was 
associated with short stature and increased total cholesterol levels, and could 
potentially contribute to the known elevated cardiovascular disease risk in TS.
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Long-Term Cortisol Levels Are Elevated in Erythropoietic Protoporphyria Patients 
and Correlate With Body Mass Index and Quality of Life
DEAR EDITOR, Erythropoietic protoporphyria (EPP) is a rare, inherited disorder of 
haem biosynthesis, characterized by severe photosensitivity from early childhood.1 
In most countries, no effective treatment is available and the behavioural 
adaptations needed to avoid sunlight, in addition to pain and sleep deprivation 
associated with phototoxic episodes, are important stressors in patients with 
EPP.2 This might be reflected in increased long-term cortisol levels, which can be 
measured in scalp hair. Hair cortisol concentrations (HCC) have previously been 
shown to be positively correlated with chronic stress.3 In this study, we investigated 
HCC in patients with EPP and the possible relationship with body mass index (BMI), 
self-reported perceived stress, quality of life (QoL) and disease severity.
Adults with a confirmed diagnosis of EPP, attending our Porphyria Center at the 
Erasmus Medical Center (Rotterdam, the Netherlands), were invited to participate 
in the study. At the time of inclusion, patients were not receiving any treatment 
for EPP. Patients were age- and sex-matched to controls from our historical 
cohort4 with a ratio of 1 : 3. Participants with insufficient hair growth, concomitant 
disorders of the hypothalamus-pituitary-adrenal (HPA) axis or continuous 
exogenous corticosteroids use in the past 3 months were excluded.
In both groups, a lock of scalp hair was cut from the posterior vertex and processed 
for determination of long-term cortisol exposure as described elsewhere.4 We 
further collected data on age, sex, BMI, medication use and hair-related factors 
in all participants. In addition, the EPP group were asked to fill out the 14-item 
Perceived Stress Scale (PSS),5 the EPP-specific QoL questionnaire (EPP-QoL)6 and 
to report the time they could spend in direct sunlight without symptoms.
This study was approved by the local medical ethics committee and was conducted 
in accordance with the Declaration of Helsinki; all participants gave written 
informed consent. Statistical analyses were performed with IBM SPPS Statistics 
version 21 (IBM, Armonk, NY, U.S.A.). Differences between groups were assessed 
with ANCOVA and correlations were tested using Pearson’s or Spearman’s rho 
correlation coefficient. The level of significance was set at α = 0·05.
Fifteen participants with EPP and 45 controls were included. There were no 
significant differences between the groups in baseline or hair characteristics, 
except for natural hair colour (P = 0·022). The EPP group had significantly higher 
HCC than matched controls [geometric  mean,  17·06 pg  mg-1,  95% confidence 
interval (CI) 13·02–22·35 vs. 8·28 pg mg-1, 95% CI 5·88–11·64, Cohen’s d = 0·83, 
P = 0·021, Fig. 1]. Adjustments for age, sex and hair colour did not change the 
results. Scores on the EPP-QoL, PSS-14 and sunlight sensitivity were available 
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in nine, 15 and 13 patients, respectively. There was a strong inverse association 
between long-term cortisol exposure and EPP-QoL scores (q = -0·703, P = 0·035). 
No correlation was found between HCC and PSS scores, or between HCC and the 
time that could be spent in sunlight. In the EPP group, we additionally observed a 
positive correlation between HCC and BMI (r = 0·672, P = 0·012).
In this study, we have demonstrated that patients with EPP have higher long-term 
cortisol levels than age- and sex-matched controls and that this was correlated 
with lower QoL and higher BMI. Stress in patients with EPP is related to limitations 
in their social and professional life, but also to pain from phototoxic reactions and 
a deep-rooted fear of sunlight.6 In addition, reduced light exposure and alterations 
in the day-night rhythm, common in these patients,2 could disturb the circadian 
cortisol rhythm and induce alterations in HPA-axis activity.
The strong correlation between HCC and scores on the EPP-QoL suggests that the 
measurement of hair cortisol could be a useful addition in the study of EPP and 
the efficacy of new treatments, such as afamelanotide,6 as it assesses all aspects 
of stress, including biological stress. Furthermore, the association between HCC 
and BMI, as found in the EPP group, has previously been described in other study 
participants.7,8 It could be suggested that there is a vicious circle in patients with 
EPP in which weight gain because of stress, pain or reduced physical activity may 
lead to greater stress-induced cortisol production, thereby promoting further 
weight gain.
Figure 1: Long-term cortisol exposure as measured in scalp hair of study and control 
participants.
Hair cortisol concentrations in the erythropoietic protoporphyria (EPP) group and the age-and sex-
matched control group (a), and their associations with body mass index (BMI) (b) and EPP-specific 
quality of life (EPP-QoL) questionnaire score (c) in the EPP group. Hair cortisol concentrations are 





Long-Term Cortisol Levels Are Elevated in Erythropoietic Protoporphyria Patients 
and Correlate With Body Mass Index and Quality of Life
The main limitation of this study is the small sample size, which is related to 
the rarity of EPP.1 Furthermore, we did not take into consideration the seasonal 
variance of EPP-related symptoms or potential seasonal effects on hair cortisol 
levels in both groups. Whether EPP-related symptoms affect cortisol production 
should be assessed in further studies.
In conclusion, we show that long-term cortisol levels, as measured in hair, are 
elevated in patients with EPP and that these are associated with a lower QoL and 
higher BMI. Hair cortisol analysis might be a valuable tool to monitor stress-related 
comorbidities and disease-related QoL in patients with EPP.
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Context: Medical schools are challenged to create academic environments that 
stimulate students to improve their study progress without compromising their well-
being.
Objectives: This prospective comparative cohort study investigated the effects 
of raising Year-1 standards on academic performance and on students’ chronic 
psychological and biological stress levels.
Methods: In a Dutch medical school, students within the last Bachelor's degree co- 
hort (n = 410) exposed to the 40/60 (67%) credit Year-1 standard (67%-credit cohort) 
were compared with students within the first cohort (n = 413) exposed to a 60/60 
(100%) credit standard (100%-credit cohort). Main outcome measures were Year-1 
pass rate (academic performance), mean score on the Perceived Stress Scale (PSS, 
psychological stress) and hair cortisol concentration (HCC, biological stress).
Results: Year-1 pass rates were significantly higher in the 100%-credit cohort (odds 
ratio [OR] 4.65). Interestingly, there was a significant interaction effect (OR 0.46), 
indicating that raising the standard was more effective for male than for female 
students. PSS scores (n = 234 [response rate [RR]: 57%] and n = 244 [RR: 59%] in 
the 67%- and 100%-credit cohorts, respectively) were also significantly higher in the 
100%-credit cohort (F(1,474) = 15.08, P < .001). This applied specifically to female 
students in the 100%-credit cohort. Levels of HCC (n = 181 [RR: 44%] and n = 162 
[RR: 39%] respectively) did not differ between cohorts, but were significantly higher 
in female students (F(1,332) = 7.93, P < .01). In separate models including cohort and 
gender, both PSS score (OR 0.91) and HCC (OR 0.38) were significantly associated 
with Year-1 performance. Only students with both high PSS scores and high HCC 
values were significantly at risk of lower Year-1 pass rates (OR 0.27), particularly male 
students.
Conclusions: Raising the Year-1 performance standard increased academic 
performance, most notably in male students. However, it also increased levels of 
perceived stress, especially in female students. In particular, the combination of high 
levels of perceived stress and biological stress, as measured by long-term cortisol, was 
related to poor academic performance. The study suggests a relationship between 
raising performance standards and student well-being, with differential effects in 
male and female students.
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Introduction
The challenge for medical schools worldwide is to create academic environments 
that stimulate students to improve their study progress,1 without compromising 
their health.2 The urge to seek measures to improve student progress is driven 
by the substantial investment in students made by both the students themselves 
and society.3,4 A possible strategy for achieving this involves the implementation 
of academic dismissal policies that require students to make satisfactory study 
progress.1 Failure to meet set standards leads to significant delay in a student’s 
progress (eg, in systems in which students are unable to proceed to the subsequent 
year if they fail to achieve the required credits, such as in year classes) or academic 
dismissal. Academic dismissal policies are common at universities in the USA 
and have been applied at Dutch universities for the last two decades. However, 
the literature on academic dismissal policies is scarce and the limited evidence 
regarding their impact on study progress is inconclusive.5,6 Furthermore, policy 
interventions shown to be effective in some schools have proved unsuccessful 
in other disciplines,1,5 and their effectiveness depends on characteristics of the 
student population.5 Additionally, although data on the possible side-effects of 
these policy interventions are lacking, there is increasing fear that such measures 
imply a cost to student well-being.7
The introduction of an academic dismissal policy that required students to obtain 
at least two-thirds of the total number of Year-1 credits was found not to affect 
dropout, completion and study rates during the first 2 years of medical school, 
but was accompanied by higher rates of attendance at support sessions.1 The 
lack of effect on study progress may be explained by the fact that an academic 
dismissal policy focuses on minimum standards rather than on the benefits of an 
optimal study rate. This raises the question of what might happen if the minimum 
requirements were to be set to the maximum, or, in other words, if students were 
expected to obtain all Year-1 credits within 1 year.8 To the best of our knowledge, 
the impacts of a stricter dismissal policy on student well-being and academic 
performance in general, and within medical school more specifically, remain 
unknown.
Studies have found high prevalences of distress amongst medical students in 
comparison with age-matched controls including non-medical student peers,9,10 
which hampers learning, interferes with professional development and, in the 
long term, affects personal well-being and patient care.11 Previous research has 
shown that not only student-related factors, such as gender, but also school-
related factors, such as evaluation or grading systems and learning environments, 
affect student distress12 and consequently influence student well-being.13 An 
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important issue concerns whether there is an optimum level of stress for academic 
performance. Whereas acute stress may have some metabolic, immunological and 
cognitive benefits, chronic stress may cause cognitive decline, adverse effects in 
the hippocampus, and increase the risk for neurodegenerative disease, as well 
as cardiometabolic disease.14,15 To date the scarce research in medical students 
has focused mainly on acute perceived stress and less on biological stress.12 
Additionally, the methods used previously to measure levels of cortisol, the main 
stress hormone (eg, in blood, urine and saliva) are complicated by the circadian 
rhythm and pulsatile process of cortisol secretion, and by the influence of acute 
stress. Therefore, little is known about the relationship between chronic stress 
and academic performance. Current models of emotions, based on appraisal 
processes, emphasise the individualistic way in which people respond to stressful 
circumstances.13 An individual’s responses (psychological and biological) to 
demands (eg, the difficulty of an examination) that threaten an important goal 
(eg, becoming a doctor or a lawyer) are highly dependent on that individual’s 
perceptions of the demands and the resources (eg, student characteristics) that 
person has available to meet those demands. Given the high prevalences of distress 
amongst medical students in comparison with their age-matched controls,9,10,16,17 it 
is vital to gain understanding of how the (increased) use of academic dismissal 
policies relates to stress and performance amongst students. In view of the 
differential individual responses to stressful circumstances, we consider it crucial 
to also take student characteristics into account. More specifically, we will look 
at differences between the genders as a recent review suggested that female 
medical students tend to experience higher levels of stress invoked by assessment 
than male students, although this finding was not consistent across all studies.12 
Our basic claim is that for a proper understanding of the impacts of implementing 
academic dismissal policies, the potential for these policies both to positively affect 
academic outcomes and to induce chronic stress, and consequently a decline in 
student well-being and academic outcomes, must be investigated. It is, therefore, 
imperative to take both academic outcomes and student stress levels into account 
in order to uncover the impact and relevance of academic progress policies.
The present study investigated the effects of raising Year-1 standards on academic 
performance and on students’ chronic psychological and biological stress levels. 
The changes in policy at our medical school offered us the rare opportunity to 
respond to calls for research that compares differential effects for assessments 
with different stakes (high and even higher18), has relatively long follow-up 
durations and looks at the long-term effects of ongoing exposure to assessment.12 
In this study, we used a relatively novel parameter by measuring cortisol 
concentrations in scalp hair because these reflect the long-term cortisol levels of 
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recent months. This method has been well validated.19 We and others have shown 
that this method provides a unique opportunity to reliably measure the biological 
effects of stressful circumstances in humans (cf. Groeneveld et al,20 Staufenbiel et 
al,21 Stalder et al22).
We aimed to answer the following research questions: (a) What are the effects 
of raising Year-1 standards on academic performance and on medical students’ 
chronic perceived and biological stress levels?, and (b) Is there a differential effect 
for male and female students?
Methods
Context
The present study was carried out at the Erasmus MC Medical School in Rotterdam, 
the Netherlands. The first year of the integrated and theme-oriented Bachelor 
curriculum at this school is composed of thematic blocks and competence-based 
learning lines for which students can obtain a maximum of 60 credits under the 
European Credits Transfer System. From 2005 the Erasmus MC Medical School 
implemented an academic dismissal policy whereby substandard progress resulted 
in academic probation (at 12 months) or academic dismissal (at 24 months) 
(Table 1). Until 2014, students whose progress was substandard (ie, students 
who achieved less than 40 credits) at 12 months were allowed to repeat Year 1 
(probation), whereas students with 41-59  credits at 12 months were allowed to 
engage in Year-2 modules alongside their remaining Year-1 module(s). 
Credits were awarded for each module provided the student obtained a  sufficient 
grade  (ie, ≥ 5.5 out of a maximum of 10.0) on the examination. In 2014, the Year-
1 credit standard was raised from 67% (40/60 credits) to 100% (60/60 credits). 
Students were required to achieve an average grade of at least 6.0 on the nine 
examinations, but two grades of 5.0-5.49 were allowed under the condition that 
they were not obtained in the same thematic block. The intention of raising the 
Table 1: Academic probation and dismissal policies.
Time from 
enrolment, months
Type of action Standard 
(maximum)
67%-credit cohorta 100%-credit cohortb
12 Academic probation <40 credits (60)
12 Academic dismissalc <60 credits (60)
24 Academic dismissalc <60 credits (120)
a Lowest grade allowed: 5.5, minimum grade point average (GPA); 
b Two grades of 5.0-5.49 were allowed, minimum GPA: 6.0; 
c Dispensation possible for 1 year for temporary personal circumstances.
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standard was to increase the academic progress of Bachelor students.8 Students 
who failed to earn the required number of credits at the end of the first year 
(12 months) were not allowed to repeat Year 1 but were immediately subject 
to academic dismissal. The change in the assessment policy was the only major 
curriculum alteration in recent years.
Participants and procedure
Participants in this study were students in two consecutive cohorts, which included 
the last cohort to be subject to the requirement to obtain 67% of credits (entering 
in 2013, 67%-credit cohort) and the first cohort to be subject to the requirement to 
obtain 100% of credits (entering in 2014, 100%-credit cohort) and comprised 410 
and 413 students, respectively. In order to collect data on psychological stress, all 
students in both cohorts were invited to complete a survey at 1.5 months before 
the final Year-1 examination, which is taken in early July. Students were recruited 
during a single large-scale lecture and online. To determine average biological 
stress levels during the last 3 months of the academic year, scalp hair samples 
were collected from student volunteers in both cohorts on the last day of the 
academic year. Students were recruited immediately after completing their final 
examination. We deliberately planned to administer the survey on psychological 
stress in the middle of the 3-month period covered by the hair samples.
Data on academic performance were derived from the university student 
administration system and confidentiality was guaranteed. As data were collected 
as part of regular academic activities and only aggregate data are reported, 
individual consent was not necessary. For the measures of psychological and 
biological stress, written informed consent was obtained from all participants and 
confidentiality was guaranteed. Students were able to participate voluntarily and 
were not given incentives for participation. Prior to the analyses, all data were 
coded and saved without direct identification information. The current study 
was carried out in accordance with the Declaration of Helsinki and was deemed 
exempt from review after evaluation by the Medical Ethics Committee of Erasmus 
MC University Medical Centre Rotterdam.
Outcome measures
Perceived stress 
The Perceived Stress Scale (PSS) questionnaire23 consists of 14 items assessing 
both general distress and inability to deal with stress. Example items are: ‘In the 
last month, how often have you felt nervous and stressed?’ and ‘In the last month, 
how often have you felt that you could not cope with all the things that you had 
to do?’ Items are scored on a 5-point Likert scale (0 = never; 4 = very often). Higher 
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scores reflect a higher level of perceived stress (total score range: 0-56). We used 
a validated Dutch version of this questionnaire.21
Biological stress
To assess biological stress levels, we collected scalp hair samples from the 
posterior vertex. From each hair sample, the 3 cms most proximal to the scalp 
was analysed to provide data on average cortisol exposure in the preceding 3 
months. Cortisol was extracted from scalp hair using methanol and hair cortisol 
concentration (HCC) was measured using an enzyme-linked immunosorbent assay 
(ELISA) kit (DRG Instruments GmbH, Marburg, Germany) as described previously.24 
Additionally, students completed a questionnaire on hair-related factors that could 
potentially affect cortisol concentration, such as hair colour, washing frequency, 
use of corticosteroids during the previous 6 months, other medication use and 
distressing life events (herein referred to as the ‘hair questionnaire’). Hair cortisol 
values were log-transformed to normalise the distribution.
Academic Performance
The academic performance indicator used in this study was the Year-1 curriculum 
pass rate, which was defined as the proportion of students in each cohort who 
earned all 60 credits in the Year-1 curriculum within 12 months after enrolment.
Statistical analysis
To enable valid comparisons, the 67%- and 100%-credit cohorts were compared 
on the pre-admission variables of gender, using chi-squared tests, and on age and 
pre-university education grade point average (pu-GPA), using analyses of variance 
(ANOVAs). Pre-university GPA represented the mean grade obtained by a student 
during the final year of pre-university education. Final pu-GPAs were based 
half on school examinations and half on the national examination. Additionally, 
the cohorts were compared on the different variables measured in the hair 
questionnaire using chi-squared tests. We first conducted exploratory analyses 
comparing the 67%- and 100%-credit cohorts and male and female students on 
the three outcome measures. Differences in percentages were tested using chi-
squared tests and differences in means using Student’s t-test. As measures of 
effect size, we included odds ratios (ORs) (values of 1.22, 1.86 and 3.00 represent 
small, medium and large effects, respectively) or inverse equivalents (values of 
0.82, 0.54 and 0.33 represent small, medium and large effects, respectively)25 and 




Next, we used logistic regression to calculate an OR for the effect of the academic 
dismissal policy (67%-credit versus 100%-credit requirement) on Year-1 pass rate. 
Statistical interaction terms were used to study the potentially differential effects 
of the academic dismissal policy by gender. We included ORs as measures of effect 
size.25 We used a two-way ANOVA to examine the effect of the academic dismissal 
policy and gender on PSS sum scores and on HCC values. Generalised omega-
squared was computed as a measure of effect size as recommended by Olejnik 
and Algina,27 with values of 0.01, 0.06 and 0.14 indicating small, medium and large 
effects, respectively.
Finally, we used logistic regression to test three models: (a) a model including the 
academic dismissal policy, gender and PSS; (b) a model including the academic 
dismissal policy, gender and HCC, and (c) a model including the academic dismissal 
policy, gender and a compound score based on median values for PSS score and 
HCC. The compound score divided participants into four groups: (a) LowLow (≤ 
median for both PSS score and HCC value); (b) HighLow (> median for PSS score 
and ≤ median for HCC value; (c) LowHigh (≤ median for PSS score and > median 
for HCC value), and (d) HighHigh (> median for both PSS score and HCC value). All 
variables were entered simultaneously in a multivariable logistic regression model.
Analyses were performed in spss Version 21.0 (IBM Corp., Armonk, NY, USA). A 
P-value of <.05 was considered to indicate differences of statistical significance.
Results
Student characteristics
The PSS was completed by the majority of the students (67%-credit cohort, n = 
234 [57%]; 100%-credit cohort, n = 244 [59%]). All respondents answered all items 
on the questionnaire. With respect to biological stress, we collected scalp hair 
samples from 181 students in the 67%-credit cohort (44%) and from 162 students 
in the 100%-credit cohort (39%). All of these students also completed the hair 
questionnaire.
The 67%- and 100%-credit cohorts did not show significant differences with 
respect to gender (66% female and 67% female, respectively), mean age (19.27 
years and 19.26 years, respectively) and pu-GPA (7.15 and 7.16, respectively). 
The only significant difference on the hair questionnaire was a higher score 
in the 100%-credit cohort for distressing life events, most of which referred 
to examinations as indicated by the students (41% and 71% in the 67%- and 
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Academic performance
The exploratory analyses showed significantly higher Year-1 pass rates in the 
100%-credit cohort compared with the 67%-credit cohort, both for the total 
cohorts and for men and women separately (Table 2). Female students had a 
significantly higher Year-1 pass rate than male students (Table 3).

















































































a Odds ratio; 
b Percentage of all students from initial cohort; 
c Cohen’s d. 
Abbreviations: ES, effect size; HCC, hair cortisol concentrations; PSS, Perceived Stress Scale.
Table 3: Academic performance and stress measures in male and female students.
Gender Statistics
Male Female
n % n % χ2 P-value ESa
Year-1 completionb 155 56 350 64 5.56 <.05 1.42
n Mean n Mean t P-value ESc
PSS 143 23.72 335 26.97 3.72 <.001 0.38
HCC 133 20.21 210 25.39 2.51 <.05 0.26
n % n % χ2 P-value ESa
Compound Score
PSS Low HCC Low
PSS High HCC Low 
PSS Low HCC High





















a Odds ratio; 
b Percentage of all students from initial cohort; 
c Cohen’s d. 
Abbreviations: ES, effect size; HCC, hair cortisol concentrations; PSS, Perceived Stress Scale.
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The logistic regression analysis revealed that Year-1 pass rates were significantly 
higher in the 100%-credit cohort (Wald χ2(1) = 34.77, P < .001; OR 4.65, 95% CI 
2.79-7.75) and in female students (Wald χ2(1) = 11.39, P < .001; OR 2.05, 95% CI 
1.35-3.11). Furthermore, a significant interaction effect (Wald χ2(1)  = 6.00, P < .05; 
OR 0.46, 95% CI 0.25-0.86) indicates that raising the standard was more effective 
for male than for female students (Figure 1A).
Stress
Students in  the  100%-credit  cohort  scored  significantly  higher  on the PSS than 
students in the 67%-credit cohort (Table 2). Subanalyses by gender revealed that 
only female students had significantly higher PSS scores in the 100%-credit cohort 
compared with the 67%-credit cohort. In general, female students had significantly 
higher PSS scores than male students (Table 3).
In line with these findings, the two-way ANOVA revealed significantly higher PSS 
scores in the 100%-credit cohort (F(1,474) = 15.08, P < .001, ωG2 = 0.03) and in 
female students (F(1,474) = 16.29, P < .001, ωG2 = 0.03). There was no significant 
interaction effect (F(1,474) = 3.84, P = .051, ωG2 = 0.01) (Figure 1B).
Figure 1: Year-1 performance and stress outcomes in study cohorts of medical 
students tasked with achieving 67% and 100% of Year-1 credits, respectively.
A, Year-1 pass rates in the total 67%-credit (n = 410) and 100%-credit (n = 413) cohorts, and separately 
in each cohort for female (n = 270 and n = 275, respectively) and male (n = 140 and n = 138, respectively) 
students. B, Mean ± standard error (SE) scores on the Perceived Stress Scale (PSS) for all participants 
in the 67%-credit (n = 234) and 100%-credit (n = 244) cohorts, and for female (n = 166 and n = 169, 
respectively) and male (n = 68 and n = 75, respectively) students. C, Mean ± SE untransformed hair 
cortisol concentration (HCC) in all participants in the 67%-credit (n = 181) and 100%-credit (n = 162) 
cohorts, and in female (n = 114 and n = 96, respectively) and male (n = 67 and n = 66, respectively) 
students. Statistical analyses were performed to show differences between cohorts (total or subgroup) 
or between male and female students within a cohort. *P < .05
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Students in the two cohorts did not significantly differ in HCC values (Table 2). 
However, female students had higher HCC levels than male students (Table 3). 
These findings were confirmed by the two-way ANOVA. Hair cortisol concentrations 
did not differ between the cohorts (F(1,343) = 0.33, P = .57), but were significantly 
higher in female students (F(1,343) = 7.55, P < .01, ωG2 = 0.02); there was no 
interaction effect (F(1,343) = 0.15, P = .69) (Figure 1C).
Stress and academic performance
Both PSS and HCC data were available for 135 students (33%) in the 67%-credit 
cohort and for 133 students (32%) in the 100%-credit cohort. There was no 
significant correlation between PSS  score and HCC (r(268) = .11, P = .07). In 
separate models including cohort and gender, both PSS (Wald χ2(1) = 33.35, P < 
.001; OR 0.91, 95% CI 0.89-0.94) and HCC (Wald χ2(1)  = 4.17, P < .05; OR 0.39, 95% 
CI 0.16-0.96) were significantly associated with Year-1 performance. Only students 
with high values (above median) on both the PSS and HCC were significantly at risk 
of lower Year-1 academic performance (Wald χ2(1) = 9.22, P < .01; OR 0.26, 95% CI 
0.11-0.62), particularly male students (Figure 2). Notably, the gender proportion 
was not comparable within the four compound score groups (χ2(3)  = 8.68, P < .05) 
as male students were more likely to have both low PSS scores and low HCC values 
than female students (39% and 25%, respectively; OR 1.88) (Table 3).
Figure 2: Year-1 performance and compound Perceived Stress Scale (PSS) scores and 
hair cortisol concentration (HCC) values.
Year-1 pass rates for all participants combined (n = 268) and by gender (ie, female [n = 178] and male [n 
= 90]) divided according to compound score based on median values for PSS (26.00) and HCC (25.30). 




This study shows that raising the Year-1 performance standard increased academic 
performance, most prominently in male students. However, it also increased levels 
of perceived stress, especially in female students. There was no effect on levels of 
biological stress as measured by long-term cortisol secretion. Nevertheless, the 
combination of high perceived stress and high biological stress was found to be 
related to poor academic performance.
It is not surprising that Year-1 performance improved after the Year-1 standard 
was raised because this is in line with findings in previous studies that have shown 
superior performance on tests with higher stakes28-30 (ie, higher consequences of 
performance) or with higher performance standards31,32 (ie, higher demands in 
order to pass). However, it is not in line with previous findings by ourselves and 
others on the effectiveness of implementing academic dismissal policies.1,5,6,33 An 
important difference between the current and these previous studies is that the 
present study is the first to investigate the effect of setting the minimum standard 
to be equivalent to the maximum. To date, two possible explanations have been 
suggested for the limited effects of academic dismissal policies on medical student 
performance: (a) a threshold effect, which assumes that students may reduce their 
efforts after obtaining the minimum number of credits required, and (b) a ceiling 
effect based on the assumption that there is little room for improvement given 
the already high Year-1 pass rates of medical students.8 Our study suggests that 
the first explanation is more plausible because some students were apparently 
able to improve their study progress after they were (strongly) encouraged to do 
so.
A striking finding concerned the gender-related difference in the effectiveness of 
the measure and the observation that male students were able to surpass female 
students in Year-1 performance. It is possible that the threshold effect applies more 
to male than to female students. Previously, it has been suggested that despite 
the importance of intrinsic motivation, external triggers (ie, higher performance 
standards) may have a powerful additional effect on academic motivation.18 Our 
data suggest that this additional effect may be stronger for male than for female 
students. This is in line with findings in previous studies, which have shown that 
male students tend to have higher extrinsic or controlled motivation and lower 
intrinsic or autonomous motivation than female students.34,35
The increased academic performance coincided with increased levels of perceived 
stress, especially in female students. Higher levels of assessment stress or anxiety 
in female students than in male students have been reported previously, but this 
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gender effect was not consistent across the studies included in the review by Lyndon 
et al.12 One possible explanation for the gender-related differences in perceived 
stress refers to personality traits, of which the combination of neuroticism and 
conscientiousness in particular has been found to be more commonly present in 
female medical students and to be associated with higher levels of stress.36 Other 
potential explanations for the gender-related differences in perceived stress refer 
to previously identified gender-based differences in levels of overestimation37 
and of rumination.38 Despite the increase in perceived stress brought about by the 
implementation of the new policy, our students generally reported lower levels of 
perceived stress than medical students in the USA39 and Pakistan.40
Raising the standard did not have an effect on levels of biological stress. However, 
students who scored highly on both stress outcomes, particularly male students, 
showed worse study performance. This finding emphasises the individual 
approaches of students in evaluating their well-being during medical school. 
Furthermore, differences in dynamics between psychological and biological stress 
may explain the non-significant relationship between the two stress outcomes. 
Future studies may want to investigate the differential consequences of high 
levels of both biological and psychological stress in male and female students.
The current study has several strengths and limitations that should be mentioned. 
A first strength is that we included a rather large sample size in both cohorts, 
which increased the power to identify differences and allowed us to perform 
multiple group comparisons. Nevertheless, it may be that our subsamples were 
not representative of the total cohorts. However, we do not have any reason to 
suspect differences in non-participants between the two cohorts. Focusing on 
the participants from whom we collected hair samples revealed no significant 
differences with respect to gender, mean age and pu-GPA between the two 
cohorts, and similar conclusions with respect to academic performance and 
perceived stress. Another strength of our study is that the students were well 
characterised for both individual parameters at admission and different stress 
parameters at the end of Year 1. An important limitation is that no data were 
collected on stress-related psychological and physical effects, which makes it 
difficult to infer anything about the consequences of higher levels of stress in this 
population. Additionally, it is not possible to infer causality on the basis of our data, 
despite the fact that data on stress and academic performance were collected 
at different time-points. To ascertain definitive causal pathways, further studies 
that measure stress levels throughout the first year are required. Although the 
groups were quite similar regarding pre-admission variables and the 100%-credit 
cohort more frequently reported examination-related life events, the use of 
Chapter 11
214
historical control subjects in the study design prevents us from drawing definitive 
conclusions about the effects of the academic progress policy on the outcomes. 
This study has some practical implications for medical schools that aim to improve 
their students’ progress and offers some directions for future research. First, our 
findings suggest a relationship between the raising of performance standards and 
student well-being. As we noted earlier, an important aspect of the relationship 
between stress and academic performance relates to the issue of whether there is 
an optimum level at which students can perform best. In this study, we found that 
an increased academic demand was associated with better performance, as well 
as relatively higher PSS scores, reflecting psychological stress levels in the past 
month, whereas no differences were found in average long-term biological stress 
experienced over the preceding 3 months. Despite the use of measurements to 
detect chronic stress, it remains uncertain whether the higher levels of perceived 
stress observed were present during the whole of the first year and continued 
into the second year. This is of particular importance given the relatively high 
frequencies of depression, as well as suicidal thoughts, in medical students.41 
Therefore, we recommend that medical schools monitor their students’ stress 
levels when implementing measures to increase study progress and consider 
implementing interventions to improve student well-being, such as wellness 
programmes that teach mind- and body-based stress reduction skills and formal 
faculty advisor/mentor programmes for small groups.2
Second, our study revealed gender-related differences in the effects of the 
raising of standards. This suggests that changes in the academic environment may 
have differential effects in male and female students. Therefore, as in medical 
practice, we urge medical educationalists to take differential effects in subgroups 
into account, both in designing and implementing, and in evaluating the effects 
of educational innovations. This may be particularly important for educational 
innovations that influence feelings of autonomy. Generally, autonomous 
motivation is reported to be associated with greater psychological well-being than 
controlled motivation.42 Further research is required to explore possible gender-
based differences in that pattern, especially in an academic environment.
Conclusions
Raising the Year-1 performance standard increased academic performance, most 
prominently in male students. However, it also increased levels of perceived 
stress, especially in female students. In particular, the combination of a high 
level of perceived stress and a high level of biological stress was related to poor 
academic performance. Our study suggests a relationship between the raising of 
performance standards and student well-being, with differential effects in male 
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Children’s Hair Cortisol as a 






In a previous study, we examined hair cortisol concentrations (HCC) in children when 
first entering elementary school (at 4 years). In this follow-up study, we examined 
their HCC when they entered third grade (at 6 years), where the more playful first 
grades proceed into a more formal learning setting. Participants were 30 six-year-old 
children (14 boys). Hair samples (≥ 5 cm) were collected two months after the summer 
holidays. Hair analysis was conducted using two 2-cm long segments, reflecting the 
first two months of school attendance in grade 3 (the scalp-near segment), and two 
months prior to the start in grade 3. Between these two sections, we left a gap of 
1 cm to avoid overlap of periods (due to differences in hair growth rate). Children 
showed a significant increase in cortisol levels when they entered third grade. This 
increase was not associated with social fearfulness or academic achievement, but 
did show significant associations with inhibitory control: children with less inhibitory 
control had higher cortisol levels after entering third grade, and larger increases in 
cortisol than children with higher scores on inhibitory control. This suggests that the 
ability to inhibit or control impulsive responsivity is important for children’s stress 
regulation when making the transition to a more formal school environment.
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Introduction
In a previous study, we showed that starting elementary school is accompanied 
by increased stress hormone levels in four-year-old children, by analyzing their 
hair cortisol concentrations (HCC; Groeneveld et al., 2013). Cortisol is a well-
known stress hormone which in humans is the final product of activation of the 
hypothalamic-pituitary-adrenal axis. In the past, cortisol levels have mainly been 
determined in urine, blood or saliva. To assess cortisol levels over a prolonged 
period of time, repeated sampling is needed at different daily time points over 
several days. Currently, cortisol can also be determined in human scalp hair to 
determine long-term cortisol levels (Bates, Salsberry, & Ford, 2017; Russell et al., 
2012; Stalder & Kirschbaum, 2012). Because hair grows at an average of 1 cm/ 
month, assessment of hair cortisol can reflect changes over time. In our previous 
study, we showed that HCC were higher after school entry than before, especially 
for fearful children. This finding supported our hypothesis that a rise in HCC can 
be specifically linked to a stress-related transition: the first entry into elementary 
school. In this follow-up study, we examined the same children’s HCC when they 
entered third grade at six years of age, where the more playful first grades proceed 
into a more formal learning setting.
Although researchers have used HCC widely to approximate stress levels in adults 
(Sauve et al., 2007; Stalder & Kirschbaum, 2012; Stalder et al., 2017; Staufenbiel 
et al., 2013), this measure is less often used in early childhood (Bates et al., 2017; 
Golub et al. 2019; Gray et al., 2018). The studies that measured HCC in children 
especially focused on chronic stress, not on stress during transitions (Yamada et 
al., 2007). Because HCC allows a retrospective assessment of cortisol exposure, 
this method seems very valuable when studying the effects of major transitions 
in life. Previous studies, using saliva measures, showed that it can be expected 
that the transition from grades is stressful (Bruce et al., 2002). We expect that 
especially the transition from the more playful first grades into a phase with more 
formal requirements can be stressful for young children. In the third grade children 
have to focus on reading, writing, and math skills, working at their own desk, and 
experience ratings on tests (Smeets, 2014; Smeets & Resing, 2013). The main 
research question of this study is: Do cortisol levels increase when children make 
this transition to formal learning in grade 3? These increased stress levels might 
have a negative effect on the development of children. Although stress responses 
are necessary for survival, chronic exposure to stress can change from adaptive 
into maladaptive (De Kloet et al 1999; Segerstrom & Miller, 2004). Previous studies 
have shown that higher stress levels in children are related to behavior changes, 
anxiety, sleep problems, and illness (Alink et al. 2018; Forbes et al. 2006; Golub et 
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al. 2019; Kenny et al. 2002, Lipton et al. 2005; Turner Cobb & Steptoe, 1998; Windle 
& Windle, 1996).
It can be expected that the transition to formal learning is more stressful for a 
subgroup of children, for example, children with a difficult temperament. In 
our previous study, we showed that especially children scoring high on social 
fearfulness showed an increase of cortisol levels when entering elementary school 
(Groeneveld et al., 2013), probably due to the new situation, with unfamiliar children 
and teachers. This temperamental characteristic has more often been linked to 
individual differences in children’s stress reactivity in young children in childcare 
(Talge et al., 2008; Vermeer & Groeneveld, 2017; Watamura et al., 2003), although 
other studies did not find any associations between a fearful temperament and 
cortisol reactivity in childcare (Watamura, Sebanc, & Gunnar, 2002; Ahnert et al., 
2004; Groeneveld et al, 2012) or during the start of a new school year (Davis, 
Donzella, Krueger, & Gunnar, 1999).
In addition to temperament, academic skills can also be an important factor in 
explaining individual differences in cortisol levels in a school setting. It could be 
argued that especially low achievers show an increase in cortisol levels when they 
enter third grade. In a study conducted with adolescents, it was shown that those 
students who were at the bottom of the scholastic hierarchy in the classroom, 
defined as students with less academic success and more troublesome behaviors, 
had higher cortisol levels (West et al., 2010) compared to their peers. 
Finally, behavioral inhibition, i.e. the ability to regulate and control behavioral 
impulses, might be related to higher cortisol levels after the transition to third 
grade at age six. This executive cognitive ability is important since other executive 
functions appear to depend on it: working memory, self-regulation of affect, 
motivation, and arousal, internalization of speech, and reconstitution (Barkley, 
1997). Individual differences in children’s inhibitory control have been found to 
be related to internalizing and externalizing behavior of children (Eisenberg et 
al., 2001) and teacher-child conflict (Berry, 2012). Moreover, it has been shown 
that inhibitory control is related to (salivary) cortisol responses in preschoolers 
(Blair, Granger, & Razza, 2005). Overactivity of the stress systems may impact the 
development of prefrontal regulatory systems, and as a consequence increase the 
risk for both attention- and emotion-regulatory problems (for a review, see Loman 
& Gunnar, 2010). With the transition to formal learning, it seems important to be 
able to inhibit behavioral responses that enable children to direct their attention 
and behavior. Thus, higher levels of inhibitory control would be expected to be 
associated with lower cortisol levels when making the transition to formal learning. 
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To summarize, in the current study, we measure HCC alterations in young children 
before and after a potential stressful transition, that is, their entry into formal 
learning at school. We hypothesize that children’s HCC are higher after entry in 
third grade than before entry. Furthermore, we study whether alterations in HCC 




The current study is a follow-up of the (Groeneveld et al., 2013) study that started 
in 2012. A total of 284 families from Leiden (the Netherlands) were invited by 
postal mail to participate. Recruitment material was in Dutch. Registration for the 
study was closed after agreement from 50 families. In 2012, eight children were 
excluded for analyses, (n = 4 hair was too short and n = 4 extremely high cortisol 
values with  > 3 SD above the mean). The remaining 42 families were again invited 
to participate in the study of 2014. An additional 9 families declined participation 
(n = 3 moved/ not able to contact, n = 3 did not want to cut hair, n = 3 were too 
busy). After the home visits another three children were excluded (n = 2 hair too 
short, n = 1 extremely high cortisol values with  > 3 SD above the mean). This 
resulted in a final sample of 30 children (45% boys). There were no significant 
differences between the families who participated in the first study and the follow 
up study (e.g. maternal or paternal education or age, child fearfulness, time spent 
in childcare, or children’s HCC). In the follow up study, children’s age ranged from 
6.5 to 6.8 years during the home visit (M = 6.6, SD = 0.08). Parents’ educational 
level was coded as the number of years of education after age 6. Mean educational 
level across mothers and fathers was 14.90 years (SD = 1.90). All children had at 
least one Dutch parent with the Dutch nationality, six children had one Dutch 
parent, and one parent with a different nationality (Egypt, Afghanistan, Hungarian, 
Chilean, German, and Japanese). 
Home visit
All children were visited at home, in a two week period, approximately two 
months after they started in grade 3. Prior to the home-visit, parents received 
a questionnaire, with questions about the background of the parents and the 
children and the temperament of the children. During the home visit children’s hair 
was collected. In addition, children administered tasks to measure their academic 
skills and a computerized inhibition control task. All procedures were carried out 
with adequate understanding and written consent of the parents. Ethical approval 
for this study was provided by the Research Ethics Committee of the Institute of 




The Child Behavior Questionnaire (CBQ) short form was used to measure the 
child’s temperament (Rothbart, Ahadi, & Hershey, 1994; Rothbart, Ahadi, Hershey, 
& Fisher, 2001). Parents were asked to fill out the CBQ based on their child’s 
behaviour during the last six months. The questionnaire was sent to them a few 
weeks before the home visit. The CBQ is a 7-point rating scale for the assessment 
of different aspects of temperament in children aged 3-7 years. For this study, 
we used the subscale fearfulness (12 items, Cronbach’s alpha = .86). An example 
item is ‘How often was your child afraid of the dark?’ answers can range from ‘1 
never’ to ‘7 always’. Higher scores on the fear scale represent more fearfulness in 
children. In 2012, parents were also asked to fill out the CBQ about their child when 
they were four years of age. Scores of the two questionnaires were significantly 
correlated, r = .71, p < .01.
Academic skills
The Rapid Automatized Naming (RAN; CB&WL [Continu Benoemen en Woorden 
Lezen]; Van den Bos & Lutje Spelberg, 2007) task was used to measure children’s 
academic skills. The CB task consists of four components: colors, letters, numbers, 
and objects. For each component, children were asked to name 50 symbols 
or objects as rapid as they can, from paper forms. The time was recorded per 
component using a stopwatch. A mean score of the time of these four components 
represents children’s academic skills. Higher scores represent lower academic 
skills, since the children took longer to finish the naming tasks. The RAN is a 
reliable instrument for children aged 5 to 16 years, judged by the COTAN (Dutch 
Commission for Test Materials of the Dutch Institute of Psychologists that test the 
quality of psychodiagnostic instruments). 
Inhibitory control
A computerized Go/NoGo task was administered during the home visit to measure 
inhibitory control on a laptop. In this task, children had to catch all the mice that 
appeared on the screen (Go-stimuli) by pressing a red button. When a cat appeared, 
children had to inhibit their reaction, and should not press the button (NoGo-
stimuli). The task consisted of a practice session, in which five mice and five cats were 
presented (in alternating order), and a test session, in which 30 mice and 10 cats 
were displayed in random order. Only during the practice session the child received 
feedback. Commission errors (responses to NoGo-stimuli) were used as a measure 
for a lack of inhibitory control (Groot, De Sonneville, Stins, & Boomsma, 2004). To 
generate a measure for inhibitory control the sum score of the commission errors 
was subtracted from the total number of NoGo-stimuli (10 – number of commission 
errors), with higher scores representing more inhibitory control. 
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Scalp hair collection
Hair was collected during home visits, which were planned approximately two 
months after the children had started school. Visits were conducted by the first 
author or trained (under)graduate students. Hair collection was performed as 
described previously (Manenschijn et al., 2011). A sample containing around 300 
hairs was cut from the posterior vertex as close to the scalp as possible. The sample 
was taped to a piece of paper, the scalp end marked, and stored in an envelope at 
room temperature until analysis. 
Prior to the home-visit, parents received a questionnaire, with questions about 
age, educational level, and birth country of the parents, and the following 
information concerning the participating child: after-school care, hair colour, hair 
washing frequency, use (and type) of corticosteroids during last six months, other 
medication use, and chronic diseases. 
Hair processing and analysis
Hair analysis was conducted using two 2-cm long segments, reflecting the first two 
months of school attendance in grade 3 (the scalp-near segment), and two months 
prior to the start in grade 3. Between these two sections, we left a gap of 1 cm to avoid 
overlap of periods (due to differences in hair growth rate). As described previously 
(Manenschijn et al 2011), we weighed and cut the hair segments into small pieces 
in glass vials using surgical scissors. Cortisol was extracted by 16h incubation in 
one mL methanol at 52°C while gently shaking. Subsequently, the methanol was 
transferred to disposable glass vials, and evaporated under a constant stream of 
nitrogen. The samples were then dissolved in 250 μL phosphate buffered saline, 
pH 8.0, and vortexed for one min. Prior to analysis, samples were vortexed again 
for 30s. Cortisol concentrations were measured using a commercially available 
salivary cortisol ELISA kit (DRG Instruments GmbH, Marburg, Germany) according 
to manufacturer’s directions. We applied a correction factor to take background 
signal into account. As stated by the manufacturer, antibody cross reactivity is as 
follows: corticosterone 29%, cortisone 3%, 11-deoxycortisol <1%, 17-OHP <0.5%, 
prednisone <0.1%. Intra-assay variation was 2.6% and the inter-assay variation was 
6.7%, as stated by the manufacturer.
Data analysis
Because the distributions of the cortisol measurements were positively skewed, 
log10 transformations were used for analysis. After log10 transformation, HCC did 
not deviate from normality. To test whether HCC differed before and after school 
entry, we conducted a repeated measure MANCOVA with time as within-subject 
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variable. To analyse associations with temperament, academic skills, and inhibitory 
control, multivariate regression analyses were conducted, using interaction terms.
Results
Descriptive statistics of HCC during wave 1 (transition to grade 1) and wave 2 
(transition to grade 3) are shown in Table 1. HCC before and after entering a new 
grade showed stability across time (wave 1 r = .80, p < .001; wave 2 r = .52, p = .004). 
In addition, HCC prior to entering third grade (wave 2, pre HCC) were related to 
HCC in wave 1 (pre r = .36, p = .05; post r = .37, p = .04), while HCC after entering 
third grade (wave 2, post HCC) were not related to HCC in wave 1. HCC in wave 2 
were not significantly related to any of the child characteristics (gender, hair color, 
hair washing frequency, use of corticosteroids, other medication, hours in group 
care), or parent characteristics (educational levels fathers and mothers).  
Change in HCC
A repeated measures MANCOVA on children’s HCC yielded a significant main 
effect of time (Pillais, F[1, 29] = 5.22, p = .03, η2partial = .15). Children’s HCC were 
significantly lower during the holiday (M = 12.61 SD = 10.11) than after the start 
in third grade (M = 16.54, SD = 12.78). The Ratio of Change (RC) ((Post HCC – pre 
HCC)/pre HCC) was not correlated between the two waves (r = .11, p = 57), which 
means that an increase in HCC when entering first grade was not associated with 
an increase in HCC when entering third grade. Nevertheless, almost half of the 
children (46.7%) showed an increase in HCC after entering both first and third 
grade (Figure 1).
Table 1: Descriptive statistics of HCC in wave 1 (transition grade) and wave 2 
(transition grade 3).
Correlations





















HCC: hair cortisol concentrations; W1: Wave 1; W2: Wave 2
*p <.05; **p <.01
229
12
Children’s Hair Cortisol as a Biomarker of Stress at School: A Follow-Up Study
Table 2: Descriptive statistics of child characteristics and correlations with hair 
cortisol concentrations wave 2.
Correlations cortisol wave 2




















The correlations between HCC in wave 2 and social fearfulness, academic 
achievement, and inhibitory control are shown in Table 2. There were no significant 
correlations between these child characteristics and pre HCC, post HCC, or change 
in HCC. In addition, we found no interaction effect for social fearfulness (B = -0.17, 
SEB = 0.19, β = -0.15, p = .37, R2 = .32) or academic skills (B = -0.01, SEB = 0.01, β = 
-0.25, p = .14, R2 = .34) when predicting post HCC. 
Figure 1: HCC ratio of change in waves 1 and 2.
Note: A = increase in HCC in waves 1 and 2,  n =  14.  B = decrease  in  HCC  in  waves  1  and  2,  n =  1. 
C = increase in wave 1, but decrease in wave 2, n = 6. D = decrease in wave 1 but increase in wave 2, 
n = 9. HCC: hair cortisol concentrations.
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For inhibitory control, significant main effects and an interaction effect were 
present. In Table 3 it is shown that pre HCC and inhibitory control predicted post 
HCC (R2 = 0.36, p < .01). The interaction between pre HCC and inhibitory control 
significantly improved the model (∆R² = .14, p < .05).  
For graphic concerns, we made a median split in inhibitory control (Median = 8). In Figure 
2 it is shown that children scoring low on inhibitory control show a large increase in their 
HCC after entering grade 3 (Pillais, F[1, 14] = 14.70, p < .01, η2partial = .51), while HCC 
from children scoring high on inhibitory control do not change (Pillais, F[1, 14] = 0.02, 
p = .89, η2partial < .01).
Table 3: Inhibitory control predicting post HCC.
Step 1 (R2 = .36*) Step 2 (R2 = .50*)
B SEB β p B SEB β p
Constant 1.13 0.05 1.14 0.04
Pre HCC 0.57 0.16 0.55 <.01 0.47 0.15 0.46 <.01
Inhibitory control 0.07 0.03 0.30 .06 0.07 0.03 0.30 .04
Pre HCC * inhibitory control 0.31 0.11 0.40 .01
HCC: hair cortisol concentrations.
*p < .05.
Figure 2: HCC levels of children scoring high or low on inhibitory control.
HCC: hair cortisol concentrations.
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Discussion
In this study, we showed that on average HCC increase when children enter third 
grade at six years of age. This increase was not associated with social fearfulness or 
academic achievement, but we did find associations with inhibitory control: children 
with less inhibitory control had higher cortisol levels after entering third grade, and 
larger increases in cortisol, than children with higher scores on inhibitory control. 
As expected, children show an increase in HCC when they entered grade three, 
where the more playful first grades proceed into a more formal learning setting. 
This corresponds to our earlier finding of HCC increases after entering grade one 
(Groeneveld et al., 2013). HCC in this follow up study were lower in terms of absolute 
values (pre and post) than in the previous study. Because we measured differences 
between the manufacturer’s standards (optimized for measuring cortisol in saliva) 
and our own standard curve (prepared in PBS, like the HCC samples), we computed a 
correction factor and corrected the absorbance values of the samples based on the 
standards from the kit. This is something we have decided to apply with increased 
knowledge over time and could probably be one of the reasons for the difference 
with the earlier study.
When studying child characteristics, we focused on inhibitory control, temperament, 
and academic skills. First, we found that children scoring low on inhibitory control 
showed an increase in their HCC after entering grade 3, while HCC from children 
scoring high on inhibitory control do not change. This implies that especially children 
who find it difficult to inhibit reactions experience the transition to formal learning 
as more stressful. This seems logical because the dynamics change from the more 
playful first years, to the more scholastic environment. For example, in third grade 
the time children spend playing inside and outside decreases considerably, and at 
the same time they are requested to sit still at their desk, and focus on fine motoric 
skills, learning how to write, read, and do math (Smeets, 2014; Smeets & Resing, 
2013). On the other hand, it might also be possible that cortisol levels influenced 
the inhibitory control levels of the children. It has been shown that overactivity of 
the stress systems may impact the development of prefrontal regulatory systems, 
and as a consequence increase the risk for emotion-regulatory problems (for a 
review, see Loman et al. 2010), but these studies are primarily based on animal-
models (Brake et al. 20004), or on children with severe early life stress (Nemerof, 
2004), so the relevance for humans is not clear yet. Previous studies with humans, 
focusing on the effect of cortisol levels on inhibition showed a positive association: 
higher cortisol levels increase inhibitory control (Shields, Bonner, & Moons, 2015). 
But these studies mainly focus on short term increases in (salivary) cortisol. A meta-
analysis has shown that cortisol improves inhibition from 15 min to 135 minutes 
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post-administration, but cortisol begins to impair inhibition after 136 minutes 
(Shields et al., 2015). This could imply that the increases in cortisol levels with the 
transfer to third grade have resulted in impaired inhibition. A pretest measure of 
inhibition scores before entry in third grade should be conducted to test causality. 
Secondly, we tested the moderation effect of social fearfulness, because this 
temperamental subscale was a significant moderator in our previous study 
(Groeneveld et al., 2013). High fearful children showed the highest rise in HCC after 
school entry in grade 1. In the current study, it seemed conceivable that the same 
pattern would be present when entering grade 3, with new unfamiliar teachers, 
and more focus on formal learning. This hypothesis was however not confirmed. 
The increase in cortisol levels of fearful children was comparable to the increases 
of HCC of their less fearful peers. It is possible that, although children entered a 
new classroom with new peers and teachers, the presence of familiar peers and the 
familiar school environment and routine is a buffer for these children. 
Third, no association was found between cortisol levels and academic skills, 
although some studies did find this association for older children (West et al., 
2010). Stress may interfere with academic performance by diverting attention from 
cognitive tasks to worry and feelings of being overwhelmed (Matheny, Aycock, & 
McCarthy, 1993). It might be possible that children were not yet aware of (and thus 
stressed by) their lower academic skills in the first weeks after they entered grade 
3. This effect might be present a few months later when children have experienced 
more academic tests. In addition, parental educational levels were quite high. A 
larger, more diverse sample including families from lower SES is needed to further 
explore these associations. 
To conclude, in this study, we showed that cortisol levels increase when children 
make the transition to a school phase with formal learning. It is important to 
study this transition, since higher levels of stress in the school and classroom 
are related to more mental health problems, adjustment problems in school, 
and lower academic achievement (Kaplan et al., 2005; Kenny et al., 2002, Windle 
& Windle, 1996). It might be helpful for children to learn strategies to cope with 
the transition, or even to cope with stress. Previous studies have shown a positive 
effect of interventions to decrease stress in children (Bothe et al. 2014; Haraldsson 
et al. 2008). Bothe et al (2014) showed that a 10-minute daily stress management 
technique was helpful for reducing anxiety scores and improving the ability to relax 
in school-age children. These daily sessions included deep breathing, movement, 
and guided imagery and were provided by the teacher, in the classroom for four 
months. In addition, there are several other resources that seem to help students 
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to cope with stress, such as improved social skills, problem-solving orientation, and 
social support. An important source of support in the educational setting is the 
teacher. In childcare studies, it has been shown that higher caregiver sensitivity and 
quality of care are associated with lower diurnal cortisol production in preschoolers 
(Vermeer & Groeneveld, 2017). In addition, lowering teachers’ occupational stress 
may be effective, since this occupational stress has been linked with children’s 
physiological stress regulation as well (Oberle & Schonert-Reichl, 2016).
We showed that especially children scoring low on inhibitory control showed 
these increased cortisol levels. This means that this group of children deserves 
extra attention in schools: how can we support these children to regulate their 
inhibitory control (for specific tasks) and how can we adapt the school environment 
to support these children? Several intervention use self-regulation techniques such 
as relaxation, yoga, and imagery to improve well-being, health related issues, and 
cognitive or emotional control in children (Bell & Deater-Deckard, 2007; Bothe et al 
2014; Ehud et al. 2010; Goldbek & Schmid, 2003; Lee & Olness, 1996). The Bothe et 
al (2014) intervention with the 10-minute daily stress management technique also 
included these self-regulation techniques. It would be interesting to test whether 
this intervention might positively affect children’s inhibitory control as well. In 
addition, the school environment might also be adapted, for example by giving 
children more room in the third grade to move around. It has been shown that 
physical activity can positively affect important brain areas, which might lead to 
increases in working memory,  planning skills, and cognitive control in the short and 
long term (Hillman et al. 2009; Davis et al. 2011; Mullender-Wijnsma et al. 2015). 
A recent intervention in third grade children, including physically active academic 
lessons, showed an increase in mathematics and reading scores of children who 
participated in the intervention compared to children in a control group who 
received regular lessons (Mullender-Wijnsma et al. 2015). These physically active 
academic lessons might be especially effective for children scoring low on inhibitory 
control. More research is needed for this group of children.
To summarize, the current study showed that cortisol levels increase when children 
make the transition to formal learning, especially children scoring low on inhibitory 
control. It is important to study this transition to grade three and possible resources 
to regulate the stress responses of children, because this transition is the basis of 
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Posttraumatic stress disorder (PTSD) is associated with altered hypothalamic-
pituitary-adrenal (HPA) axis function. Measurement of hair cortisol concentrations 
(HCC) allows retrospective assessment of HPA axis regulation over prolonged periods 
of time. Currently, research investigating HCC in PTSD remains sparse. Previous cross-
sectional studies have included only civilian populations, although it is known that 
trauma type moderates associations between PTSD status and HPA axis function. We 
investigated differences in HCC between trauma-exposed female police officers with 
current PTSD (n = 13) and without current and lifetime PTSD (n = 15). To investigate 
whether HCC was associated with neural correlates of PTSD, we additionally 
performed exploratory correlational analyses between HCC and amygdala reactivity 
to negative affective stimuli. We observed significantly lower HCC in participants with 
PTSD than in participants without PTSD, d = 0.89. Additionally, within participants 
with PTSD, we observed positive correlations between HCC and right amygdala 
reactivity to negative affective (vs. happy/neutral) faces, r = .806 (n = 11) and left 
amygdala reactivity to negative affective (vs. neutral) pictures, r = .663 (n = 10). 
Additionally, left amygdala reactivity to negative faces was positively correlated with 
HCC in trauma-exposed controls, r = .582 (n = 13). This indicates that lower HCC is 
associated with diminished amygdala differentiation between negative affective and 
neutral stimuli. Thus, we observed lower HCC in trauma-exposed noncivilian women 
with PTSD compared to those without PTSD, which likely reflects prolonged HPA 
axis dysregulation. Additionally, HCC was associated with hallmark neurobiological 
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Introduction
Posttraumatic stress disorder (PTSD) is associated with altered hypothalamic-
pituitary-adrenal (HPA) axis function; this has mainly been investigated by assessing 
acute cortisol levels and glucocorticoid receptor (GR) function (Olff & van Zuiden, 
2017). Insight into chronic HPA axis dysregulation may be gained by assessing 
cortisol in scalp hair, which allows retrospective assessment over prolonged 
periods of time (Staufenbiel, Penninx, Spijker, Elzinga, & van Rossum, 2013). 
Research on hair cortisol concentrations (HCC) in PTSD has been relatively sparse. 
In one cross-sectional study, higher levels of HCC were observed in individuals with 
PTSD compared to trauma-exposed controls (TCs) in a mixed-gender sample of 
refugees with ongoing distress (Steudte et al., 2011). In another study, the authors 
found lower levels of HCC in trauma-exposed individuals with and without PTSD 
compared to non-trauma-exposed controls in a predominantly female sample 
(Steudte et al., 2013). Additionally, no HCC differences were found between 
female refugees with stress-related disorders and TCs (Schalinski, Elbert, Steudte-
Schmiedgen, & Kirschbaum, 2015) or between male refugees who had recently 
fled their country of origin with and without PTSD (Mewes, Reich, Skoluda, Seele, 
& Nater, 2017). In a longitudinal study, pretrauma HCC did not differ between 
female adolescent earthquake survivors with and without PTSD at 7 months after 
the earthquake (Luo et al., 2012). Acute posttrauma HCC was elevated in both 
groups but had normalized at 5–7 months after the earthquake in TCs. At the final 
assessments, survivors with subsequent PTSD had lower HCC than TCs (Luo et al., 
2012). In a prospective study, high HCC in the acute posttrauma period predicted 
subsequent PTSD symptoms in a predominantly female sample of individuals 
hospitalized with physical injuries (Pacella, Hruska, Steudte-Schmiedgen, George, 
& Delahanty, 2017). In the only study to our knowledge that has used a noncivilian 
sample, low predeployment HCC predicted PTSD symptom development in male 
soldiers upon trauma exposure during deployment (Steudte-Schmiedgen et al., 
2015). Trauma type has been shown to moderate the association between PTSD 
and acute cortisol levels (Meewisse, Reitsma, de Vries, Gersons, & Olff, 2007). To 
date, associations between HCC and PTSD have been predominantly investigated in 
female civilian populations. It remains unknown whether previous findings extend 
to noncivilian populations, particularly those at risk for cumulative exposure to 
work-related traumatic events.
To understand the pathophysiology and clinical and phenotypic heterogeneity 
of PTSD, it is of interest to investigate whether chronic HPA axis dysregulation 
is associated with neural correlates of PTSD. Glucocorticoid receptor and 
mineralocorticoid receptor (MR) activation affect amygdala excitability and 
synaptic connectivity and may induce anxiogenic responses, with exact effects 
Chapter 13
242
depending on duration, timing, and amount of current and prior glucocorticoid 
exposure (de Quervain, Schwabe, & Roozendaal, 2017). This is of relevance for 
PTSD as several meta-analyses have observed significant amygdala hyperreactivity 
in individuals with PTSD (Hayes, Hayes, & Mikedis, 2012; Koch et al., 2016a; Patel, 
Spreng, Shin, & Girard, 2012; Sartory et al., 2013; Stark et al., 2015). This fits with 
the predominant neurocircuitry model for PTSD, which posits a central role for 
increased salience and threat hypersensitivity by brain areas within the salience 
network, including the amygdala, that is paralleled by inadequate top-down 
regulation by ventromedial prefrontal areas (Koch et al., 2016a). In these meta-
analyses, specifically those related to right amygdala hyperreactivity in response 
to non-trauma- related negative stimuli (Stark et al., 2015), differences in amygdala 
functioning between trauma-exposed individuals with and without PTSD were 
observed, whereas no differences in amygdala reactivity to trauma-related stimuli 
were observed between PTSD and TC groups (Sartory et al., 2013).
In the current study, we investigated HCC differences between trauma-exposed 
female police officers with (n = 13) and without PTSD (n = 15). We additionally 
performed exploratory analyses to assess associations between HCC and amygdala 
reactivity to non-trauma-related negative affective stimuli and a mixture of non-
trauma-related and potentially trauma-related negative affective stimuli. The 
current study comprised a subsample of a larger neuroimaging study that included 
both women and men. In the larger study, we did not observe significant group 
differences in amygdala reactivity toward negative affective stimuli (Koch et al., 
2016b). However, although TCs showed increased amygdala reactivity to negative 
compared to neutral or positive affective faces, this differential reactivity was 
absent in participants with PTSD, indicating there may be increased saliency 
attributed to potential affective aspects of faces (Koch et al., 2016b).
Methods
Participants
This study was part of a randomized controlled trial on neural effects of a single 
oxytocin administration in male and female trauma-exposed police officers with 
and without PTSD who were between 18 and 65 years of age (Koch et al., 2016b). 
Data presented in the current manuscript were collected at baseline or during 
the session in which they received a placebo. For the current study, we included 
female participants only, as the overlarge majority of male participants did not 
have sufficient hair length for HCC determination. Hair segments were available 
for 14 participants with PTSD and 16 TCs. One participant with PTSD and one TC 
were excluded due to extreme HCC values (described later), which resulted in 13 
patients with PTSD and 15 TCs. Additionally, two patients with PTSD dropped out 
243
13
Associations Among Hair Cortisol Concentrations, Posttraumatic Stress Disorder Status, 
and Amygdala Reactivity to Negative Affective Stimuli in Female Police Officers
of the study prior to the placebo-scanning session, and one additional participant 
with PTSD did not complete the picture task during this session. Thus, for 
participants with PTSD, imaging data were available for 11 participants for the 
faces task and 10 for the pictures task (tasks are described later in this article). 
Imaging data were available for all TCs, but one TC was excluded due to a scanning 
artefact in the temporal cortex.
Participants with PTSD fulfilled criteria given in the fourth edition of the Diagnostic 
and Statistical Manual of Mental Dis- orders (DSM-IV) for current PTSD, with a total 
score on the Clinician-Administered PTSD Scale for DSM-IV (CAPS) of  45 or higher 
(Blake et al., 1995). Exclusion criteria for participants with PTSD were current severe 
major depressive disorder (MDD) with psychotic symptoms and/or suicidal intent, 
suicidal ideation, alcohol/substance abuse (except smoking), bipolar disorder, and 
psychotic disorder. Individuals in the TC group had to have reported at least one 
DSM-IV Criterion A traumatic event and scored a 15 or less on the CAPS. They were 
matched to patients based on sex, age, education, and years of service. Exclusion 
criteria for TCs were lifetime MDD or PTSD or any current DSM-IV Axis I psychiatric 
disorder. Exclusion criteria for all participants were daily use of psychoactive 
medication (incidental use was allowed as long as it had not occurred less than 
24 hr prior to scanning) or systemic glucocorticoids, serious medical conditions, 
a history of neurological disorders, and several common contraindications for 
magnetic resonance imaging (MRI) and oxytocin administration (Koch et al., 2016b).
We did not observe significant group differences in demographic or health 
characteristics (Table 1). There were 12 TCs (80.0%) and six participants with PTSD 
(50.0%) who were in active  police duty,  Fisher’s  exact test = 0.13, p = .127; this 
likely explained why TCs reported nominally more types of work-related traumatic 
events than participants with PTSD, t(25) = 1.82, p = .080. Hair color differed 
between groups— the majority of participants with PTSD had brown hair whereas 





Participants were recruited through a diagnostic outpatient center for police 
personnel  (PDC; Diemen, the Netherlands; n = 3 participants with PTSD) and 
advertisements (n = 11 participants with PTSD and all TCs). All participants 
provided verbal and written informed consent prior to study initiation. At baseline, 
inclusion and exclusion criteria were assessed using diagnostic clinical interviews 
and self-report questionnaires. For patients recruited via the diagnostic outpatient 
Table 1: Demographic and clinical characteristics of study participants.
PTSD (n=13) Trauma-Exposed controls (n=15)
Characteristic M SD n % M SD n % p
Age (years) 42.00 7.96 38.00 9.98 .257a
Years of police service 15.88 9.91 18.73 8.13 .795a
Current active executive duty 6 50.0 12 80.0 .127d
PLES total score 12.92 8.38 18.73 8.13 .080a
ETI-SF total score 5.42 5.90 4.40 5.49 .648b
CAPS total score 69.38 10.91 4.00 4.60 <.001a
Major depressive order 4 30.8 0 0.0 .035d
Body mass index (kg/m2) 25.00 4.14 26.43 3.26 .321a
Current smoker 3 25.0 5 33.3 .696d
AUDIT total score 3.17 4.13 3.60 1.64 .712a
Hormonal contraceptive use 5 41.7 7 46.7 1.000c
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• 3-4 times per week














Hair treatment within past 3 monthsc 7 53.8 7 46.7 .705c
Days between hair collection and scanning 
session
3.09 7.33 -0.33 15.24 .443b
Scanning session time of day (hh:mm) 14:09 1:38 15:12 2:05 .185a
Note. PLES = Police Life Events Scale; ETI = Early Trauma Inventory-Self-report form; AUDIT = Alcohol Use Disorder 
Identification Test; CAPS = Clinician-Administered PTSD Scale for DSM-IV. 
a Independent samples t test used. 
b Mann-Whitney U test used. 
c Chi-square test used. 
d Fisher’s exact test used. 
e Includes coloration, bleaching, and/or permanent wave. 
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center, clinical interviews administered during intake were used. After inclusion, 
participants completed two scanning sessions (described later). Participants were 
asked to abstain from alcohol and drugs 24 hr before scanning and from rigorous 
exercise, beverages except water, and nicotine for 2.5 hr before scanning. Prior to 
scanning, intranasal oxytocin (40 IU) and a placebo (0.9% saline) were administered 
in a randomized double-blind crossover design. For this study, we only included 
imaging data collected under placebo. For most participants (i.e., 10 participants 
with PTSD who completed scanning, 90.1%; and 11 TCs, 73.3%), scalp hair for HCC 
determination was collected before trial medication administration. We found that 
HCC did not significantly differ between TCs whose samples were collected prior 
to versus after trial medication administration, t(13) = −0.81, p = .431. The average 
time in days between hair collection and placebo scan did not significantly differ 
between groups (Table 1). The study was approved by the Institutional Review 
Board of the Amsterdam University Medical Centers, location Academic Medical 
Center, Amsterdam, the Netherlands, and was registered in the Netherlands Trial 
Registry (NTR3516).
Measures
PTSD symptoms. All participants with PTSD were originally diagnosed by a licensed 
clinician prior to study inclusion. For all participants, current PTSD symptom 
severity was assessed using the validated Dutch version of the CAPS (Blake et 
al., 1995; Hovens et al., 1994). The CAPS is the gold standard structured clinical 
interview for diagnosing PTSD and assessing PTSD symptom severity according to 
DSM-IV criteria. It assesses the three symptom clusters: reexperiencing (five items, 
with a possible score range of 0–40), avoidance (seven items, with a possible score 
range of 0–56), and hyperarousal (five items, with a possible score range of 0–40), 
and distinguishes between estimated symptom frequency (score range: 0–4) and 
intensity (score range: 0–4) in the previous month. We calculated a total symptom 
severity score by summing the intensity and frequency scores for all items. 
Higher scores indicate a higher level of symptom severity in the past month. The 
Cronbach’s alpha value for internal consistency for all items was high, Cronbach’s α 
= .98. As stated, participants met inclusion criteria for the PTSD group if their total 
score was 45 or higher; this cutoff was used to ensure current symptom severity 
above the clinical threshold. This cutoff has high sensitivity for PTSD diagnosis 
(Weathers, Ruscio, & Keane, 1999).
Other Axis I disorders. Dutch versions of the Mini International Neuropsychiatric 
Interview (M.I.N.I; Sheehan et al., 1998) or the Structured Clinical Interview for 
DSM-IV (SCID; First, Spitzer, Gibbon, & Williams, 2002) were used to assess other 
DSM-IV Axis I psychiatric disorders (the SCID was used for patients recruited 
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through the diagnostic center). Both structured clinical interviews are widely 
used, valid, and reliable for diagnosing current and lifetime psychiatric disorders 
(Lobbestael, Leurgans, & Arntz, 2011; Sheehan et al., 1998).
Work-related trauma exposure. The 42-item Dutch Police Life Events Checklist 
(PLES) was used to assess the number of different police work-related traumatic 
events participants had encountered (Carlier & Gersons, 1992). A total score was 
calculated using the first 41 items, each of which inquired about a different event, 
by summing the number of endorsed items (possible score range: 0–41).
Childhood trauma exposure.  The Dutch translation of the short self-report version 
of the Early Trauma Inventory (ETI-SF) was used to assess trauma exposure 
during childhood (Bremner, Bolus, & Mayer, 2007; Rademaker, Vermetten, Geuze, 
Muilwijk, & Kleber, 2008). This is a valid and reliable measure of childhood trauma 
(Bremner et al., 2007). The questionnaire consists of 21 items that assess whether 
participants were exposed to different types of physical (nine items), sexual (six 
items), and emotional abuse (five items) as well as general traumas (11 items) 
before 18 years of age. We calculated a total score by summing the number of 
endorsed items (range: 0–21).
Alcohol abuse. The Dutch translation of the validated Alcohol Use Disorder 
Identification test (AUDIT; Bush, 1998) was used to assess current alcohol use and 
level of alcohol-related risk. It contains 10 items that assess alcohol consumption 
and indicators of dependence and harmful drinking. A total score was calculated 
by summing all item scores (range: 0–40). In the current sample, Cronbach’s 
alpha for all items was questionable, α = .64, presumably because all participants 
except one obtained the lowest possible scores for all seven items inquiring about 
dependence and harmful drinking whereas scores on the three items regarding 
consumption quantity varied. Additionally, participants self-reported demographic 
characteristics, current active police duty (executive function), weight, and height 
to calculate body mass index, current smoking status, medication and hormonal 
contraceptive use, and hair characteristics (color, washing frequency, coloration, 
bleaching, and permanent wave application in past 3 months).
Hair cortisol assessment. Hair was collected from the posterior vertex. Upon 
collection, samples were taped to paper and stored in closed envelopes at 
room temperature. We assessed cortisol concentrations in the most proximal 3 
cm of scalp hair, covering HCC in the 3 months before sample collection, using 
a validated protocol (Manenschijn, Koper, Lamberts, and van Rossum, 2011). 
Samples were cut, weighted, and incubated with 1.0 mL methanol for 16 hr at 
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52 °C. Then, methanol solutions containing cortisol extracts were transferred to 
new vials and evaporated under a nitrogen stream. After dissolving dried contents 
with 250 μl phosphate buffered saline (PBS), HCC were quantified with enzyme-
linked immunosorbent assay (ELISA; DRG Instruments GmbH, Marburg, Germany) 
following the manufacturer’s protocol. The previously determined lower-end 
detection limit for this assay is 1.5 nmol/l. The upper detection limit according to 
the manufacturer’s protocol is 220.69 nmol/l. All measurements were performed 
in duplicate in one assay. The intra-assay variability for internal controls was on 
average 1.3% (range: 0.4%–2.3%). As reported by the manufacturer, the assay 
cross-reactivity with other steroid hormones is corticosterone (29.0%), cortisone 
(3.0%), 11-deoxycortisol (less than 1.0%), 17-OH progesterone (less than 0.5%), 
testosterone (less than 0.1%), and estradiol (less than 0.1%). As is standard in 
steroid hormone hair analysis, HCC were converted to pg/mg, taking the weight of 
the hair samples into account (M 15.1 mg, SD 11.7, Mdn 12.0, range: 5.77–67.93 mg). 
Hair weight and final HCC were not significantly correlated, r = −.06, p = .754. Two 
samples were excluded from all analyses due to nondetectable (in one participant 
with PTSD) and extremely high (in one TC; HCC: 180.73 pg/mg, standardized z 
score = 4.86) HCC.
Functional MRI (fMRI). Structural and functional MRI images were acquired with 
a 32-channel head coil on a 3T Philips (Andover, MA) Achieva MR system. During 
the two scanning sessions, we presented two versions of each task, including 
different stimuli, in randomized counterbalanced order. Scanning sessions were 
scheduled in the afternoon or early evening (for more details concerning fMRI 
data acquisition, see Koch et al., 2016b). Amygdala reactivity to negative affective 
pictures was assessed using a distraction task with three conditions: (a) passive 
viewing of 20 neutral pictures, (b) passive viewing of 20 negative affective 
pictures, and (c) working memory performance during presentation of 20 negative 
affective pictures (McRae et al., 2010). Pictures were presented using an event-
related design with pseudorandom order for trial type. All trials were separated 
by an intertrial interval, which consisted of a fixation cross presented for 2000 
ms. In the current study, we used data collected during the two passive viewing 
conditions. Pictures were selected from the International Affective Picture System 
(IAPS), based on normative valence and arousal ratings (Lang, Bradley, & Cuthbert, 
2008). Pictures in the task versions were matched for normative valence, arousal, 
complexity, and luminescence. Negative pictures included scenes related to events 
police officers may encounter in their line of work (e.g., violence, accidents) and 
more general aversive scenes  (e.g., malnourished children, war-related scenes; 
Koch et al., 2018). Amygdala reactivity to negative affective faces was assessed 
using an emotional face-matching task that contained three conditions: (a) angry-
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fearful faces, (b) neutral-happy faces, and (c) scrambled faces (visuomotor control; 
Hariri, Tessitore, Mattay, Fera, & Weinberger, 2002). Each trial consisted of three 
stimuli, with a cue stimulus presented on top and two target stimuli presented 
below. Participants were instructed to match the emotional expression (emotional 
condition) or the orientation (visuomotor control) of the cue stimulus with one 
of the target stimuli. Faces were selected from the NimStim face stimuli set (see 
Koch et al., 2016b, for more details).
Data Analysis
Functional MRI data were analyzed using SPM8. Preprocessing steps included 
realignment, slice-time correction, coregistration, normalization to the Montreal 
Neurological Institute (MNI) template, and smoothing (faces: 5 mm full- width 
half maximum [FWHM] kernel; pictures: 6 mm FWHM kernel, mirroring primary 
analyses in the larger study). At first level, the six realignment parameters were 
included, images were high-pass filtered, and temporal autocorrelation was 
removed with the AR(1) process (Koch et al., 2016b). One TC was excluded due 
to a scanner artifact in the temporal cortex. Two participants with PTSD did not 
complete the placebo scanning session. Additionally, one participant with PTSD 
did not complete the pictures task.
For the affective pictures, we only used first-level contrast images, which were 
obtained by subtracting amygdala reactivity to passive viewing of neutral pictures 
from reactivity to passive viewing of negative pictures (negative > neutral). 
Individual contrast estimates were extracted from 5 mm spheres surrounding left, 
xyz = −24, −8, −20, and right, xyz = 20, −6, −14, amygdala peak task activation within 
the region of interest (ROI) anatomical mask (Harvard–Oxford 50% probabilistic 
atlas) across participants in the larger study during the placebo session (whole-
brain family-wise error corrected, pFWE < .05; Koch et al, 2018).
For the affective faces, contrast images were obtained by subtracting amygdala 
reactivity during the control condition from reactivity to angry-fearful faces 
(angry-fearful > control) and happy-neutral faces (happy-neutral > control). 
Individual contrast estimates were extracted from 5 mm spheres surrounding left, 
xyz = −20, −8, −16, and right, xyz = 24,    −10, −14, amygdala peak task activation 
within the ROI anatomical mask (Harvard–Oxford 50% probabilistic atlas) under 
placebo across participants and emotion conditions in the larger study (all pFWE 
< .05). For the purpose of comparing results with results from amygdala reactivity 
to affective pictures, contrast estimates for amygdala reactivity toward neutral-
happy faces (vs. control) were subtracted from contrast estimates for amygdala 
reactivity toward angry-fearful faces (vs. control; angry-fearful > happy-neutral).
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Subsequent analyses were performed in SPSS (Version 24). We investigated 
whether data were normally distributed and contained outliers, standardized z 
score > |3.29|. Aside from the one removed extreme HCC value, no outliers were 
removed. Questionnaire data other than hair characteristics and medication use 
were missing for one participant with PTSD. Participants with missing data were 
excluded from analyses pairwise. Group differences in participant characteristics 
were assessed with independent sample t tests (normally distributed continuous 
variables); Mann-Whitney U tests (nonnormally distributed continuous variables); 
chi-square tests (categorical variables with cell frequencies of 5 or above), or 
Fisher’s exact tests (categorical variables with cell frequencies less than 5). Group 
difference in (normally distributed) HCC was first assessed using an independent 
sample t test and Cohen’s d effect size (representing the standardized difference 
between group means, with d = 0.2, d = 0.5, and d = 0.8 commonly interpreted as 
small, medium, and large effects, respectively (Cohen, 1977), followed by analyses 
of covariance (ANCOVA)s to control for potential confounders. To minimize the 
influence of included covariates on calculated effect size, generalized eta squared 
(ηG2) was calculated, reflecting the amount of variance in HCC explained by 
PTSD versus TC status. As a benchmark, ηG2 = .01, ηG2 = .06, and ηG2 = .14 can 
be interpreted as small, medium, and large effects, respectively (Olejnik & Algina, 
2003).
Exploratory correlation analyses (Pearson’s r for normally distributed variables; 
Spearman’s rho for nonnormally distributed variables) were performed to 
investigate associations between HCC and amygdala reactivity and negative 
affective stimuli within the PTSD and TC groups separately. To test whether 
correlation coefficients significantly differed between groups, we applied Fisher’s 
z tests to compare correlation coefficients for both groups (Diedenhofen & Musch, 
2015). Partial correlations were performed to investigate potential confounding 
influences of age and daytime of scanning. Additionally, we investigated 
correlations with PTSD symptom severity in participants with PTSD only due to 
selected low symptom severity in TCs. We considered p values less than .050 
(two-sided) to be statistically significant. Data are expressed as means and 
standard deviations for continuous variables and absolute frequency and relative 
percentage for categorical variables.
Results
Group Differences in HCC
Participants with PTSD had significantly lower HCC levels (M = 15.85 pg/mg, 
SD = 13.23) than trauma-exposed participants without PTSD (M = 25.23 pg/mg, 
SD = 8.01), t(19.179) = 2.227, p = . 038, 95% CI [0.57, 18.19] (Figure 1). Cohen’s 
Chapter 13
250
d was 0.86, indicating a large effect size. This difference remained significant 
after controlling for work-related traumatic events, F(1, 24) = 8.00, p = .009, ηG2 
(i.e., explained variance in HCC by PTSD status) = .248, estimated t(24) = 2.83, 
95% CI [3.20, 20.46]; and current active executive police duty, F(1, 24) = 5.84, p 
= .024, ηG2 = .189, estimated t(24) = 2.42, 95% CI [1.44, – 18.22]. Additionally, the 
difference remained significant after controlling for hair color, F(1, 25) = 9.15, p = 
.006, ηG2 = .247, estimated t(25) = 3.025, 95%  CI  [3.83,  20.18], as well as several 
characteristics that did not differ between groups but are known to influence HCC, 
including age, body mass index, frequency of hair washing, hair treatment within 
the past 3 months, and  current use of local glucocorticoids (inhalation), alcohol, 
nicotine, and hormonal contraceptives, ps of group difference = .009–.047. Within 
PTSD patients, HCC were not significantly correlated with total symptom severity, 
r = .16, p = .603, 95% CI [−.73, 55].
Figure 1: Hair cortisol concentrations (HCC) in 3 cm–long hair strands taken from the 
scalp of trauma-exposed female police officers with (n = 13, left) and without (n = 15, 
right) posttraumatic stress disorder (PTSD).
Points depict HCC values for each individual participant. Descriptive characteristics for each group are 
depicted as means (bars) and standard deviations (error bars).
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Correlations Between Amygdala Reactivity and Negative Affective Stimuli
We investigated whether HCC was correlated with amygdala reactivity to negative 
affective stimuli in participants with PTSD and TCs and whether the magnitude of 
the correlation coefficient differed between groups. For right amygdala reactivity 
to negative affective faces compared to positive/neutral affective faces in the 
emotional face-matching task, the magnitude of the correlation was significantly 
different between groups, z = 2.18, p = .030, 95% CI [0.06, 1.27], with a strong 
positive correlation with participants with PTSD, r = .81, p = .003, 95% CI [.55, .96]; 
and a nonsignificant correlation in TCs, r = .11,  p = .715, 95% CI [−.36, .58] (Figure 
2, Panel A). No differential correlation with HCC was observed for left amygdala 
reactivity to negative faces, z = -0.05, p = .963, 95% CI [−0.74, 0.63]. In both groups, 
HCC was not significantly associated with amygdala reactivity: ρ = .28, p = .401, 
95% CI [−.41, .88] for the PTSD group and r = .50, p = .068, 95% CI [.07, −.78] for 
the TC group (Figure 2, Panel B). However, after controlling for the time of day 
when scanning took place, the magnitude of the correlation between HCC and left 
amygdala reactivity to negative faces was marginally increased for both groups: 
ρ = .49,  p = .131,  95% CI [−.21, .94] for the PTSD group and r = .58, p = .036, 95% 
CI [.13, .86] for the TC group. Regarding passive viewing of the IAPS negative 
affective pictures compared to neutral pictures, no differential correlation with 
HCC was observed for right amygdala reactivity to negative affective pictures and 
no significant correlations were observed within groups, z = 1.05, p = .292, 95% CI 
[−0.40, 1.18], and r = .16, p = .658, 95% CI [−.41, .73] for the PTSD group and r = −.33, 
p = .243, 95% CI [−.84, .14] for the TC group (Figure 2, Panel C). The magnitude of 
the correlations between groups significantly differed for left amygdala reactivity, 
z = 2.40, p = .016, 95% CI [0.29, 1.48]. We observed a strong positive correlation 
within participants with PTSD, r = .66, p = .037, 95% CI [.15, .93], which was absent 
in the TC group, ρ = −.36, p = .203, 95% CI [−.80, .38] (Figure 2, Panel D). Partial 
correlations controlling for age and time of day the scanning took place did not 
alter magnitudes of observed correlations, other than those that have already 
been described. Amygdala reactivity to both negative faces and negative pictures 
was not significantly correlated to total symptom severity within participants with 
PTSD, rs = −.182–.298. Amygdala reactivity to the two types of negative stimuli was 




Compared to female trauma-exposed police officers without PTSD, we observed 
significantly lower HCC in female police officers with PTSD. This finding is in 
line with what was reported by Luo and colleagues (2012), who observed lower 
HCC in individuals with PTSD compared to TCs in a sample of female adolescent 
earthquake survivors several months after the earthquake; mean HCC in women 
with PTSD was also comparable to what was found in the current study. Our 
observed group difference is, however, in apparent contrast to results reported 
Figure 2: Scatterplots representing correlations between hair cortisol concentrations 
(HCC, in pg/mg) and contrast estimates of amygdala reactivity (arbitrary units) toward 
negative emotional faces (A = right; B = left) and negative affective pictures  
(C = right; D = left) in female trauma-exposed police officers with (circles, dashed line) 
and without (squares, solid line) posttraumatic stress disorder (PTSD).
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in two cross-sectional studies, both of which found comparable HCC in trauma-
exposed individuals with and without PTSD in two predominantly female samples 
of individuals for whom a longer period of time had elapsed since trauma exposure 
(Schalinski et al., 2015; Steudte et al., 2013). Interestingly, however, in the only 
study to our knowledge that used similar immunoassays to those used in the 
current study (Russell et al., 2015), the observed mean HCC in individuals with 
PTSD was highly comparable to our observed mean HCC (Schalinski et al., 2015). 
Our finding is in apparent contrast with findings of higher HCC in individuals with 
PTSD compared to TCs in a mixed-gender sample of internally displaced refugees 
of whom most individuals with PTSD, but not TCs, had pronounced ongoing 
distress (Steudte et al., 2011).
Steudte-Schmiedgen, Kirschbaum, Alexander, and Stalder (2016) recently 
proposed a model on the course of trauma-induced changes in cortisol output. 
It poses that cortisol output changes in a dose- and time-dependent quadratic 
manner in response to trauma exposure, with initial elevated and subsequent 
chronically attenuated cortisol, independent of whether exposed individuals 
develop PTSD. This nonlinear association between trauma exposure and cortisol 
output may, in part, mediate the repeatedly reported dose-response association 
between increasing trauma load and increasing PTSD risk (but see also Kessler et 
al., 2017, for more recent findings on PTSD risk depending on type of previous 
trauma in combination with lifetime psychiatric history prior to index trauma). 
Notably, cross-sectional studies that compare trauma-exposed individuals with 
and without PTSD, including studies that assess HCC, typically report higher trauma 
exposure in individuals with PTSD. Although this fits with the earlier-mentioned 
dose-response relationship between trauma load and PTSD risk, it may confound 
cross-sectional investigations. Interestingly, our trauma-exposed police officers 
without PTSD reported nominally higher work-related trauma exposure than 
police officers with PTSD. Nevertheless, we still observed significantly lower HCC 
in participants with PTSD, which remained significant after controlling for work-
related trauma exposure. This suggests that in our noncivilian female sample, 
PTSD was associated with lower HCC independent of the effects of accumulating 
trauma exposure. As our female police officers with PTSD reported lower work-
related trauma exposure than their matched TCs, it is conceivable that they were 
more vulnerable to adverse mental health consequences of traumatic stress. 
Although our study had no longitudinal design, this fits with previously observed 
low pretrauma HCC (Steudte-Schmiedgen et al., 2015) and high pretrauma 
glucocorticoid receptor function (van Zuiden et al., 2012) as predictive of PTSD 
symptom development in male soldiers. However, we only investigated the amount 
of work-related traumatic event types participants had encountered and not time 
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since exposure. This is relevant as the model proposed by Steudte-Schmiedgen et 
al. (2016) describes elevated cortisol output in the acute period after trauma, prior 
to attenuated output. Additionally, the authors of a recent meta-analysis found 
significant positive associations between ongoing chronic stress and HCC (Stalder 
et al., 2017). Thus,  an alternative explanation is that our observed group difference 
reflects relatively elevated HCC in TCs due to ongoing or more recent exposure to 
work-related traumatic stress rather than of a PTSD-related attenuation. However, 
as the difference in HCC remained significant after controlling for current active 
police duty, we deem this alternative explanation less plausible. Additionally, the 
mean HCC observed in our TC group was comparable to the mean HCC reported 
in a mixed-gender sample of TCs with little trauma exposure within the last year 
(Steudte et al., 2011).
Long-term HCC is thought to be a relatively stable and reliable measure of long-
term cortisol output of the HPA axis (Staufenbiel et al., 2013). Therefore, the 
most intuitive interpretation is that our finding supports repeated findings on 
more acute measures of HPA axis function, indicating PTSD is associated with 
dysregulation of the HPA axis (Olff & van Zuiden, 2017). As previous studies have 
reported that HPA axis dysregulation may precede trauma exposure and PTSD 
development (van Zuiden, Kavelaars, Geuze, Olff, & Heijnen, 2013), chronic HPA 
axis dysregulation may be causally involved in pathophysiological processes 
underlying phenotypical expression and maintenance of some PTSD symptoms. 
Nevertheless, observed associations between HCC and PTSD status could also be 
influenced by PTSD risk factors associated with altered cortisol output, such as 
pain (Gaab et al., 2005), or health behaviors commonly associated with PTSD or 
general psychopathology, such as tobacco use (Olff et al., 2006) and decreased 
physical activity (Fekedulegn et al., 2018). However, we applied stringent inclusion 
and exclusion criteria and added several health behavior–related covariates to 
address potential confounders.
To further investigate whether and how HCC may be associated with the phenotypical 
expression of PTSD, we performed exploratory analyses to investigate whether HCC 
was associated with previously observed neural correlates of PTSD. We focused on 
amygdala reactivity to two types of negative affective stimuli—nontrauma related 
stimuli (faces) and a mixture of trauma-related and non-trauma-related stimuli 
(pictures)—as authors of a recent meta-analysis found higher bilateral amygdala 
reactivity in individuals with PTSD compared to TCs in response specifically to 
non-trauma-related stimuli (Stark et al., 2015). To facilitate comparison of results 
for both types of stimuli, we subtracted amygdala reactivity toward the neutral 
conditions from reactivity toward the negative conditions. Within participants 
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with PTSD, but not in TCs, we observed a moderate-to-strong positive correlation 
between HCC and right amygdala reactivity to negative affective faces compared 
to neutral or positive faces. Furthermore, after correction for the time of day 
the scanning took place, a significant positive correlation between HCC and left 
amygdala reactivity to negative faces emerged for TCs, and a moderate positive 
correlation was observed for participants with PTSD, although this was not 
significant. We also observed a moderate-to-strong positive correlation between 
HCC and left amygdala reactivity to negative affective pictures compared to 
neutral pictures in participants with PTSD. Thus, lower HCC, in itself associated 
with PTSD status, was associated with diminished differentiation in amygdala 
reactivity between negative and neutral affective stimuli. This association was 
most pronounced for participants with PTSD.
If the peripheral findings related to HCC reflect persistent changes in circulating 
central cortisol, speculatively, the observed association between HCC and 
diminished differentiation in amygdala reactivity may be influenced by long-
term compensatory changes in central GR and/or MR signaling pathways, such 
as upregulated receptor expression and binding affinity or changes at the 
signaling route downstream of the receptor. Such changes may have occurred in 
the amygdala or other brain areas that modulate amygdala reactivity, changing 
amygdala reactivity to perceived negative stimuli. On the other hand, decreased 
HCC may result from high signaling in these receptor pathways, leading to 
reduced cortisol output by the HPA axis (Buckingham, 2006; De Bosscher, Van 
Craenenbroeck, Meijer, & Haegeman, 2008; de Quervain et al., 2017). Based on the 
current literature on GR and MR function in PTSD, neither of these two directions 
can be excluded.
In our larger study, we observed that, in contrast to TCs, police officers with PTSD 
did not show differentiation in amygdala reactivity to negative versus positive or 
neutral faces (Koch et al., 2016b). We hypothesized that participants with PTSD 
may have interpreted neutral faces in the neutral/positive faces condition as 
ambiguous stimuli signaling potential threat (i.e., increased attributed saliency), 
resulting in decreased differentiation in amygdala reactivity toward the two 
affective conditions. Such a lack of differentiation between negative and neutral 
stimuli may result from deficits in context processing (i.e., a diminished capacity 
to interpret the environment in a situation-specific manner). A recent model 
addresses diminished context processing by hippocampal–prefrontal–thalamic 
brain circuitry modulating amygdala reactivity as key in the pathophysiology of 
PTSD and specifically intrusive symptomatology (Liberzon & Abelson, 2016). This 
brain circuitry is critically modulated by GR activation, with GRs mediating effects 
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on contextual learning and memory consolidation depending on activation of 
beta-adrenergic receptors in the basolateral amygdala (Quirarte, Roozendaal, 
& McGaugh, 1997). Clearly, although we observed that activation clusters for 
the negative pictures task extended posteriorly from the amygdala toward the 
hippocampus (Koch et al., 2018), the hypothesis that our observed correlation 
between HCC and decreased amygdala differentiation between negative and 
neutral emotional stimuli could be associated with context processing should be 
further investigated.
This study was the first, to our knowledge, to investigate associations between 
HCC and PTSD in a female noncivilian trauma-exposed sample, but it had some 
important limitations. First, the study had a cross-sectional design, and therefore, 
we cannot address questions of causality and directionality. In theory, relatively 
long hair strands provide the possibility to retrospectively assess HCC and 
therefore investigate HCC changes over time in relation to trauma and PTSD 
development. However, this seems more relevant when the demarcation of a 
single traumatic event in time is more apparent than it was in our sample. Also, 
the small sample size resulted in modest statistical power. Based on Bender and 
Lange’s (2001) recommendation that multiple comparison corrections should not 
be applied for studies of an exploratory nature, we opted not to apply corrections 
for multiple testing in the correlational analyses. It should however be stressed 
that hypotheses derived from our exploratory correlational analyses warrant 
future confirmatory studies with adequate statistical power. Also, although 
affective faces are generally designated as non-trauma-related, the pictures task 
contained a mixture of non-trauma-related and likely trauma-related stimuli that 
we could not further subdivide into separate conditions. Therefore, it remains to 
be investigated whether observed associations are specific to non- trauma-related 
stimuli or also hold for trauma-related stimuli. Additionally, as we only included 
female police officers willing to participate in our pharmacological neuroimaging 
study, we cannot be certain that our findings generalize to the larger population 
of female police officers. Additionally, it remains to be investigated whether 
observed findings also extend to men. Furthermore, as mentioned, frequency 
and time since trauma exposure were not investigated nor was non-work-related 
trauma exposure during adulthood. We were also not able to include a trauma-
naive control group with similar demographic and work-related characteristics 
as the included trauma-exposed participants, as active police service for several 
years is generally associated with exposure to traumatic events in the line of duty. 




Associations Among Hair Cortisol Concentrations, Posttraumatic Stress Disorder Status, 
and Amygdala Reactivity to Negative Affective Stimuli in Female Police Officers
In summary, we observed lower long-term hair cortisol levels in female police 
officers with PTSD compared to trauma-exposed female police officers without 
PTSD. Exploratory analyses indicated that lower HCC was associated with lower 
differentiation of amygdala reactivity between negative and neutral affective 
stimuli, which was more pronounced in participants with PTSD. Future studies 
should further investigate the associations between HCC, trauma, and PTSD, as 
well as associated neurobiological mechanisms.
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This thesis contains our work in which we have focused on the role of endogenous 
and exogenous glucocorticoids in obesity and stress-related diseases. In this 
chapter, we summarize our findings and discuss these in the context of existing 
literature and their clinical and societal relevance. We will conclude with future 
perspectives regarding screening and treatment of obesity especially in light of 
glucocorticoid use and elevated glucocorticoid exposure. 
1. Obesity
The impact of obesity on health, society, and economics is becoming increasingly 
evident with the rising number of patients over time. More than a third of the 
adult population in the United States is currently obese (1) which is accompanied 
by an estimated annual cost of over 200 billion dollars (2). The prevalence rate in 
the Netherlands is more favorable with one in six adult individuals being obese, 
however, numbers have been nearly doubled within one generation time (3). 
Unhealthy dietary habits and less physical activity are generally considered as 
the culprits. Tackling obesity should, in theory, be relatively simple by reversing 
these factors, but unfortunately, the results of many attempts are not in keeping 
with what would be expected. The complexity of obesity originates in, among 
others, its multifactorial etiology and biological resistance to weight loss. 
Scientific observations have established various obesogenic factors other than 
lifestyle which are assumed to induce weight gain and/or impede weight loss. 
Glucocorticoids, with the stress hormone cortisol as the predominant hormone, 
are potentially important determinants in this context.
2. Glucocorticoids and obesity
Stress and obesity are generally linked to adverse health consequences, however, 
the link between these entities is somewhat less clear. This is in part due to 
differential effects of acute and chronic stress. Short-term overactivation of the 
hypothalamus-pituitary-adrenal (HPA) axis and thus temporarily increased cortisol 
secretion is in fact beneficial. Acute stress with for instance public speaking or 
exercising increases alertness, suppresses appetite, and tightens the muscle to 
prepare for a fight or flight reaction. The adverse effects of stress become evident 
in case of ongoing stressors in which the HPA axis is chronically overactive and 
the stress hormone cortisol is constantly flooding into the circulation. There is no 
certain cutoff regarding the duration in terms of chronic stress, but it would be 
anticipated in certain conditions as low socioeconomic state, chronic diseases and 
pain, and ongoing psychological distress. Chronic stress negatively impacts the 
architecture and function of the brain, muscles, bone, reproduction organs, and so 
on. With respect to metabolism, cortisol induces insulin resistance, glycolysis, and 
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gluconeogenesis which eventually leads to impaired glucose tolerance. Elevated 
long-term cortisol exposure additionally leads to an increased appetite (4) with a 
special preference for high-caloric foods. Moreover, it stimulates accumulation 
of fat cells in the visceral area and inhibits the favorable thermogenic activity 
of brown adipose tissue (5). This may eventually lead to central adiposity which, 
independent of other glucocorticoid-related metabolic events, is a harbinger of 
metabolic syndrome. The latter constitutes a combination of several risk factors 
(i.e. visceral obesity, high blood pressure, high triglycerides, low HDL-cholesterol, 
and glucose intolerance) which increases the risk of developing diabetes mellitus 
and serious cardiovascular conditions like stroke and myocardial infarction. 
Since many individuals with a hypercortisolistic state develop (centripetal) obesity 
and other cardiometabolic conditions as frequently observed in common obesity, 
it was soon suggested that the latter might be a consequence of too much cortisol. 
As mentioned in the general introduction, it was indeed found that individuals with 
obesity had higher cortisol concentrations in comparison to non-obese subjects. 
In chapter 2 we investigated in a population of 408 individuals with obesity the 
prevalence of a variety of obesogenic factors. We found that nearly half of the study 
population was using a potentially weight-inducing drug with corticosteroids as the 
most commonly used agent. Over one in four was using any type of corticosteroids 
at time of visit clinic. Interestingly, among subjects who had experienced a period 
of marked weight gain drug use and especially use of corticosteroids was reported 
as the most common trigger. In chapter 3 we focused on corticosteroid use in the 
past three months and assessed the differences in use between our outpatient 
population with obesity and non-obese controls from two other Dutch cohorts. 
Here, we also found that corticosteroids were significantly more often used in 
obesity with nearly doubled prevalence in comparison to non-obese subjects. The 
most striking was the relatively higher use of local corticosteroids and especially 
of inhaled administration forms with obesity (13.9% versus 3.0% and 3.8% in non-
obese cohorts). 
Glucocorticoid use during weight loss attempt
A variety of strategies are available that individuals can try to lose weight, 
however, lifestyle adaptations including a healthy diet and sufficient physical 
activity are essential for sustainable weight loss. Before commencing a weight-loss 
intervention, a thorough evaluation of obesogenic factors as described in chapter 2 
is necessary to recognize and, if possible, to tackle those which could hamper 
weight loss. Participants with obesity who participated in our 75-week combined 
lifestyle intervention with cognitive behavioral therapy were hence at start and 




Nearly one in every fifth subject had however used systemic corticosteroids during 
the intervention despite specific instructions to both the participants and their 
general practitioners to avoid these unless absolutely necessary. There were 
overall great improvements in anthropometrics which were also sustained till 
the end of the intervention, however, weight change was less beneficial in users 
of systemic corticosteroids (chapter 8). This emphasizes the need for careful 
consideration of corticosteroid use in individuals with obesity and especially 
in those who are engaging in a weight loss intervention. Unfortunately, there 
is currently a lack of high-quality randomized controlled trials (RCTs) that have 
investigated interventions to remedy weight gain in patients in whom systemic 
corticosteroid use is inevitable. A recent systematic review focused on this topic 
and could identify only three RCTs with overall poor quality, small sample size, 
and just one study with adult participants (6). This concerned a trial in which 23 
overweight female patients with systemic lupus erythematosus and on treatment 
with systemic corticosteroids were assigned to a six-week diet-intervention aimed 
at a low glycaemic index or calorie restriction (7). Both interventions led to significant 
and comparable improvements in weight, waist- and hip circumferences. Given the 
short-term intervention and no follow-up assessments, it is of concern whether 
patients can sustain these beneficial changes in the long-term if guidance is no 
longer offered and due to compensatory biological mechanisms (e.g. increased 
appetite, decreased resting energy expenditure) as frequently observed after 
(intense) dietary interventions (8,9). 
Consequences of local corticosteroid use
It is often acknowledged that serious adverse events with corticosteroid use 
are limited to systemic corticosteroids as prednisolone or dexamethasone. 
Broersen et al. showed in an extensive meta-analysis that use of systemic forms 
was associated with around 50% risk of developing adrenal insufficiency (10), a 
consequence of the negative feedback system which occurs in case of prolonged 
supraphysiological exposure to glucocorticoids. In the same study, the authors 
also showed that local corticosteroids as topical, nasal, and inhaled types can also 
induce adrenal insufficiency. This risk was especially prominent in users of inhaled 
corticosteroids (absolute risk of 7.8% [95% CI, 4.2 – 13.9]) with differing percentages 
based on duration and dosage of corticosteroid use (10). These inhaled types are 
usually prescribed for pulmonary conditions like asthma and chronic obstructive 
pulmonary disease. The prevalence of adrenal insufficiency in asthmatic patients 
using only inhaled corticosteroids ranged for example from 1.5% with low doses 
to 18.5% with high doses, and 1.3% in case of short-term duration to 20.3% in long-
term users (10). Within our cohort of individuals with obesity, asthma was also the 
most prominent indication for corticosteroid use (chapter 3). 
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There are nowadays several inhaled corticosteroids available with various 
pharmacokinetic and pharmacodynamic properties. These agents can enter the 
systemic circulation by at least two different pathways (Figure 1). In general, 
depending on the type of inhaled corticosteroid, a large proportion of the inhaled 
agent is deposited in the oropharyngeal area. This bulk is transported to the 
gastrointestinal tract and absorbed from there to subsequently be exposed to the 
first-pass metabolism by the liver. On the other hand, a fraction of the inhaled 
dose will be deposited in the lung and completely absorbed into the circulation. 
The oral bioavailability after liver passage and the pulmonary bioavailability make 
up the portion of the inhaled agent what eventually gets absorbed in the systemic 
circulation and thus could potentially induce serious glucocorticoid-related 
adverse event (Figure 1). 
Figure 1: Pathways to systemic uptake of inhaled corticosteroids.























This of course raises the question of whether the use of inhaled corticosteroids 
does indeed lead to systemic adverse events. A convenient way to assess this is by 
reviewing the incidence of adverse events similar to the clinical phenotype as seen 
in patients with endogenous Cushing’s syndrome. A panel of experts from three 
medical associations (American College of Chest Physicians, American Academy of 
Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and 
Immunology) reviewed literature up to the year 2000 to assess evidence for five 
serious glucocorticoid-related adverse events with inhaled corticosteroid use in 
patients with asthma (12) (Table 01). They found that various studies indeed observed 
evident adverse outcomes with use of inhaled corticosteroids, but results were not 
consistent for the different complications which could be due to differences in for 
instance study design, assessment of specific outcomes, or other methodological 
flaws. It is not clear why the panel chose to investigate these specific complications 
especially giving the fact that lipodystrophy and weight gain have repeatedly been 
reported as one of the most common adverse events with systemic corticosteroid 
use (13,14). There is currently a paucity of studies investigating the link between 
adiposity and cardiometabolic outcomes with inhaled corticosteroids or with any 
of the other frequently prescribed local administration forms.







1 Growth retardation A Therapy with ICSs is associated with a decrease in short-
term growth rates in children, but the overall effect is small 
and may not be sustained with long-term therapy. 
2 Skin thinning / 
ease of bruising
B The risk of skin thinning and easy bruising is elevated in 
patients receiving ICS. Dose, duration of use, and patient 
gender are important variables affecting overall risk.
3 Reduced bone 
mineral density
C Adult asthma patients generally do not sustain a significant 
reduction in BMD in response to ICS treatment, although 
the effect may become clinically important in patients recei-
ving high-dose ICSs for many years.
4 Cataracts C The risk of subcapsular and nuclear cataracts associated 
with ICS use is negligible in young asthma patients, however, 
it may be elevated in older patients.
5 Glaucoma F The risk of glaucoma associated with ICS use is likely to be 
small, however, further study is warranted.
Data derived from Leone et al. (12). The grading of evidence (level A - F) was designed for the specific study with grade 
A-C indicating sufficient data for evaluation of the relationship between inhaled corticosteroids and complications. 
Grade D indicates insufficient or conflicting data and grade F denotes failed evidence review. Abbreviation: BMD, 
bone mineral density; ICS, inhaled corticosteroids
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In a population-based study including 140.879 adult individuals, we investigated 
the association between inhaled corticosteroids and other administration 
forms with various cardiometabolic traits including body mass index and waist 
circumference (chapter 4). We additionally studied the relationship between local 
and systemic corticosteroid use with metabolic syndrome which is deemed present 
in case of several predefined cardiometabolic risk factors (i.e. abdominal obesity, 
hypertension, dyslipidemia, and hyperglycemia). The relevance of metabolic 
syndrome in this case is that glucocorticoids are being linked to all of the listed 
risk conditions (15,16). Moreover, the health consequences of metabolic syndrome 
are far-reaching as patients have an increased risk of developing type 2 diabetes 
mellitus and cardiovascular diseases, including coronary heart diseases and stroke 
(17-19). We found that use of locally applied corticosteroids was associated with an 
increased waist circumference in male and female users whereas women also had 
significantly higher body mass index. These associations were mainly with use 
of inhaled corticosteroids. Users of inhaled agents had significantly higher waist 
circumference as well as a higher body mass index in comparison to nonusers in 
both sexes. Metabolic syndrome was also more common in corticosteroid users 
when compared to nonusers. Interestingly, the relative difference in prevalence in 
metabolic syndrome between nonusers and overall corticosteroid users was nearly 
doubled in women in comparison to men (+5.3% vs. +2.7%). After full adjustments 
for potential covariates, only female corticosteroid users were more likely to have 
metabolic syndrome and especially in users of systemic and inhaled corticosteroids. 
A number of hypotheses could be proposed for this sexual dimorphism, with the 
most obvious that women are more adherent to medication than men. Sundberg 
et al. observed that among asthmatic patients women indeed reported higher 
compliance and had a more positive attitude concerning drug use in comparison 
to men (20). Female patients were also more likely to report anxiety and insomnia 
which are, interestingly, known adverse events of systemic glucocorticoids and 
thus possibly related to increased systemic glucocorticoid exposure. Other possible 
explanations to be considered are the differences in pharmacokinetics between 
sexes (21) and reduction in sex hormones with corticosteroid use which could yield 
different cardiometabolic effects in men and women (22,23). Giving the fact that 
abdominal adiposity is a major driver of adverse metabolic changes (24), it could 
also be suggested that glucocorticoid-induced visceral fat accumulation becomes 
more prominent in female users since men naturally tend to have a higher waist 
circumference than women. Nevertheless, other studies investigating adverse 
events of corticosteroids also reported sex differences with women being more 




The relevance of genetics and glucocorticoid receptor sensitivity
A crucial link in the trail of glucocorticoid action is the glucocorticoid receptor. 
When in the inactive state, the glucocorticoid receptor remains in the cytoplasm 
where it is being coupled to chaperone proteins. Binding with glucocorticoids 
activates the receptor upon which it releases from the protein-complex and 
translocates to the nucleus. Activated glucocorticoid receptors can eventually 
by a variety of pathways positively and negatively alter gene expression (28). It is 
generally assumed that an increased transactivational activity (i.e. upregulation 
of transcription) leads to the cardiometabolic traits as seen in patients with 
endogenous and exogenous Cushing’s syndrome (29). Downregulation of the 
transcription of certain genes like interleukin-2, interleukin-6, and tumor necrosis 
factor-α is known as transrepression and is the mode of action as preferred 
with therapeutic corticosteroid use (30,31). Earlier studies have identified several 
functional polymorphisms of the glucocorticoid receptor and found these to be 
associated with an altered glucocorticoid sensitivity and accompanying clinical and 
biochemical features (32).
In continuation of our findings in chapter 4, we further focused on the association 
between corticosteroid use with cardiometabolic outcomes and metabolic 
syndrome by glucocorticoid receptor genotype (chapter 5). We performed a 
genome-wide association study in over 10.000 individuals of the same study 
population and extracted genotypes of four functional glucocorticoid receptor 
variants. Overall corticosteroid use was significantly associated with a higher 
body mass index, waist circumference, and metabolic syndrome in users with a 
wild-type or glucocorticoid hypersensitive genotype (BclI and/or N363S) but not 
in users harboring glucocorticoid resistant variants (ER22/23EK and/or 9β). These 
findings were especially evident in users of inhaled corticosteroids. With respect 
to waist circumference, however, inhaled type users of all three genotypes had 
a significantly worse outcome in comparison to nonusers. The findings in users 
of systemic corticosteroids were less consistent which is probably partly due to 
the relatively small numbers (i.e. 5.3% of the total group of users). Earlier studies 
investigating the link between systemic corticosteroid use and adverse events found 
however that carriers of hypersensitive variants indeed more often developed 
glucocorticoid-related adverse events. Children with acute lymphoblastic 
leukemia for example were more likely to develop hepatotoxicity, glucose 
abnormalities, and Cushingoid-like symptoms such as adiposity and hypertension 
(33,34) when treated with systemic corticosteroids. On the other hand, patients with 
hypersensitive polymorphisms also had a better therapeutic response to inhaled 
corticosteroids in asthma (35) or treatment with systemic agents in different clinical 
conditions (33,36-38). In contrast, systemic corticosteroids seemed less effective in 
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children with glucocorticoid resistant variants treated for inflammatory bowel 
disease (39) or nephrotic syndrome (38). These and our observations may indicate 
that glucocorticoid receptor genotype partially influences the effectiveness as 
well as the occurrence of adverse events such as adiposity, cardiometabolic traits, 
and metabolic syndrome with corticosteroid use. It remains however difficult to 
fully separate the individual effect of these functional variants since they are to 
different extents associated with changes in transactivation or transrepression 
(40,41) and given more recent clues about both pathways to be somewhat dependent 
on each other (42). 
3. Complex interplay between glucocorticoids and obesity
Although the relationship between glucocorticoids and obesity seems 
straightforward, the truth is that not each individual with high glucocorticoid 
exposure will develop obesity and vice versa. Circulating free cortisol 
concentrations, whether endogenously secreted or exogenously administered, 
are of utmost importance in the extent of glucocorticoid action. With respect to 
biological response, synthetic glucocorticoids generally possess a much higher 
glucocorticoid activity than endogenous cortisol. In comparison to cortisol, 
prednisone and prednisolone have for instance four times higher glucocorticoid 
activity whereas dexamethasone is relatively 25 times more potent (43). As to 
inhaled corticosteroids, we described in chapter 4 that the synthetic compounds 
budesonide and fluticasone were predominantly used in our study population. The 
relative binding affinity to the glucocorticoid receptor of these corticosteroids 
is respectively 94 and 180 greater than cortisol (11). As discussed previously, 
considerable research has been conducted on the link between functional 
glucocorticoid receptor polymorphisms and anthropometric features and body 
composition and found this indeed to be interrelated to varying degree. There 
are however also other factors that could influence glucocorticoid availability and 
sensitivity such as the concentration of corticosteroid-binding globulins, activity 
of 11β-hydroxysteroid dehydrogenases, number of glucocorticoid receptors, post-
translational modification of the glucocorticoid receptor, activity of multidrug 
efflux pumps, and so on (44). The significance of alterations in any of these elements 
in obesity is currently still matter for future research. 
In the schematic overview of the relationships between glucocorticoids and 
obesity (Figure 2), it is important to also consider the presence of environmental 
and behavioral factors that could increase the secretion of glucocorticoids such as 
sleep deprivation (45), alcohol intake (46), and shift work (47). Unfortunately, obesity 
per se is also often accompanied by various individual characteristics leading 




and eventually weight gain or difficulties in weight-loss attempts. Jackson et al. 
found for example that perceived weight stigma in obesity was associated with 
higher long-term cortisol concentrations than individuals with obesity who did 
not experience weight-discrimination (48). Moreover, obesity is a considerable risk 
factor for the development of a variety of physical disorders (e.g. asthma, arthrosis, 
hypertension, and diabetes mellitus) which often require pharmacological 
interventions with potentially weight-inducing drugs like corticosteroids, beta 
blockers, and insulins. 
4. Glucocorticoids and cerebral effects
In addition to anthropometric and cardiometabolic alterations, corticosteroids are 
also notorious for affecting the central nervous system. Glucocorticoid receptors 
are diffusely present in the brain and overexposure to glucocorticoids is associated 
with cognitive and neuropsychiatric disorders. Glucocorticoids are known for 
inducing neurotoxic effects and it was Varney and colleagues who invented the 
term “steroid dementia” after witnessing cognitive changes as with dementia in 
patients treated with high-dose corticosteroids (49). Patients showed impairments in 
several cognitive processes including memory retention, attention, concentration, 
and mental speed and efficiency (49). Studies in patients with endogenous Cushing’s 
syndrome also revealed impaired memory and concentration (50) as well as lower 
IQ scores and worse performance in terms of processing of visual and spatial 
information, reasoning, and verbal fluency (51). Imaging studies even showed loss 




Behavioral changes and psychological symptoms are unfortunately also often 
encountered with supraphysiological exposure to glucocorticoids. Insomnia, 
restlessness, euphoria, (hypo-)mania, depression, anxiety, and even psychoses 
are in the spectrum of steroid-related neuropsychiatric conditions (55). Numbers 
in literature about the occurrence of these mental alterations differ. Fardet et 
al. prospectively followed a cohort of systemic corticosteroid naïve patients who 
were put on long-term prednisone (13). Three months after initiation of therapy, just 
over half of the subjects reported insomnia and neuropsychiatric conditions (e.g. 
irritability, anxiety, depression, and euphoria) with some even being admitted to 
hospital due to mental disorder. In chapter 6 we showed that in the general adult 
population overall use of corticosteroids was associated with reduced executive 
cognitive functioning as well as a higher likelihood of mood and anxiety disorder. 
Impairments in nonverbal fluency, which is part of executive cognitive functioning, 
were especially evident in systemic corticosteroid users. Significantly lower scores 
Figure 2: The interaction between the stress system and obesity.
Adapted from van der Valk, Savas, and van Rossum (54). GC, glucocorticoids; GR, glucocorticoid receptor; 








































were however also observed in users of inhaled types. Moreover, mood and anxiety 
disorders were also more likely to occur in users of local corticosteroids and again 
in especially inhaled corticosteroid users which altogether suggest systemic 
availability of these formulations. Mental distress and neuropsychiatric conditions 
like mood- and anxiety disorders are also more frequent in obesity, especially with 
abdominal adiposity (56), and are linked to increased chronic stress and cortisol 
levels. In short, the bidirectional relationship between the stress system and 
obesity is complex and depends on a wide range of individual characteristics. This 
emphasizes the importance of a personalized approach with a thorough evaluation 
of potential weight- and stress-inducing factors in individuals with obesity who are 
willing to lose weight.
5. Magnitude of corticosteroid use
In our cross-sectional analysis in chapter 4, we showed that nearly one in every nine 
individuals of the adult general population was using one or more corticosteroid 
agents. The main administration routes were local types (>95%) and in particular 
the inhaled, nasal, and topical formulations. The Dutch National Health Care 
institute keeps record of the annual consumer data of prescribed drugs in the 
Netherlands and makes it online available (www.gipdatabank.nl). According to 
their Drug Information System (Dutch: Genees- en hulpmiddelen Informatie Project 
(GIP) databank), there were at least 13 million corticosteroids prescribed in 2018 
(most actual data). Interestingly, corticosteroids were mentioned 17 times among 
the top 100 drugs with most users in the same year in the Netherlands (Figure 3). 
In terms of total number of prescriptions, dermal corticosteroids were most often 
prescribed (~3.9 million times) followed by inhaled corticosteroids (~2.9 million 
prescriptions), nasal corticosteroids (~2.7 million prescriptions), and systemic 
corticosteroids (~2.7 million prescriptions). 
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6. Scalp hair glucocorticoids 
Scalp hair glucocorticoids as screening tool
Most of the serious adverse events of too much glucocorticoids manifest after an 
extended period of time. The currently employed tests for assessment of cortisol 
Figure 3: Corticosteroids with the most number of users in 2018 in the Netherlands 
with corresponding numbers in the past years.
Numbers before corticosteroid formulations depict their place in the top 100 drugs with most users 
in 2018. Colors illustrate the type of corticosteroid: blue, dermal; red, systemic; green, nasal; yellow, 
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levels make use of blood, saliva, and urine. These matrices are only convenient 
in capturing short-term cortisol exposure ranging from seconds to minutes with 
serum and saliva and hours to days with urinary samples. Measurement of long-
term cortisol exposure is however possible with scalp hair analysis. As hair growths 
with nearly one centimeter per month, it can be used to assess cumulative cortisol 
concentrations over the past months to years depending on the length of the 
collected sample. There has been a lot of development in recent decade towards 
the analytical methods and usefulness of hair scalp glucocorticoids. We are now 
able to quantify with high sensitivity and specificity cortisol and the inactive variant 
cortisone as well as several other steroid hormones in a single hair sample by using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) (57). Concerning 
endogenous Cushing’s syndrome, current diagnostic guideline recommends 
screening with traditional matrices (58). In chapter 7 we demonstrated in a 
multicenter, multinational, prospective, case-control study that hair cortisol and 
hair cortisone possess high diagnostic performances in screening for Cushing’s 
syndrome. In terms of diagnostic efficacy, our findings were quite comparable 
to midnight salivary cortisol and urinary free cortisol as shown in pooled data 
from literature (59). Interestingly, we found that hair cortisone was superior to 
hair cortisol in differentiating Cushing patients from controls. Further research is 
needed to determine whether scalp hair cortisone could serve as a better marker 
of accumulated cortisol exposure over time. In line with this hypothesis, however, 
a previous animal study in which guinea pigs were injected with radiolabeled 
cortisol showed a radioactive peak in hair analysis coinciding with the compound 
cortisone (60). Moreover, in another study by Kapoor and colleagues it was also 
observed that a considerable amount of administered radiolabeled cortisol was 
taken up as cortisone in primate hair (61). The authors suggested that perhaps the 
lower polarity of cortisone in comparison to cortisol could favor incorporation in 
hair matrix. Another explanation could perhaps lie in the conversion of cortisol to 
cortisone by the enzyme 11 beta-hydroxysteroid dehydrogenase type 2 which is 
among others located in hair follicles but also in salivary glands. This could play 
a role in our observation and also explain the relatively high concentration of 
cortisone found with hair and salivary assessments.
 Besides the fact that scalp hair analysis allows evaluation of long-term 
glucocorticoid exposure, it also has advantages over other assessments in 
terms of collection, storage, and ease for patients. In the case of screening for 
Cushing’s syndrome, hair analysis should just like the other cortisol tests be limited 
to individuals with a high a priori probability given the rarity of endogenous 
Cushing’s syndrome and high prevalence of conditions associated with a (mild) 
hypercortisolistic state like obesity and diabetes mellitus. Another important 
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notion with the current scalp hair analysis is that quantification with LC-MS/MS 
requires expensive machinery and highly-skilled personnel limiting assessments 
to certain centers with sufficient capability. Furthermore, caution is required 
with assessments of timelines since concentrations seem to decrease across hair 
shaft (57) probably due to increased exposure to damaging factors (e.g. ultraviolet 
radiation, chemical agents) potentially leading to wash-out and/or cross-linking 
between hair matrix and glucocorticoids (62).
Scalp hair glucocorticoids and obesity
Since assessment of scalp hair glucocorticoids provides insight into relatively 
chronic glucocorticoid exposure, it has become an interesting tool to study whether 
common obesity is indeed associated with long-term increased cortisol levels. In 
our earlier study we investigated scalp hair cortisol in subjects with different weight 
classes and found that individuals with obesity had significantly higher levels (30.8 
pg/mg) in comparison to others who were overweight (8.5 pg/mg) or normal 
weight (8.4 pg/mg) (63). We additionally showed a positive association between 
hair cortisol concentrations and body mass index in a specific study population 
consisting of patients with erythropoietic protoporphyria (chapter 10). Concurring 
with our observations, a recent comprehensive meta-analysis demonstrated that 
an increase of 2.5 body mass index points was associated with 9.8% higher cortisol 
concentrations (64). The same study also confirmed a positive association between 
scalp hair cortisol and other glucocorticoid-related features as higher waist-to-hip 
ratio and systolic blood pressure. Although cortisol and adiposity are mutually 
reinforcing, it is often unknown which of these factors precede. The causal role 
of cortisol in the development of visceral adiposity and adverse cardiometabolic 
features is clear giving the findings in patients with pathological concentrations 
like with Cushing’s syndrome. On the other hand, there are also indications that 
weight gain per se can induce HPA axis activation. A small group of lean men for 
instance deliberately gained an average of 20% of their body weight by excessive 
intake of calories and were found to have an increased cortisol production rate 
and excretion of cortisol metabolites (65). In chapter 8 we further hooked on this 
by investigating whether weight loss in individuals with obesity altered long-term 
glucocorticoid concentrations in hair. Participants with obesity who completed our 
75-week combined lifestyle intervention with cognitive behavioral therapy showed 
sustained weight loss as well as beneficial changes in waist circumference and 
body mass index and also lower cortisol concentrations at end of the intervention. 
Regarding the latter, alterations in HPA axis activity and/or cortisol metabolism 
including 11β-hydroxysteroid dehydrogenases would be expected. Although we did 
not assess cortisol metabolites, the peculiar course of cortisone during intervention 




alterations at the level of 11β-hydroxysteroid dehydrogenases especially giving 
the decrease in cortisol/cortisone-ratio over time. In line with this, earlier findings 
in bariatric patients losing weight after surgery showed indeed a lowered ratio 
of cortisol/cortisone-metabolites in urine (66) as well as a reduced expression of 
11β-hydroxysteroid dehydrogenase type 1 in adipocytes (67,68). Interestingly, in the 
same chapter, we did not observe a significant association between changes in 
anthropometrics (i.e. weight, body mass index, and waist circumference) and hair 
glucocorticoids. This could perhaps be explained by changes in other HPA-axis 
related factors which are additionally influenced by the intervention. It would be 
expected that the intervention consisting of guidance in diets and exercising with 
psychotherapy not only leads to weight loss but also less psychological distress, 
improvements in sleep pattern, and a healthier dietary composition which could 
additionally influence glucocorticoid dynamics. Moreover, individuals with obesity 
are considered to have a low-grade inflammatory state (69) and losing body weight 
and especially visceral adiposity might alter inflammatory markers which are 
associated with HPA axis activation. Askarpour and colleagues recently conducted 
a meta-analysis regarding the changes in pro-inflammatory factors after weight 
loss in patients with obesity who had undergone bariatric surgery (70). They found 
among others a reduction in the pro-inflammatory cytokines interleukin-6 and 
tumor necrosis factor-α, both known to stimulate HPA-axis activity (71). These and 
other factors related to both obesity and HPA-axis activity are currently being 
investigated in participants engaging in our combined lifestyle intervention with 
cognitive behavioral therapy.
Scalp hair glucocorticoids and stress-related features
Glucocorticoid-related adverse events other than weight gain and cardiometabolic 
alterations would also be expected in subjects exposed to supraphysiological 
cortisol concentrations. In chapter 9 and chapter 10 we evaluated scalp hair 
cortisol concentrations in patients with Turner syndrome (TS) and erythropoietic 
protoporphyria (EPP). These patient populations generally have clinical features 
that are known to be associated with hypercortisolism. We showed that both 
groups indeed have significantly higher long-term cortisol concentrations in 
comparison to age- and sex-matched controls. Despite the fact that TS and EPP 
are genetic disorders, it seems implausible to assume that the increased cortisol 
levels are the result of genetic alterations at HPA axis level. Psychological distress 
could potentially have induced higher biological stress levels since both groups 
experience various mental stressors in daily life from a young age. Several 
explanations could be proposed for this such as exclusion or teasing because of 
short stature (72) or low self-esteem and depression due to infertility in TS (73) to 
pain and fear of sunlight-induced skin lesions causing limitations in personal life in 
EPP (74). The observed association between high hair cortisol concentrations with 
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short stature and lower quality of life in respectively patients with TS and EPP fits 
in with this. Moreover, van Uum et al. showed that chronic pain was associated with 
higher perceived stress as well as increased hair cortisol concentrations (75). There 
was however no significant association between perceived stress as measured 
with the Perceived Stress Scale (PSS) questionnaire and cortisol concentrations 
(75), something we also observed in our patient populations (chapters 9, 10, and 
11). This could perhaps be due to differences in the period of interest covered 
with the assessments (i.e. months with scalp hair and past four weeks with PSS), 
stability of the outcomes over time, and/or dependence on other specific factors. 
The relevance of mental stress on scalp hair glucocorticoids was also assessed in 
chapter 11 in which Year 1 medical students before and after raising academic 
performance standards were investigated. This measure indeed led to higher 
passing rates and especially in male students. Hair cortisol concentrations however 
did not differ between both cohorts, whereas perceived psychological stress was 
higher in the group with raised performance standards and particularly in female 
students. Combining both stress outcomes revealed that only those with above-
median biological and psychological stress levels were at risk for poor academic 
performance. 
The possibility to assess cortisol levels over different time points with one 
sample is unique to scalp hair analysis compared to the traditional matrices. This 
enables evaluation of cortisol concentrations before and after certain events or 
interventions. We previously showed that cortisol concentrations in scalp hair of 
four-year-old children increased after entering elementary school (76). In chapter 12 
we investigated the same population after entering third grade two years later and 
found again an increase in cortisol concentrations. The degree of cortisol increase 
after school entry was however not the same for everyone. In the previous study, 
we found that a high social fearfulness was linked to a larger cortisol increase, 
whereas in the current observation higher cortisol levels after school entry were 
found to be associated with less inhibitory control. Different circumstances could 
have played a role hereby giving the fact that these children now had to make 
a transition to formal learning which could be more challenging in those with a 
difficult temperament. Alternatively, high cortisol levels or stress reactivity might 
have affected prefrontal regulatory systems and thereby impaired executive 
abilities (77) leading to altered behavioral inhibition. 
Regarding the link between long-term cortisol concentrations and neural 
correlates we measured scalp hair cortisol and performed neuroimaging with 
functional magnetic resonance in trauma-exposed police officers (chapter 




concentrations which correspond to the long-term findings in survivors of a 
natural disaster who subsequently developed such disorder (78) which might be 
the result of HPA axis dysregulation (79). Interestingly, differentiation in amygdala 
reactivity between negative affective stimuli and neutral affective stimuli was 
lowered in participants with low scalp hair cortisol and especially in those with 
posttraumatic stress disorder. The exact mechanisms behind these findings 
need to be elucidated, possible explanations could perhaps lie in the prominent 
availability of glucocorticoid receptors in the amygdala (80) and dynamic changes 
in cortisol secretion with posttraumatic stress disorder over time (81).
7. Methodological considerations and limitations
The studies included here possess a variety of strengths such as relatively large 
number of participants, in-depth phenotyping, and the availability of unique and 
high-quality data in most. However, some general methodological considerations 
and limitations must be mentioned. With respect to the analyses regarding 
corticosteroid use, we unfortunately had no data on the cumulative exposure 
of these agents. The most profound associations were observed with inhaled 
corticosteroid use and since these types are generally used in a chronic fashion 
(e.g. asthma and chronic obstructive pulmonary disease) it would be expected 
that many of the agents were prescribed for an extended period of time. Despite 
previous research that has hinted at systemic availability and adverse effects 
of local and especially inhaled corticosteroids, the observational design of our 
studies does not prove causality and thus further randomized controlled trials are 
needed to address temporality. Potential confounding by indication could also 
be considered as an important limitation, however, we have performed various 
sensitivity analyses in which many of the main findings persisted. Finally, future 
studies are needed to reveal whether the findings in our study population with 
obesity can be extrapolated to individuals with obesity in the general population. 
8. Concluding remarks and future perspectives
Glucocorticoids and obesity are linked to each other in a complex interaction. 
This complexity necessitates a thorough evaluation of potential obesogenic 
factors in individuals with obesity since adiposity can directly and indirectly 
increase glucocorticoid concentrations and vice versa. Our studies suggest that 
the use of systemic but also local exogenous glucocorticoids, and especially of the 
often overlooked inhaled corticosteroids, should be considered as an important 
obesogenic factor in obesity. This statement is further emphasized by the fact 
that these agents are one of the most commonly used drugs, with over ten 
million being prescribed annually in the Netherlands only. We would recommend 
to ascertain whether the indication for corticosteroids is still present in users 
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and to assess whether alternatives are available when dealing with obesity, 
increased cardiovascular risk and/or mental problems. Evidence is accumulating 
about various asthmatic phenotypes in obesity with differential insensitivity for 
glucocorticoids (82) and thus perhaps avoidable use of inhaled corticosteroids in 
specific subpopulations. It was also shown that nearly half of asthmatic patients 
with obesity did not have asthma after pulmonary testing of which a part was 
still on inhaled corticosteroids (83). More awareness is needed for the potential 
serious cardiometabolic and mental adverse events in case that use of (inhaled) 
corticosteroids is necessary and unavoidable.
Interesting developments are ongoing in the pursuit of selective glucocorticoid 
receptor ligands which are designed to minimize the transactivational activity and 
thus unwanted adverse events while increasing the desired transrepressional and 
anti-inflammatory effects. Schäcke et al. identified a novel nonsteroidal selective 
glucocorticoid receptor agonist (compound ZK 216348) which was proven to 
show anti-inflammatory effects comparable to prednisone with less adverse 
events as induced by transactivation in rodent models (84). In vivo experiments 
with rats showed no significant changes in blood glucose whereas levels increased 
in a dose-dependent manner with prednisone (84). Similar dissociated effects 
with preferential transrepressional activity were also demonstrated for the 
glucocorticoid receptor ligand AL-438 (85). These compounds would presumably 
have no benefit regarding HPA axis suppression and adrenal insufficiency in 
comparison to current glucocorticoids since the regulation of corticotropin-
releasing hormone and adrenocorticotropic hormone (ACTH) seems to be via 
transpressional activity (86). Compound ZK 216438 and prednisone were indeed 
shown to suppress ACTH levels to similar extents (84). On the other hand, newer 
inhaled corticosteroids are also (becoming) available which possess better 
pharmacokinetic profiles compared to older agents. A number of conditions for an 
ideal inhaled corticosteroid with regard to the agent as well as the inhaler device 
have been proposed earlier. As suggested by Kemp, the formulations should have 
“a high affinity for and potency at the glucocorticoid receptor; prolonged retention in 
the lung; minimal or no oral bioavailability; and rapid, complete systemic inactivation.” 
(87). Inhaled corticosteroids that meet these requirements should in theory have 
maximum efficacy with minimal systemic adverse events. Ciclesonide, a relatively 
novel inhaled corticosteroid agent, is interesting in this context giving its excellent 
pharmacokinetic properties which largely meets the proposed conditions. This 
formulation is inactive upon inhalation and is converted on-site into the biologically 
active desisobutyryl-ciclesonide (des-cic) by esterases in bronchial epithelial cells 
(88). The active compound possess a 12 times higher receptor affinity compared to 




1% with nearly complete protein-binding (88). Moreover, des-cic forms conjugates 
with fatty acids in the lungs in a reversible fashion which ensures a prolonged 
retention in the lung given the slow-release of the compound over time (88). A 
high systemic clearance by the liver (88,89) further contributes to its favourable 
properties. Previous trials have demonstrated a high efficacy of ciclesonide and 
showed it to be superior to other inhaled corticosteroids in terms of local adverse 
events (e.g. oral candidiasis, hoarseness, pharyngitis) and HPA axis suppression (90). 
Several trials with different treatment durations showed that ciclesonide, even in 
high doses, did not induce significant cortisol suppression in comparison to placebo 
(91-93), which was also confirmed in a meta-analysis investigating urinary cortisol 
suppression for several inhaled corticosteroids (94). Future research should reveal 
whether use of ciclesonide as inhaled corticosteroid also goes with less potential 
systemic adverse events such as weight gain and cardiometabolic alterations.
Apart from exogenous glucocorticoids, individuals with obesity are more likely to 
have an increased endogenous cortisol secretion. Since the regulation of cortisol is 
complex and regulated at different levels, future studies will also have to show which 
central and/or peripheral factors play an important role in the hypercortisolistic 
state in obesity and whether these can be influenced with beneficial effects 
regarding adiposity and cardiometabolic profile. We have at least demonstrated 
that a combined lifestyle intervention with cognitive behavioral therapy leads to 
sustained improvements in anthropometry and body composition and also lowers 
long-term endogenous cortisol levels. Our work and efforts have even resulted 
in the implementation of comparable interventions in the basic health insurance 
for Dutch citizens enabling novel options in combating overweight and obesity in 
individuals who were not eligible or were not willing to undergo bariatric surgery. 
Other works that are ongoing regarding lowering endogenous cortisol levels 
involve drug treatments aimed at inhibiting 11β-hydroxysteroid dehydrogenase 
type 1 (and thus lowering conversion of cortisone into active cortisol) (95) and 
blocking glucocorticoid receptor with its antagonist mifepristone (96,97).
With respect to quantifying endogenous glucocorticoids, scalp hair cortisol seems a 
promising biomarker for monitoring long-term cortisol and cortisone exposure. The 
significance and meaning of higher cortisone concentrations in Cushing’s syndrome 
need further research which could answer whether it resembles accumulative 
exposure to cortisol and/or is the result of conversion by 11β-hydroxysteroid 
dehydrogenases in cutaneous appendages. Finally, international collaboration is 
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Glucocorticoids, in particular the main effector hormone cortisol, are important 
endocrine regulators essential for a myriad of physiological and mental functions. 
The concentration and action of glucocorticoids, also known as stress hormones, is 
delicately controlled by the hypothalamus-pituitary-adrenal axis as well as through 
other means at different levels. The importance of this becomes clear giving that 
too much glucocorticoid action can have detrimental effects with respect to 
essentially every aspect of human functioning. There are various ways by which 
this can occur such as increased secretion of endogenous glucocorticoids as well 
as due to administration of corticosteroids, i.e. drugs which contain synthetic 
glucocorticoids. The metabolic effects, including the development of (abdominal) 
obesity, are of special interest since they are frequently observed with high 
glucocorticoid action and can increase the risk of comorbidities as type 2 diabetes 
mellitus, cardiovascular diseases, depression, and stroke. This becomes even 
more relevant giving the fact that the prevalence of obesity has taken pandemic 
proportions. In this thesis, we describe the findings of our scientific work in which 
we focus on endogenous and exogenous glucocorticoids and their role in obesity 
and stress-related diseases. 
In chapter 1 we provide a general background into the field of endogenous 
and exogenous glucocorticoids. The synthesis of glucocorticoids, methods of 
quantification, the magnitude of corticosteroid use, the diverse adverse effects 
of glucocorticoids as well as the link with obesity are among the topics that are 
discussed. 
Chapter 2 describes our findings of a comprehensive evaluation of potential 
obesogenic factors besides diet and physical activity in an adult cohort of 408 
individuals with obesity. Interestingly, genetic analysis in participants suspected 
of a monogenic cause or syndromic obesity yielded a definitive diagnosis in 2.0% 
whereas 5.6% was found to carry likely pathogenic contributing genetic variants. 
Furthermore, nearly half of the complete cohort were using one or more drugs 
which are associated with weight gain and this especially included the use of 
corticosteroids. One in six individuals reported to have experienced period(s) 
of marked weight gain preceded by the use of obesogenic drugs among which 
corticosteroids were mentioned most frequently. 
In chapter 3 we compared the recent use of corticosteroids in persons with obesity 
compared to individuals without obesity from two different cohorts. We found 
that overall corticosteroid use was twice more likely in the group with obesity. The 
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largest differences were found for the use of local corticosteroids and especially 
for the inhaled types. 
We subsequently investigated the associations between different corticosteroid 
forms with metabolic syndrome and body mass index in over 140.000 adults 
from the general population. In chapter 4 we describe our findings concerning 
significantly higher body mass index and waist circumference in users of inhaled 
corticosteroids from both sexes. Moreover, users of systemic as well as local 
corticosteroids, more specifically for the inhaled and nasal types, were more likely 
to have metabolic syndrome but only in female users. These findings were largely 
persistent in users of systemic and inhaled corticosteroids when stratified by 
menopausal status, inflammatory status, and obesity.
In chapter 5 we further elucidated the previous findings by investigating the role 
of glucocorticoid receptor polymorphisms related to a relative glucocorticoid 
resistance (ER22/23EK and 9β variants) or glucocorticoid hypersensitivity (BclI 
and N363S variants) in over 10.000 individuals from the adult general population. 
Overall, corticosteroid users harboring wild-type or glucocorticoid hypersensitive 
variants were more likely to have adverse anthropometric features in terms 
of increased body mass index, waist circumference, and increased presence of 
metabolic syndrome in comparison to nonusers with strongest associations found 
for users of inhaled types. The differences in users with glucocorticoid resistant 
variants were less pronounced and only reached statistical significance for waist 
circumference in users of inhaled corticosteroids.
In chapter 6 we extended the scope of potential adverse effects of exogenous 
glucocorticoids by investigating the link with executive cognitive functioning and 
neuropsychiatric disorders. In 83,592  adults from the same population-based 
cohort study, we analyzed outcomes on the Ruff Figural Fluency test (i.e. cognitive 
test for measuring nonverbal fluency as part of executive cognitive functioning) 
and the Mini-International Neuropsychiatric Interview survey. We found that 
corticosteroid use, especially of systemic and inhaled administration forms, was 
associated with lower executive cognitive functioning and was independent of 
inflammation as proxied by high-sensitive CRP. Overall corticosteroid use was 
also associated with a higher likelihood of mood and anxiety disorders. These 
associations were especially present in users of inhaled types and were independent 
of physical quality-of-life as assessed with the RAND-36  questionnaire.
With respect to quantifying endogenous glucocorticoid concentrations, we 




of Cushing’s syndrome in chapter 7. For this purpose, we analyzed hair samples 
of 295 controls from the general population and 89 patients with endogenous 
Cushing’s syndrome from two different centers by using a state-of-the-art LC-MS/
MS technique. High diagnostic performances were found for both hair cortisol and 
cortisone concentrations in screening of Cushing’s syndrome. Interestingly, hair 
cortisone was more accurate than hair cortisol and sum of both in differentiating 
patients from controls. 
In chapter 8 we investigated the effects of combined lifestyle intervention 
with cognitive behavioral therapy in obesity. Participants showed significant 
improvements in body weight, waist circumference, body mass index, and body 
composition after the first evaluation at 10 weeks and maintained these at the 
end of the intervention at 75 weeks. The weight course was different in systemic 
corticosteroid users compared to nonusers. No significant weight change at end 
of the intervention was observed in users of systemic corticosteroids. There 
were no significant changes in hair cortisone between the start and end of the 
program whereas hair cortisol concentrations dropped significantly. The changes 
in anthropometrics and hair glucocorticoids were however not associated with 
each other. This suggests that other factors than weight loss per se could have 
been influencing long-term cortisol levels during the intervention. 
In chapter 9 we investigated hair cortisol concentrations in patients with Turner 
syndrome and age-and-sex matched controls from the general population. 
This syndrome originates from a (partial) loss and/or abnormalities of the 
X-chromosomes and is amongst the most prevalent genetic syndromes. Patients 
are often encountered with a variety of physical and psychological difficulties 
including stress-related features as diabetes mellitus, hypertension, and obesity. 
We found that patients with Turner syndrome have a worse cardiometabolic profile 
in comparison to controls with regard to fasting glucose and triglycerides. Long-
term cortisol was also significantly higher in patients and was associated with higher 
total cholesterol and seemed to be inversely related with height. No significant 
associations were found with psychological measures regarding perceived stress 
(PSS-14), fatigue (CIS-20), and health-related quality of life (RAND-36).
In another study (chapter 10) we focused on patients with erythropoietic 
protoporphyria, which is a rare metabolic disorder caused by an enzyme deficiency 
in the haem biosynthetic pathway. As with Turner syndrome, patients with 
erythropoietic protoporphyria frequently suffer from a multitude of (disease-
related) stressors. In this study, we analyzed long-term cortisol concentrations 
in scalp hair of 15 patients and 45 age-and-sex matched controls. We found that 
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patients with erythropoietic protoporphyria had significantly higher cortisol 
concentrations in comparison to controls. Importantly, we showed that higher hair 
cortisol concentrations were associated with a  higher body mass index as well as 
a lower quality-of-life in these patients. 
In chapter 11 we report the findings of our prospective comparative cohort study 
investigating the effects of raising performance standards in medical students. 
We focused on psychological well-being, biological stress levels, and academic 
performance in student cohorts before (n=410) and after (n=413) raising academic 
performance standards. First-year students, especially male individuals, were 
more likely to pass whereas perceived psychological stress (PSS-14) was increased 
in case of raised standards. In contrast, no differences were observed in biological 
stress as measured with hair cortisol concentrations. The combination of high 
perceived psychological and biological stress was found to be associated with a 
lower passing rate.
In chapter 12 we investigated scalp hair cortisol concentrations in school 
children before and after entering third grade. This study was a follow-up to our 
previous research concerning first school entry which showed that hair cortisol 
concentrations increased after entering elementary school and in particular for 
fearful children. We found that entering third grade was also associated with 
increasing hair cortisol concentrations. However, this was only associated with 
increasing cortisol levels in children with low inhibitory control and was not linked 
to social fearfulness or academic achievement. This suggests a crucial role of 
controlling impulsive responsivity in stress regulation in children who make the 
transition to formal learning.
In chapter 13 we studied long-term cortisol level and its neural correlates as 
measured with functional magnetic resonance imaging in trauma-exposed 
female police officers. We found that hair cortisol concentrations were lowered 
in participants who had developed a post-traumatic stress disorder. Furthermore, 
hair cortisol levels showed to be associated with important post-traumatic stress 
disorder-related neurobiological correlates as reduced differentiation between 
negative affective and neutral stimuli in the amygdala was observed with lower 
cortisol levels.
In the final chapter 14, we discuss our findings in the context of current literature 





Glucocorticoïden, met name het belangrijkste hormoon cortisol, behoren tot 
de meest essentiële hormonale regulatoren en zijn noodzakelijk voor een groot 
aantal fysiologische en mentale functies. De concentratie en het uiteindelijke 
effect van glucocorticoïden, die ook wel bekend staan als stresshormonen, 
wordt gereguleerd door de hypothalamus-hypofyse-bijnier-as en verschillende 
regelmechanismen op allerlei niveaus. Dit is van wezenlijk belang aangezien te 
veel glucocorticoïden werking vrijwel elk aspect van het menselijk functioneren 
nadelig kan beïnvloeden. Een verhoogd glucocorticoïd effect kan op verschillende 
manieren plaatsvinden, zoals door een verhoogde secretie van endogene 
glucocorticoïden maar ook door het gebruik van geneesmiddelen die synthetische 
glucocorticoïden bevatten. De metabole effecten, waaronder de ontwikkeling 
van (abdominale) obesitas, zijn van bijzonder belang omdat ze vaak worden 
waargenomen bij  een verhoogde glucocorticoïd blootstelling. Hierbij wordt het 
risico op comorbiditeiten zoals diabetes mellitus type 2, hart- en vaatziekten, 
depressie en beroerte verhoogd. Dit wordt des te relevanter omdat obesitas 
pandemische proporties heeft aangenomen. In dit proefschrift beschrijven we de 
bevindingen van ons wetenschappelijke werk waarin we ons richten op endogene 
en exogene glucocorticoïden en hun rol bij obesitas en stress gerelateerde ziekten.
In hoofdstuk 1 geven we een algemene achtergrond op het gebied van 
endogene en exogene glucocorticoïden. De synthese van glucocorticoïden, 
kwantificatiemethoden, omvang van het gebruik van corticosteroïden, de diverse 
nadelige effecten van glucocorticoïden en het verband met obesitas passeren de 
revue.
Hoofdstuk 2 beschrijft onze bevindingen van een uitgebreide evaluatie van 
mogelijke obesogene (‘dikmakende’) factoren naast voeding en fysieke activiteit 
in een volwassen cohort van 408 personen met obesitas. Interessant is dat 
genetische analyse bij deelnemers die verdacht werden van een monogenetische 
oorzaak of syndromale obesitas een definitieve genetische diagnose opleverde 
bij 2,0%, terwijl 5.6% drager bleek te zijn van mogelijk pathogene bijdragende 
genetische varianten. Bovendien bleek dat bijna de helft van de personen van de 
volledige onderzoekspopulatie één of meerdere mogelijke gewichtsverhogende 
geneesmiddelen gebruikt waaronder met name de corticosteroïden. Eén op de 
zes personen meldde een periode van opmerkelijke gewichtstoename te hebben 
gehad welke voorafgegaan werd door het gebruik van obesogene geneesmiddelen 
waarbij corticosteroïden het vaakst werden genoemd. 
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In hoofdstuk 3 vergeleken we het recente gebruik van corticosteroïden bij 
personen met obesitas met personen zonder obesitas uit twee verschillende 
cohorten.  We ontdekten dat het gebruik van corticosteroïden in het algemeen 
bijna verdubbeld was in individuen met obesitas ten opzichte van de groepen 
zonder obesitas. De grootste verschillen werden gevonden voor het gebruik van 
lokaal toegediende corticosteroïden en vooral van de inhalatoren.
Vervolgens hebben we in hoofdstuk 4 de associatie onderzocht tussen het gebruik 
van verschillende typen corticosteroïden met het metabool syndroom en de body 
mass index bij meer dan 140.000 volwassenen uit de algemene bevolking. Zowel 
mannelijke als vrouwelijke gebruikers van inhalatiecorticosteroïden bleken een 
significant hogere body mass index en buikomtrek te hebben ten opzichte van niet-
gebruikers van corticosteroïden. Vrouwelijke gebruikers van zowel systemische 
als lokale corticosteroïden, met name de inhalatie en nasale typen, bleken vaker 
het metabool syndroom te hebben dan vrouwen die geen corticosteroïden 
gebruikten. Deze bevindingen bleven grotendeels onveranderd bij stratificatie 
voor menopauze, inflammatoire status en obesitas.
In hoofdstuk 5 hebben we in het verlengde van de eerdere bevindingen ook de rol 
van genetische polymorfismen van het glucocorticoïd receptor onderzocht, waarbij 
we onderscheid hebben gemaakt tussen varianten die geassocieerd zijn met een 
relatieve glucocorticoïdresistentie (ER22/23EK en 9β) of overgevoeligheid voor 
glucocorticoïden (BclI en N363S). In dit onderzoek met meer dan 10.000 individuen 
uit de volwassen algemene bevolking vonden we dat gebruikers van corticosteroïden 
met een wildtype of hypersensitieve variant meer nadelige cardiometabole en 
antropometrische kenmerken hadden wat betreft body mass index, buikomvang 
en metabool syndroom in vergelijking met niet-gebruikers. De  sterkste associaties 
werden gevonden voor gebruikers van inhalatiecorticosteroïden. De verschillen bij 
gebruikers met glucocorticoïd-resistente varianten waren minder uitgesproken, 
waarbij slechts gebruikers van inhalatiecorticosteroïden een statistisch significant 
toegenomen buikomvang hadden ten opzichte van niet-gebruikers. 
In hoofdstuk 6 hebben we ons gefocust op andere mogelijke nadelige effecten 
van exogene glucocorticoïden door het verband tussen corticosteroïdgebruik, 
executief cognitief functioneren en neuropsychiatrische aandoeningen te 
onderzoeken. Bij 83.592 volwassenen uit dezelfde populatie-gebaseerde 
cohortstudie analyseerden wij de uitkomsten van de Ruff Figural Fluency-test 
(i.e. een cognitieve test voor het meten van non-verbale fluency als onderdeel 
van executief cognitief functioneren) en de Mini-International Neuropsychiatric 




van systemische en geïnhaleerde toedieningsvormen, gepaard ging met een 
verminderd executieve cognitief functioneren welke onafhankelijk bleek te zijn 
van de mate van ontsteking (gemeten met high-sensitive CRP). Het gebruik van 
corticosteroïden ging in het algemeen ook gepaard met een grotere kans op 
stemmings- en angststoornissen. Deze associaties werden vooral waargenomen 
bij gebruikers van inhalatiecorticosteroïden en waren onafhankelijk van de fysieke 
kwaliteit van leven (gemeten met de RAND-36 vragenlijst)
Met betrekking tot het kwantificeren van endogene glucocorticoïden, hebben we 
in hoofdstuk 7 de diagnostische kwaliteiten van glucocorticoïden in hoofdhaar 
bij de screening van het syndroom van Cushing onderzocht. Hiervoor hebben we 
haarmonsters van 295 controles uit de algemene bevolking en 89 patiënten met 
endogene syndroom van Cushing uit twee verschillende centra onderzocht met 
behulp van de modernste LC-MS/MS techniek. We vonden dat zowel haar cortisol 
als haar cortison veelbelovende biomarkers zijn bij de screening op het syndroom 
van Cushing. Interessant is dat haar cortison nauwkeuriger was dan haar cortisol en 
de som van beide hormonen bij het onderscheiden van patiënten van controles. 
In hoofdstuk 8 hebben we de effecten van een gecombineerde leefstijlinterventie 
met cognitieve gedragstherapie bij individuen met obesitas onderzocht. 
Deelnemers toonden bij de eerste evaluatie na 10 weken significante verbeteringen 
in lichaamsgewicht, buikomvang, body mass index en lichaamssamenstelling welke 
ook na 75 weken (einde van de interventie) behouden bleven. Het gewichtsbeloop 
was verschillend naargelang het gebruik van systemische corticosteroïden. 
De gebruikers bleken aan het eind van het programma geen significante 
gewichtsverandering te hebben in tegenstelling tot niet-gebruikers. Tussen begin 
en einde van het programma werden geen significante veranderingen in haar 
cortison waargenomen, terwijl de haar cortisol concentraties aanzienlijk daalden. 
De veranderingen in antropometrie en haar glucocorticoïden waren echter niet met 
elkaar geassocieerd. Dit suggereert dat andere factoren dan gewichtsverlies de 
lange-termijn cortisolspiegels zouden kunnen beïnvloeden tijdens de interventie. 
In hoofdstuk 9 onderzochten we haar cortisol concentraties van patiënten met 
het syndroom van Turner en van op leeftijd en geslacht gematchte controles uit de 
algemene bevolking. Het syndroom van Turner komt voort uit een (gedeeltelijk) 
verlies en/of afwijkingen van één van de X-chromosomen en behoort tot één 
van de meest voorkomende genetische syndromen. Patiënten worden vaak 
geconfronteerd met een verscheidenheid aan fysieke en psychologische 
problemen, waaronder stressgerelateerde aandoeningen zoals diabetes mellitus, 
hypertensie en obesitas. We ontdekten dat patiënten met het syndroom van 
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Turner een ongunstiger cardiometabool profiel hebben vergeleken met de 
controles ten aanzien van nuchter glucose en triglyceridenwaarden in het 
bloed. Cortisol in hoofdhaar was tevens significant hoger bij patiënten en ging 
gepaard met een hoger totaal cholesterol en had een omgekeerd evenredig 
verband met lichaamslengte. Er werden geen significante associaties gevonden 
met psychologische uitkomsten met betrekking tot ervaren stress (PSS-14), 
vermoeidheid (CIS-20) en gezondheidsgerelateerde kwaliteit van leven (RAND-36). 
In een ander onderzoek (hoofdstuk 10) richtten we ons op patiënten met 
erytropoëtische protoporfyrie, een zeldzame stofwisselingsziekte die wordt 
veroorzaakt door een enzymdeficiëntie in de biosynthese van heem. Net als bij 
het syndroom van Turner hebben patiënten met erytropoëtische protoporfyrie 
vaak last van een veelvoud aan (ziektegerelateerde) stressfactoren. In deze 
studie analyseerden we lange-termijn cortisol in hoofdhaar van 15 patiënten en 
45 op leeftijd en geslacht gematchte controles. We ontdekten dat patiënten met 
erytropoëtische protoporfyrie significant hogere cortisol concentraties hadden 
in vergelijking met controles. Hogere cortisol concentraties in hoofdhaar waren 
tevens geassocieerd met een hogere body mass index en een lagere kwaliteit van 
leven bij deze patiënten.
 
In hoofdstuk 11 rapporteren we de bevindingen van ons prospectieve vergelijkende 
cohortonderzoek naar de effecten van het verhogen van prestatienormen bij 
medische studenten. Hierbij hebben we ons gericht op psychologisch welbevinden, 
biologische stressniveaus en academische prestaties in studentencohorten 
vóór (N=410) en na (N=413) het verhogen van de academische prestatienorm. 
Eerstejaarsstudenten, vooral mannelijke individuen, slaagden vaker bij een 
verhoogde prestatienorm. Deze studenten bleken echter ook meer psychologische 
stress (PSS-14) te ervaren. Daarentegen werden geen verschillen waargenomen in 
biologische stress zoals gemeten met haar cortisol concentraties. De combinatie 
van hoog ervaren psychologische én biologische stress ging gepaard met een 
lager slagingspercentage.
In hoofdstuk 12 hebben we cortisol concentraties in hoofdhaar van schoolkinderen 
vóór en na het start van het derde leerjaar onderzocht. Deze studie was een 
vervolg op ons eerdere onderzoek ten tijde van het eerste schooljaar, waaruit 
bleek dat haar cortisol concentraties toenamen bij start van de basisschool en in 
het bijzonder bij angstige kinderen. We ontdekten nu dat de overgang naar groep 
drie ook geassocieerd was met een toename in haar cortisol concentraties. Dit 
bleek echter alleen het geval te zijn bij kinderen met een lage ‘inhibitory control’ 




een cruciale rol van het beheersen van impulsieve responsiviteit bij stressregulatie 
bij kinderen die de overgang maken  naar formeel leren. 
In hoofdstuk 13 hebben we lange termijn cortisolspiegels en de relatie 
hiervan met neuronale correlaten, gemeten met functionele magnetische 
resonantiebeeldvorming, bij aan trauma blootgestelde vrouwelijke politieagenten 
onderzocht. We vonden lagere haar cortisol concentraties bij deelnemers die een 
posttraumatische stressstoornis hadden ontwikkeld. Bovendien bleek dat haar 
cortisolspiegels geassocieerd zijn met belangrijke posttraumatische stressstoornis-
gerelateerde neurobiologische correlaten, zoals een verminderd onderscheid 
tussen negatieve affectieve en neutrale stimuli in de amygdala, hetgeen werd 
waargenomen bij lagere cortisolspiegels.
In het laatste hoofdstuk 14 bespreken we onze bevindingen in de context van de 
huidige literatuur en gaan we in op de klinische en maatschappelijke relevantie 
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1. PhD training
General academic skills Year Work load 
(ECTS)
Basic Introduction Course on SPSS 2013 1.0
Advanced Immunology: a short course 2015 0.3
Biostatistical Methods 2015 5.7
Scientific Integrity Course 2016 0.3
Basic Course on R 2016 1.8
Microbiomics I 2017 0.6
Microsoft Excel 2010: Basic 2017 0.3
Microsoft Excel 2010: Advanced 2017 0.3
Introduction in GraphPad Prism version 6 2017 0.3
Bayesian Statistics and JASP 2017 0.3
Workshop Supervising Master and PhD students 2018 0.3
Survival Analysis 2020 0.6
Congress and Meeting Visits – 
Oral presentations
Venue Year Work load 
(ECTS)
5th Dutch Endocrine Meeting Noordwijkerhout (NL) 2015 1.0
Science Days Internal Medicine Antwerp (BE) 2016 1.0
Science Days Internal Medicine Antwerp (BE) 2016 1.0
6th Dutch Endocrine Meeting Noordwijkerhout (NL) 2016 1.0
Science Days Internal Medicine Antwerp (BE) 2017 1.0
7th Dutch Endocrine Meeting Noordwijkerhout (NL) 2017 1.0
ENDO 2017 Orlando (FL, USA) 2017 1.0
20th European Congress of Endocrinology Barcelona (ESP) 2018 1.0
25th European Congress on Obesity Vienna (AU) 2018 1.0
Science Days Internal Medicine Sint-Michielgestel (NL) 2019 1.0
9th Dutch Endocrine Meeting Noordwijkerhout (NL) 2019 1.0
Annual  Dutch Diabetes Research Meeting Wageningen (NL) 2019 1.0
ECOICO 2020 Virtual event (online) 2020 1.0
ENEA 2020 Virtual event (online) 2020 1.0
PhD Portfolio
PhD Portfolio
Summary of PhD Training and Teaching
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A
Congress and Meeting Visits – 
Poster presentations
Venue Year Work load 
(ECTS)
Science Days Internal Medicine Antwerp (BE) 2015 0.5
ENDO 2016 Boston (MA, USA) 2016 0.5
Science Days Internal Medicine Antwerp (BE) 2018 0.5
8th Dutch Endocrine Meeting Noordwijkerhout (NL) 2018 0.5
IMPROCUSH-3 Munich (GE) 2018 0.5
2. Teaching
Supervising students Year Work load 
(ECTS)
Anne Verlinde (BSc student, Biology, 
Wageningen University & Research)
2016 2.0
Simone Janmaat (MSc student, Medicine, Erasmus MC) 2017-2018 6.0
Vera Rotee (MSc student, Medicine, Erasmus MC) 2018 2.5
Zeynab Mustafa (BSc student, Liberal Arts & Sciences (Pre-Med), 
Erasmus University College)
2018-current 4.0
Education Year Work load 
(ECTS)
Lecturer skills training medicine students on endocrine topics 2015-2019 2.0
Other Year Work load 
(ECTS)
Physician at academic center of excellence in obesity CGG 
(Centrum Gezond Gewicht)
2015-2019 5.0
Erasmus MC PhD committee member (representative of all PhD 
students from the Postgraduate School Molecular Medicine)
2016-2019 1.0
Organizer monthly interdisciplinary research seminars for obesity 
center CGG affiliated research departments and collaborators
2016-2019 4.0
Peer-reviewer scientific journals 2015-current 3.0
Organizer PhD day Erasmus MC: “A healthy PhD!” 2018 0.5
3. Other
Lectures Venue Year Work load 
(ECTS)
MOSA Conference Maastricht (NL) 2015 1.0
International Obesity Genetics Collaborations 
Meeting
Amsterdam (NL) 2016 1.0
Studiedag Paramedici Apeldoorn (NL) 2017 1.0
International Obesity Genetics Collaborations 
Meeting






Katja’s Bodyscan TV (KRO-NCRV) Item about our research in stress and stress-
related diseases
2015






NU.nl and other 
websites)
Press release about our study on the relationship 
between use of inhaled corticosteroids and 
obesity/metabolic syndrome
2017
Studio Erasmus Show Talk  show about science and current affairs; item 
about meaning of stress and how to measure its 
effects
2018
Brard & Jekel: 
VetGelukkig?!
TV (NTR) Item about obesity and future obesity treat-
ments
2018
4. Awards and Prizes
Type Funder Year
Conference Participation Grant Stichting Erasmus Trustfonds 2016
Goodlife Healthcare Travel Grant Dutch Society for Endocrinology 2016
Early Career Award Endocrine Society 2016
Goodlife Healthcare Travel Grant Dutch Society for Endocrinology 2017
Best Poster Prize Erasmus Medical Center (dept. of Internal Medicine) 2018
EASO Travel Grant European Association for the Study of Obesity 2018
ESE Meeting Grant European Society of Endocrinology 2018
ESE Journal of Endocrinology 
Travel Grant
European Society of Endocrinology 2018
Conference Participation Grant Stichting Erasmus Trustfonds 2018
NASO Travel Grant Netherlands Association for the Study of Obesity 2018
Goodlife Healthcare Travel Grant Dutch Society for Endocrinology 2018
Nederlandse Lipoedeemdag Maastricht (NL) 2017 1.0
Junior Med School Rotterdam (NL) 2017 1.0
International Obesity Genetics Collaborations 
Meeting
Amsterdam (NL) 2018 1.0
Molecular Medicine Course Lecture Rotterdam (NL) 2018 1.0
The Netherlands Association for the Study of 
Obesity Spring Meeting
Utrecht (NL) 2018 1.0
Jaarcongres ClaudicatioNet Apeldoorn (NL 2019 1.0
Students Experienced in Lifestyle and Food 
(SELF)
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